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 Cancer is a significant global health concern; and traditional therapies, including 
chemotherapeutics, are often simultaneously toxic yet ineffective.  There is a critical need 
to develop targeted cancer therapeutics which specifically inhibit molecules or molecular 
pathways essential for tumor growth and maintenance.  Furthermore, a targeted therapy is 
only effective when a patient's tumor expresses the molecular target; therefore, companion 
diagnostics, including molecular imaging agents, are a necessary counterpart of targeted 
therapies.  
 Mesothelin (MSLN) is a cell surface protein overexpressed in numerous cancers, 
including triple-negative breast, pancreatic, ovarian, liver, and lung, with limited 
expression in normal tissues.  Aberrant MSLN expression promotes tumor progression, 
metastasis, and therapeutic resistance, and is correlated with poor prognoses.  Promising 
results from pre-clinical and clinical trials to target MSLN with antibodies, antibody 
derivatives, immunotoxins, and antibody-drug conjugates for therapy demonstrate the 
promise of MSLN-targeting methods; however, none are currently approved for routine 
clinical use, and limitations are emerging for targeting agents under development.  New 
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targeted diagnostic and therapeutic approaches for MSLN-positive tumors have potential 
for substantial impact in the clinic.  
 In this work, I used yeast-surface display and directed evolution to engineer novel 
proteins based on the non-antibody fibronectin (Fn3) scaffold that bind to MSLN with high 
affinity and specificity.  Soluble engineered proteins were expressed and purified to high 
yields from a bacterial system.  In vitro cytotoxicity and apoptosis assays demonstrated the 
potential of the proteins as targeted cancer therapeutics for MSLN-expressing tumors, and 
the engineered proteins enhanced cancer cell sensitivity to chemotherapy.  Towards the 
goal of using engineered Fn3 variants for targeted drug delivery applications, in 
collaboration with our collaborators, we synthesized and validated a novel protein-polymer 
conjugate drug delivery system.  Finally, I established and validated appropriate in vivo 
tumor models to evaluate our engineered proteins as molecular imaging diagnostic agents.  
 My work has provided a candidate set of engineered proteins that can be used as 
molecular targeted therapeutics, drug-delivery vehicles, and molecular imaging diagnostics 
for MSLN-positive tumors, towards the ultimate goal of providing targeted treatment and 
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1.1 Overview of Cancer 
 Cancer is a global health concern and is expected to rank as the leading cause of 
death, and the most important obstacle to increasing life expectancy worldwide, in the 21st 
century [1].  Global cancer incidence and mortality rates are increasing and reflect the 
growth and aging of the population, and changes in the prevalence and distribution of 
established risk factors, many of which are associated with socioeconomic development 
[2].  There were an estimated 18.1 million new cancer diagnoses and 9.6 million cancer 
deaths worldwide in 2018 [3].  While cancer mortality rates in the U.S have continuously 
decreased since 1991, cancer remains the second leading cause of death and 1.8 million 
new diagnoses and over 600,000 cancer deaths are expected in 2020 (Figure 1.1) [4].    
 
1.1.1 Motivation for developing targeted cancer therapeutics 
 For the majority of patients suffering from a malignant disease, intravenous 
chemotherapeutics remain an integral component of their treatment regimen.  These 
ubiquitous, cytotoxic agents eradicate cancer cells by targeting rapidly dividing cells 
through interruption of essential cell cycle events, such as DNA replication and cellular 
division (Figure 1.2) [5].  These traditional chemotherapeutics, however, are limited by 
narrow therapeutic windows due to severe toxicities from indiscriminately targeting 
rapidly dividing healthy cells, and are frequently associated with acquired resistance, both 
of which represent key clinical challenges (Figure 1.3) [6].  There is a critical need to 
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develop targeted cancer therapeutics which specifically target tumor cells by inhibiting 
molecules or molecular pathways essential for tumor growth and maintenance [6–9].  
 Improved understanding about the specific molecular drivers of cancers and their 
growth mechanisms has drastically changed treatment criteria and standards.  As opposed 
to the once heavily pursued “silver bullet” drug that could be used for all patient 
populations, cancer care has been revolutionized by the implementation of “precision 
medicine”, in which specific information about an individual person’s tumor is used to 
guide treatment plans, monitor the effectiveness of treatments, and make prognoses [10].  
Targeted therapies have made significant contributions towards more personalized 
medicine, and have resulted in increased treatment efficacy and reduced toxicities [8].  At 
present, over 100 targeted therapies have been approved for clinical use as treatments for 
a variety of diseases, including malignancies [7].    
 
1.1.1.1 The molecular hallmarks of cancer 
 Normal cells require the production and release of growth-promoting signals that 
govern their entry into, and progression through, a tightly-regulated cell cycle, to 
proliferate in a controlled manner and maintain tissue homeostasis [11].  Old or damaged 
cells undergo programmed cell death, or apoptosis, and are removed and replaced with new 
cells [12].  Cancer cells, however, acquire numerous mutations, or hallmarks, that 
dysregulate these ordered processes, resulting in a survival advantage (Figure 1.4) [13].  
The rapidly expanding repertoire of targeted therapies can be organized according to their 
effects on a particular cancer hallmark; if a hallmark is indeed important for a tumor, then 
its inhibition should impair the growth and progression of that tumor [14].  
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 These survival advantages include the overexpression of cell surface receptors 
which are subsequently stimulated by different growth factors to promote progression 
through the cell cycle (Figure 1.5A).  One of the first targeted cancer therapies, Tamoxifen, 
was approved in the 1970’s and provided an effective treatment option for estrogen 
receptor (ER)-positive breast cancer patients [15].  Tamoxifen binds to ER, thereby 
preventing estrogen from binding, and inhibits cell proliferation signaling propagated by 
ER.  Another example of a growth factor inhibitor Trastuzumab, was approved in 1998 to 
similarly target the overexpression of the human epidermal growth factor receptor 2 
(HER2) [16].   
 In addition to sustained proliferative signaling, evasion of growth suppressors, and 
resistance to cell death, other cancer hallmarks include replicative immortality, invasion 
and metastasis (the spread of cancer cells throughout the body), metabolic reprogramming, 
and angiogenesis (the formation of new blood vessels) [14].  Towards the goal of inhibiting 
angiogenesis and a cancer’s ability to acquire necessary nutrients, Bevacizumab was 
developed as a leading clinical therapy and targets vascular endothelial growth factor 
(VEGF) (Figure 1.5B) [17,18].  Finally, one of the newest types of targeted therapy 
incorporated into the clinic includes immunotherapies, designed to inhibit a tumor’s ability 
to evade our immune system.  A central role of the immune system is to distinguish 
between normal or “self” cells from those seen as “foreign”, and to attack only the foreign 
cells [19].  To distinguish self from foreign, immune cells, such as T cells, rely on their 
checkpoint molecules; cell surface proteins that need to be activated (or inactivated) to 
mount an immune response.  One checkpoint protein in particular, PD-1, is commonly 
expressed on T cells and when engaged with its ligand, PD-L1, maintains the T cells in an 
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“off” state.  Cancer cells often overexpress the PD-L1 ligand on their surfaces to keep T 
cells turned off, and efficiently avoid being attacked.  Therapies that target either PD-1 or 
PD-L1, known as checkpoint inhibitors, help activate T cells and enhance the immune 
response against cancer cells (Figure 1.5C) [20].    
 
1.1.1.2 Targeted drug delivery systems 
 Cancer therapies are often associated with unfavorable pharmacokinetics, poor 
targeting of cancer cells, and several physiological and chemical limitations that ultimately 
decrease their therapeutic efficacy.  Specific targeting of cancer therapies to tumor cells 
using a targeted drug delivery system could address these limitations currently caused by 
the systemic distribution of drugs in the body [21,22].  Furthermore, delivery vehicles have 
also been shown to increase drug solubility, protect against degradation and elimination, 
and decrease toxicity [21].  
 Receptor mediated endocytosis is a promising approach being developed to use 
native transport pathways to shuttle diverse therapeutic molecules into cells [23,24].  To 
deliver therapeutics with receptor targeting, a drug is shuttled through a native protein 
trafficking pathway as the cargo of a molecule that engages with the cell surface protein. 
Therefore, a successful targeted drug delivery complex requires a targeting domain that 
binds the trafficking receptor and is then internalized, a therapeutic entity, and some 
approach to link the targeting domain to the drug (Figure 1.6).  Protein-polymer conjugate 
systems are already routinely used in the clinic in the form of protein therapeutics 
conjugated to polyethylene glycol (PEG) and offer a system that can be easily tailored for 
targeted drug delivery to a variety of disease-specific cell types.  
 
 5 
1.1.2 The need for companion diagnostics 
 Targeted therapy is only effective when a patient's tumor expresses the specific 
molecular target; therefore, companion diagnostics, including molecular imaging agents, 
which can be used non-invasively, are a necessary component for developing targeted 
therapies.  The rapid development of these companion diagnostics can also be used to 
efficiently evaluate novel drugs, stratify patients based on expected responses or side 
effects, and monitor patient responses to therapy [25,26].   
 Moving a candidate therapeutic through the process from idea to clinical use is 
expensive and time consuming, with many opportunities for failure.  A recent study 
concluded that developing an approved therapeutic is currently estimated to cost $2.6 
billion, and while the average time to complete clinical trials has decreased, the rate of 
success has also decreased to just 12% [27].  A companion diagnostic may improve the 
economics of the drug development process by identifying the appropriate patients for each 
clinical trial, thereby reducing costs and shortening the time to approval [28].  Using the 
same targeting molecule for multiple purposes, such as for both diagnosis and treatment, 
is also highly desirable and economically advantageous.  
 There is also increased confidence that a patient will respond to a drug when using 
a companion diagnostic because it will directly identify the patients that have the exact 
molecule and binding site that a drug is targeting.  A companion diagnostic can also be 
selective; it can rule out those patients who either will not benefit, or may experience 
negative side effects, from a specific therapeutic (Figure 1.7) [9,28,29].  Further, with a 
companion diagnostic, the molecular-level response of the patient to the therapy can be 
monitored, providing earlier data on whether a treatment regimen is working compared to 
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traditional endpoints such as macroscale tumor regression.  For example, a  positive 
response can be indicated by a significant change in the level of the molecular target 
following therapy, while no change in the molecular target may imply the drug has had no 
effect on the cancer cells [29].  
 Towards the goal of delivering the right therapy to the right patient at the right time, 
the first U.S Food and Drug Administration (FDA) approval of co-developing a therapeutic 
and a companion diagnostic was Trastuzumab and HercepTest.  As previously discussed, 
Trastuzumab is an approved therapy used to treat HER2-overexpressing breast cancers.  
HercepTest is a semi-quantitative immunohistochemistry (IHC)-based test used to 
determine the expression level of the HER2 biomarker on patients’ tumors [25].  Currently, 
the majority of in vitro laboratory diagnostics are similarly restricted to tissue samples that 
can be obtained for analysis, severely limiting the predictive value of these diagnostics 
[30].  A biopsy sample from a primary tumor, for example, does not provide any 
information regarding tumor metastasis or recurrence, both of which may influence a 
particular treatment regimen.  Further, a biopsy of a single site of a tumor may not be 
representative of the entire burden of disease because patients, especially those with 
advanced disease, may demonstrate tumor heterogeneity [31].  Varied target expression, 
either within a single tumor or between tumors, can lead to incomplete therapeutic 
response. While blood samples can provide some complementary insight into disease 
progression, normal blood values cannot always exclude the presence of disease, cannot 
differentiate between localized and diffuse tumor recurrence, and provide no spatial 




1.1.3 Role of molecular imaging in cancer 
 Molecular imaging is the visualization, characterization and measurement of 
biological processes at the molecular and cellular levels in living subjects, and plays a 
central role in clinical oncology [33,34].  While conventional anatomic imaging platforms, 
including computed tomography (CT) and magnetic resonance imaging (MRI), provide 
high resolution details regarding tumor location, size, and morphology, they provide little 
information about tumor physiology [35].  Conversely, molecular imaging modalities, 
including positron emission tomography (PET), can provide important insight into a 
tumor’s biological function.  For example, because cancer cells heavily rely on aerobic 
glycolysis (“the Warburg effect”) to generate the energy needed for cellular processes, a 
glucose-analog PET tracer, fluorodeoxyglucose (FDG), can be used to detect aberrant 
metabolic activity (Figure 1.8).  PET, therefore, can offer several advantages over anatomic 
imaging modalities, and frequently distinguishes benign and malignant lesions when CT 
and MRI cannot.  Indeed, the average sensitivity and specificity of FDG-PET across all 
oncology applications have been estimated at 93% and 96%, respectively [36].  
Unfortunately, despite its high sensitivity and specificity, PET alone is limited by its low 
spatial resolution.  Accordingly, the introduction of multi-modality imaging platforms, 
such as PET/CT, have revolutionized cancer imaging by integrating the benefits of imaging 
both tumor biology and anatomic structures (Figure 1.9) [37,38]. 
 
1.1.3.1 Cost-effectiveness of PET/CT 
 With its need for high-end equipment (PET/CT systems can range in price from 
$2.5 to $3.0 million), radiotracer production, and operational costs, PET/CT scans are 
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expensive procedures.  Of the $32.1 billion total Medicare cancer expenditures, imaging 
accounted for approximately 4.6% of those costs; 1% of which was incurred from PET/CT 
[36,39].  Individual costs, however, do not necessarily reflect the cost-effectiveness of a 
diagnostic test.  PET/CT use continues to increase at stable rates for all cancer types, and 
in 2019, an estimated 2.86 million PET/CT scans, a 7% increase from the previous year, 
were performed in the U.S.  This is because PET/CT has been determined to improve 
patient management across a variety of cancers, which subsequently reduces downstream 
costs associated with incorrect management decisions [36,37,40–44].  In one study, the 
National Oncologic PET Registry (NOPR) determined that the results from PET/CT scans 
changed patient management in 49.3% of the study’s patients.  These patient management 
changes included switching to a different therapy (26.5%), adjusting the dose or duration 
of a therapy (16.6%), or switching to observation or supportive care (6.2%).  These studies 
are not without limitations, however, and only discussed intended changes in patient 
management; no data on how frequently physicians carried out these changes were 
provided.  Further, it is unknown whether any changes in management led to better clinical 
outcomes.  
 Additionally, molecular imaging is routinely used in later stages of drug 
development to select patients that are most likely to benefit from a potential treatment.  
For example, the ZEPHIR clinical trial (NCT01565200) determined the predictive value 
of a pretreatment with a Trastuzumab PET agent, a HER2-targeting molecule, in metastatic 
breast cancer patients before treatment with the corresponding treatment TDM-1.  TDM-1 
is an effective but expensive therapeutic, and the PET imaging was able to both measure 
HER2 expression for the entire disease burden, and identified non-responding patients. 
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1.1.3.2 PET/CT has expanded capabilities  
 There is tremendous incentive for detecting cancer at its earliest stages, and 
PET/CT imaging allows sensitive and specific monitoring of key molecular events 
associated with early carcinogenesis [45–47].  While molecular imaging is unlikely to 
replace biopsies in the initial assessment of target expression, imaging should be used to 
complement such biopsies because of its ability to better assess tumor heterogeneity.  In 
one study evaluating PD-L1 expression on tumors [48], PET/CT imaging demonstrated 
that while tracer uptake was generally high in tumors, it was also heterogeneous, often 
varying among lesions, patients and tumor types.  Further, the authors concluded that 
patient responses were better correlated with the imaging studies than with IHC- or 
sequencing-based studies.  
 PET/CT imaging can evaluate and inform treatment regimens in real time because 
its non-invasive nature allows for repeat assessments while avoiding the risk of 
complications associated with serial biopsies [29].  Finally, molecular processes affected 
early after therapy initiation, including tumor cell proliferation and angiogenesis, can be 
quantified by molecular imaging before traditional end points, such as tumor growth or 
shrinkage are observed by traditional anatomically-based imaging [29,49].  For example, 
for a patient undergoing chemotherapy, anatomical changes in tumor size that can be 
observed by MRI or CT frequently occur over the time scale of weeks to months.  
 
1.2 Mesothelin is a novel tumor biomarker 
 Mesothelin (MSLN) is a cell surface protein originally identified using the K1 
monoclonal antibody (mAb) generated by immunization of mice with the OVCAR-3 cells, 
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a human ovarian carcinoma cell line [50,51].  Since its discovery, MSLN has been shown 
to be overexpressed in many ovarian [50,52–56], breast [57–62], pancreatic [63–66], liver 
[67–69] and lung tumors [70–73], among others [74] (Figure 1.10).  MSLN expression is 
limited in normal tissue, with only low levels expressed on mesothelial cells lining the 
pleura, peritoneum, and pericardium [75].  The normal developmental role of MSLN 
remains unclear.  Mice with an inactivated MSLN gene display no distinguishable 
phenotype, and both male and female mice lacking MSLN are able to produce offspring 
normally, suggesting MSLN is non-essential for growth and reproduction [76].  
 
1.2.1 MSLN structure and regulation 
 The MSLN gene (chromosomal location 16p21) encodes a 69-kDa precursor 
protein which is proteolytically cleaved by furin into the 40-kDa, 
glycosylphosphatidylinositol (GPI)-linked, membrane-bound MSLN, and a 31-kDa shed 
fragment called megakaryocyte-potentiating factor (MPF) which is released from the cell 
(Figure 1.11) [50].  A soluble form of MSLN, suspected to result from cleavage of the GPI 
anchor, has also been detected in the serum and pleural effusions of mesothelioma patients, 
and the serum and ascites of ovarian carcinoma patients [77].  While several prediction 
programs have recently attempted to determine the three-dimensional structure of both the 
precursor and mature MSLN, the structure remains unknown [78].   
 At the epigenetic level, hypomethylation of CpG sites in promoters typically 
increases gene transcription, whereas hypermethylation is associated with transcriptional 
silencing [79].  Indeed, in pancreatic cancers, hypomethylation of the MSLN promoter 
correlates with increased expression and transcription, and MSLN-negative pancreatic cell 
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lines treated with demethylating agents is sufficient to induce MSLN expression [80].  In 
ovarian, endometrial, and mesotheliomas, however, while the MSLN promoter was 
hypomethylated, MSLN expression was not associated with the methylation status of the 
promoter [81].   
 Transcription of the MSLN gene is driven by a promoter, CanScript, located 
upstream from the transcriptional start site [82].  The cancer-specific upregulation of 
MSLN in several cancers has been attributed to binding of a transcription factors, TEF-1 
and YAP1, to MCAT and SP1-like motifs within CanScript, respectively [82–84].  These 
transcription factors, however, were determined to be necessary but not sufficient to induce 
MSLN expression, suggesting the existence of other unknown cofactors.  
 Finally, at the post transcriptional level, microRNA-198 (miR-198) is known to 
regulate MSLN expression.  Loss of miR-198 leads to upregulation of MSLN and is 
correlated with poor survival, whereas its reconstitution reduces tumor growth and 
metastasis and is correlated with increased survival [85].  
 
1.2.2 The MSLN-MUC16 binding interface 
 The extracellular portion of MSLN binds tumor biomarker MUC16, also known as 
CA125 (cancer antigen 125).  A 64 amino acid region of MSLN (residues 296-359) has 
been identified as the minimal domain responsible for binding MUC16 with a KD = 3.35 
nM [86].  MUC16, a member of the human mucin family, is a large (2500 – 5000 kDa), 
membrane-associated protein expressed in mucous membranes of several tissues, including 
the upper respiratory tract and reproductive organs, and functions as a lubricant for these 
epithelial luminal surfaces [87].  MUC16 domains are heavily glycosylated, with both O- 
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and N-linked oligosaccharides [88].  The N-linked glycans are responsible for the high 
affinity binding to MSLN as treatment with peptide-N-glycosidase (PNGaseF), which 
removes the N-linked glycans, has been shown to inhibit MSLN-MUC16 binding [55].  
 The interaction between MUC16 and MSLN has been shown to facilitate both 
homotypic and heterotypic cell adhesions, leading to increased tumor progression and 
metastasis.  This interaction is especially prominent in ovarian cancer metastasis in which 
ovarian cancer cells, which express both MSLN and MUC16, are uniquely shed from the 
primary tumor and disseminate throughout the peritoneal cavity, which is lined by MSLN-
expressing mesothelial cells (Figure 1.12).   
 
1.2.3 Signaling pathways influenced by MSLN 
 Several mechanisms suggest MSLN aids in cancer progression by promoting 
cancer cell survival and proliferation (Figure 1.13) [53,65,89–92].  Interleukin-6 (IL-6) is 
a pro-inflammatory cytokine implicated in cancer cell survival, and overexpression of 
MSLN leads to high IL-6 production by NF-κB activation.  High IL-6 levels result in higher 
expression levels of the cyclin E/cyclin-dependent kinase (CDK2) complex, thereby 
speeding the G1-S cell cycle transition [65,91].  In one study of pancreatic cancer, the 
overexpression of MSLN was found to significantly increase cancer cell proliferation and 
migration and resulted in larger tumors forming in mouse models, while silencing MSLN 
led to decreased proliferation and slower entry into S phase [90,91].  In models of 
malignant mesothelioma, MSLN-silencing by siRNA was shown to decrease the 
proliferation rate and reduce the invasive capacity and sphere formation in MSLN-
overexpressing cell lines.  
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 More recently, MSLN has been shown to contribute to epithelial-to-mesenchymal 
transition (EMT) and control cancer stem cell (CSC) properties in a variety of cancers 
(Figure 1.14) [70].  While EMT is traditionally an important developmental process by 
which epithelial cells acquire more mesenchymal and, therefore, motile characteristics, 
accumulating evidence suggests an important role for EMT events in malignant 
transformation and cancer progression [93,94].  MSLN overexpression upregulates both 
mesenchymal and CSC regulatory genes which are known to promote self-renewal, 
anchorage-independent growth, migration and invasion.  
 Finally, MSLN expression may also aid in cancer cell survival by conferring 
resistance to certain chemotherapy drugs, including paclitaxel [95] and TNF-α [65].  
MSLN signaling via PI3K/Akt or MAPK/ERK activation, in addition to NF-κB signaling, 
is known to inhibit production of pro-apoptotic factors such as Bad, Bax and Bim, while 
promoting the expression of anti-apoptotic genes, including Mcl-1, Bcl-xl and Bcl-2.  
Additionally, when MSLN-siRNA was combined with cisplatin, a common 
chemotherapeutic, there was a significant increase in apoptosis, compared to cells treated 
with each therapy alone, suggesting inhibiting MSLN further sensitizes cancer cells to 
chemotherapy [65]. 
 
1.2.4 MSLN-targeting therapies currently in development 
 MSLN has broad potential as a novel tumor target because of its differential 
expression pattern and its strong humoral and adaptive immunogenicity (Figure 1.15) 
[75,90].  Pancreatic cancer patients vaccinated with granulocyte-macrophage colony-
stimulating factor (GM-CSF) were shown to generate dose-dependent antitumor immune 
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responses against autologous tumors and strong MSLN-specific CD8+ T cell responses 
[96].  Mesothelioma and ovarian cancer patients were shown to have elevated levels of 
MSLN-specific antibodies compared to normal control populations [97]. The observed 
immunogenicity of MSLN is associated with its high expression on the tumor cell surface, 
as more than half of patients with MSLN-positive immunostaining had MSLN-specific 
antibodies while less than 10% of patients with negative staining had MSLN-specific 
antibodies [97].  This association was further confirmed when only 2 of 50 (4%) patients 
with pharynx/larynx squamous cell carcinoma, a malignancy with very low MSLN 
expression, were shown to develop IgG antibodies against MSLN [98].  Additionally, 
antigen-targeted immune responses are implicated in the survival of cancer patients.  
MSLN-specific, T cell-directed immune responses were shown to correlate with extended 
survival of patients with brain metastasis arising from various primary solid tumors, 
including melanoma and lung and ovarian cancers [99]. 
 
1.2.4.1 Monoclonal Antibody (MORAb-009)  
 One of the first therapies developed against MSLN was MORAb-009, a high-
affinity chimeric mAb capable of killing MSLN-expressing cell lines via antibody-
dependent cell cytotoxicity (ADCC) and inhibiting the MSLN-MUC16 binding interface 
[100,101].  In vivo, MORAb-009 demonstrated only modest anti-tumor activity against 
MSLN tumor xenografts, which was markedly increased when used in combination with 
chemotherapeutic agents.  The safety and tolerability profile of MORAb-009 was 
determined in a Phase I trial [102] before initiation of Phase 2 trials with mesothelioma 
(NCT00738582) [103] and pancreatic cancer (NCT00570713) [104] patients.   
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 Because chimeric antibodies have limited use due to the increased likelihood of 
immunogenicity, fully human antibodies, m912 and HN1, were developed [105,106].  Both 
antibodies bind MSLN with high affinity and specificity while conferring cell death by 
ADCC, and are capable of preventing MSLN binding to MUC16.   
 
1.2.4.2 Recombinant Immunotoxin (SS1P) 
 Recombinant immunotoxins (RIT) are proteins composed of a tumor-targeting 
antibody domain fused to a bacterial toxin [107,108].  Pseudomonas exotoxin A, derived 
from Pseudomonas aeruginosa, inhibits protein synthesis and induces cell death via 
apoptosis.  The engineered antibody domain specifically targets the immunotoxin to tumor 
cells, and once internalized, the molecule is degraded and the toxin is released [107].  
 SS1P is a 63-kDa RIT targeted against MSLN-expressing tumors.  When tested in 
a Phase 1 clinical trial (NCT00006981), which included patients with advanced MSLN-
expressing malignancies (mesothelioma, ovarian, pancreatic, lung), SS1P demonstrated a 
favorable safety profile. Unfortunately, efficacy of the single agent was significantly 
limited because majority of patients developed neutralizing antibodies against the PE toxin 
after just one round of therapy [109].  More recently, SS1P has been evaluated in 
combination with a lymphocyte-depleting agent (NCT01362790), and patients with 
chemotherapy refractory mesothelioma were shown to develop major responses and 
required no subsequent therapy for more than 20 months [110].  
 To make the RIT less immunogenic and prevent the development of neutralizing 
antibodies, a variety of mutations were introduced into the toxin to remove all human B-
cell epitopes.  RG7787 was developed incorporating this new generation toxin, and was 
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shown to have similar stability and in vitro activity, while reacting less with human anti-
sera [111].  RG7787 has been clinically tested in a variety of MSLN-expressing cancers 
including triple negative breast, [112], pancreatic [113], lung [114], and ovarian [115]. 
 
1.2.4.3 Therapeutic cancer vaccine (LRS-207) 
 The presence of MSLN-specific antibodies in a significant number of patients with 
MSLN-expressing cancers supports the development of a therapeutic cancer vaccine.  
Unlike prophylactic vaccines which are administered to prevent the onset of a disease, 
therapeutic vaccines are designed to strengthen a patient’s immune response to eradicate 
existing cancer cells [116].  CRS-207 is a bacterium-based vaccine developed using a live, 
attenuated Listeria monocytogenes strain engineered to express MSLN [117,118]. 
Preclinical studies demonstrated the ability of CRS-207 to stimulate the innate immune 
system and induce MSLN-specific cellular responses in mice and cynomolgus monkeys, 
and exhibited therapeutic efficacy in tumor-bearing mice [118].  While vaccination with 
CRS-207 extended the survival of pancreatic cancer patients with minimal toxicity in a 
Phase 2a clinical trial (NCT01417000) [119], a following Phase 2b trial (NCT02004262) 
did not meet the primary endpoint of improvement in overall survival for patients with 
metastatic pancreatic cancer who had received at least two prior treatments [120].   
 
1.2.4.4 Antibody-Drug Conjugate (BAY-94-9343) 
 An antibody-drug conjugate (ADC) is comprised of a targeting antibody, a stable 
linker with labile bonds, and a cytotoxic payload [121].  Upon antigen recognition and 
binding, the ADC is internalized and trafficked through endosomal vesicles to the lysosome 
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[122].  The low pH of the lysosome triggers degradation of the antibody and hydrolysis of 
the linker, thereby releasing the drug [123].  Anetumab Ravtasine (BAY 94-9343) 
[124,125] incorporates a human anti-MSLN antibody conjugated to DM4, a tubulin 
polymerase inhibitor, via a disulfide-containing linker.  In vitro studies demonstrated 
specific cytotoxicity of MSLN-expressing cells (IC50 = 0.72 nM), while in vivo studies 
confirmed MSLN-positive tumor growth-inhibition in mice xenograft models.  
Additionally, BAY 94-9343 was shown to induce bystander-killing effect on neighboring 
MSLN-negative cancer cells without affecting non-proliferating cells, a benefit ideal for 
heterogeneous antigen-expressing tumors or when ADC penetration into solid tumor is 
limited [124].  Clinical trials involving patients with a variety of cancers including 
pancreatic [126], ovarian [127], mesothelioma [128], and NSCLC [129] are ongoing.  
  
1.2.4.5 CAR-T Cell  
 Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapeutic approach 
which involves genetically modifying a patient’s T cells to express a tumor-specific CAR 
and promote T-cell function and persistence [74].  Because of its high expression on tumors 
and low expression on normal tissues, MSLN has a favorable safety profile and represents 
an ideal cancer antigen for targeted immunotherapy, and has been targeted by a variety of 
CAR-T cells [130–133].  Thus far, Phase I clinical trials have been completed to evaluate 
the safety and efficacy of CAR-T cells in patients with mesothelioma (NCT01355965), 
pancreatic cancer (NCT01897415), and ovarian cancer (NCT02159716).  Patients with 
chemotherapy-refractory pancreatic cancer experienced no dose-limiting toxicities and 
some disease stabilization with increased progression-free survival was observed [134]. 
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1.3 Overview of protein engineering  
 As life has evolved, the molecular basis of living organisms, including proteins, has 
also undergone distinct diversification.  As a result of that diversification, there is a vast 
number of different protein molecules in nature, each with unique structural and functional 
properties (Table 1.1) [135].  Once we understand how these molecules are structured and 
operate within nature, they can be further developed or engineered for novel applications 
in research, medicine, and biotechnology.  
 
1.3.1 Engineering proteins by directed evolution 
 Directed evolution is a valuable technology for engineering proteins with improved 
or novel characteristics [136]. Directed evolution recapitulates the selection and 
accumulation of desirable mutations that occurs through natural selection over millions of 
years and compresses it into a few weeks or months in the laboratory.  In order to explore 
such vast protein sequence space, large protein diversities must be generated, followed by 
identification and selection of variants with improved or new phenotypes (Figure 1.16) 
[137].  Frequently used methods for the generation of these diverse libraries include genetic 
recombination, site-directed mutagenesis and random mutagenesis [138]. Random 
mutagenesis by error-prone PCR (epPCR) involves using an error-prone, thermostable 
polymerase lacking proofreading ability (Taq polymerase) in combination with unnatural 
nucleotide analogs capable of pairing with multiple canonical nucleotides [139].  Selection 
of mutant proteins of interest is typically carried out in phage, bacteria, or yeast to allow 




1.3.2 Yeast surface display platform for protein engineering 
 Since its initial development [141], yeast surface display (YSD) has been used to 
engineer proteins for enhanced binding affinity, improved specificity, proper folding, and 
stability for a wide range of proteins [143].  Proteins that have been engineered using YSD 
include, but are not limited to, single-chain variable fragments (scFvs) [144], Fab antibody 
fragments [145], single-chain T-cell receptors [146], cytokines [147], epidermal growth 
factor receptor (EGFR) domains [148] and fibronectin type III (FN3) domains [149,150].  
 Within the YSD platform (Figure 1.17), the protein to be engineered is expressed 
as a genetic fusion to the Aga2p mating agglutinin protein.  Aga2p is linked to the Aga1p 
protein by two disulfide bonds, which is covalently linked to the yeast cell wall.  The 
protein of interest is flanked by an N-terminal hemagglutinin (HA) and C-terminal c-myc 
epitope tags, which are used for both expression confirmation of the construct on the yeast 
cell surface and to quantitate expression levels [151].   
 The YSD platform requires two main components: the yeast, EBY100 [141], and 
the plasmid, pCT.  EBY100 lacks the machinery necessary to synthesize the amino acid 
tryptophan and contains the Aga1 gene at high copy number in its genome.  The pCT 
plasmid encodes (1) the TRP1 gene, which is needed for tryptophan synthesis, (2) the 
Aga2p protein fused to the protein of interest, and (3) ampicillin resistance, for plasmid 
production in E. coli [152].  When properly transformed with the pCT plasmid, yeast will 
grow in selective media deficient in tryptophan, whereas untransformed EBY100 will not.  
To induce proper display of the protein of interest, the yeast must be switched from a 
glucose-rich medium, to a galactose-rich medium.  Each yeast cell is capable of expressing 
about 50,000 copies of a single protein variant on its surface [141].  Combinatorial libraries 
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ranging from 107 - 108 transformants are routinely created by homologous recombination, 
and high-throughput screening of yeast-displayed variants allows for the rapid isolation of 
proteins with desired properties.  
 The YSD platform offers unique advantages over other display technologies, such 
as phage display or mRNA display.  First, the presence of the yeast endoplasmic reticulum 
provides a quality control mechanism so that only properly folded proteins are displayed 
on the cell surface.  The use of eukaryotic expression machinery makes YSD specifically 
useful for displaying and engineering proteins that are difficult to produce in other formats 
[152].  The yeast platform is also capable of incorporating post-translational modifications 
such as glycosylation and disulfide bond formation [153]. Secondly, YSD successfully 
incorporates the use of traditional panning methods, including magnetic particle separation.  
A final and chief benefit of YSD is the ability to use dual color fluorescent-activated cell 
sorting (FACS) for quantitative discrimination between protein variants [154].  Because 
FACS simultaneously provides analysis data, it eliminates the need for separate expression 
and analysis steps after each round of sorting, and equilibrium binding constants and 
dissociation rate constants measured by YSD are in quantitative agreement with those 
measured in vitro [155].  Plasmid DNA can be recovered from individual yeast clones, 
providing a link between a protein variant and its DNA sequence which allows amino acid 
mutations to be identified following library screening. 
 
1.3.3 Screening yeast-displayed libraries 
 Protein engineering is heavily dependent on the ability to selectively capture the 
members of the protein library with the desired properties. Different methodologies exist 
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for different display systems to ensure recovery of favorable mutants. Magnetic-activated 
cell sorting (MACS) is a simple and convenient method for screening yeast-displayed 
libraries before using more quantitative sorting methods. MACS efficiently reduces cell 
number and library diversity (expected number of unique sequences in the library) while 
enriching the library for binders to the target of interest in a few rounds of sorting [156].  
Traditionally, bare streptavidin-coated magnetic beads are first used to deplete the library 
of yeast cells that non-specifically bind biotin, and then the beads are incubated with a 
biotinylated target of interest to capture yeast cells displaying clones that bind the target 
antigen. An important limitation of MACS is the high likelihood of binding clone loss, 
which should be compensated for by oversampling of library diversity. In addition to 
oversampling, clonal loss can be minimized through optimization of parameters such as 
density of cell suspension, incubation times and the absence of a magnetic field during 
wash steps [157]. 
 FACS is a type of flow cytometry in which cells are sorted, one cell at a time, based 
on the specific light scattering and fluorescent characteristics of each cell [138].  Measuring 
yeast surface display levels by labeling of either the N- or C-terminal epitope tags allows 
for improved stability, since yeast cell surface expression is correlated with thermal 
stability and expression levels [146].  Moreover, dual color FACS is used for library 
screening, where one fluorescent label is used to detect the c-myc epitope tag to verify full-
length expression, and a second fluorescent label is used to measure the interaction of the 
engineered protein against the binding target of interest (Figure 1.18).  This allows yeast 
expression levels to be normalized with binding affinity so that a yeast cell displaying a 
protein variant with poor expression but high binding affinity can be distinguished from a 
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yeast cell displaying a protein variant with high expression levels but weak binding affinity.  
Therefore, a two-dimensional flow cytometry plot of expression versus binding results in 
a diagonal population of yeast cells that bind the target of interest.  Finally, once library 
screening is complete, titration experiments to determine binding affinity and thermal 
stability can be performed while proteins are still displayed on the yeast surface, 
eliminating the need to solubly express and purify individual clones [144].  Initial sorting 
of large yeast-displayed libraries is limited with FACS due to technical considerations of 
the flow cytometer, which typically sort at 107 to 108 cells per hour [144].  Because it is 
important to oversample the library diversity to ensure binding clone selection, library size 
must usually be reduced by other sorting methods before screening with FACS. 
 
1.4 Overview of the fibronectin scaffold 
 
1.4.1 Rationale for a non-antibody approach 
 Growing understanding of the molecular events responsible for the initiation and 
progression of diseases has enhanced the opportunities to develop novel agents that can 
improve the sensitivity and specificity of diagnosis and treatment.  For over a century, 
mAbs have, almost exclusively, acted as the natural biomolecular scaffold for basic science 
and biomedical applications.  Due to their high affinity and exquisite specificity, low 
immunogenicity (when of mostly human origin), optimal pharmacokinetics, and low 
toxicity profiles due to limited off-target effects, mAbs have contributed to many clinical 
successes [158].  Within the past five years, mAbs have become the best-selling drugs in 
the pharmaceutical market, and are projected to generate $150 billion in revenue by 2025 
 
 23 
[158].  As of December 2019, over 79 therapeutic mAbs have been approved by the US 
FDA, including 30 mAbs for the treatment of cancer (Table 1.2) [159].  
 As research, biotechnology and medical uses have expanded, however, the 
fundamental disadvantages of antibodies for certain applications have become more 
apparent.  Antibodies are large (150 kDa) molecules composed of two different 
polypeptides (light and heavy chain), critical disulfide bonds, and functionally important 
post-translational modifications, including glycosylation (Figure 1.19).  This defined 
structure necessitates complex cloning steps and expensive recombinant production in 
mammalian cells, and can complicate additional manipulation such as for bispecific 
formats, conjugates, or immunotoxins [160].  Further, when considering in vitro 
diagnostics, highly stable engineered proteins may be superior to antibodies, which can be 
susceptible to aggregation or unfolding without proper handling, such as refrigeration 
throughout production and distribution. 
 The therapeutic effects exerted by mAbs are executed by a variety of mechanisms 
(Table 1.3) [161], but are almost exclusively limited to cells bound by antibody (exceptions 
include bystander effects,  as reviewed in [162]).  Therefore, every cell in the target tissue 
(i.e. a tumor), must be targeted to achieve a complete therapeutic response [163].  
Heterogeneous distribution and/or penetration of mAbs can leave subpopulations of cells 
untargeted, significantly reducing the therapeutic efficacy of the mAbs.  Efficient 
penetration and homogeneous distribution can be especially difficult in solid tumors 
because of their abnormal vasculature, high interstitial fluid pressure, and high viscosity of 
the tumor blood supply [164].  The large size of mAbs limits their permeability and 
diffusion, thereby limiting their physiological distribution [161,163,165–168].  
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 Antibodies also demonstrate limited effectiveness as molecular imaging agents.  A 
molecular imaging agent must provide high target to background ratios, meaning it 
accumulates in target tissues while quickly clearing from non-target tissues [169].  
Unfortunately, because of their large size, antibodies surpass the renal clearance threshold 
(70 kDa), increasing their retention time in circulation [160,167].  Antibodies also have a 
prolonged circulation time due to capture and recycling by neonatal Fc binding receptors 
[166].  Because of this slow clearance, tumors can only be visualized several days after the 
mAb injection, and patients can be burdened with significant travel and expenses to 
accommodate the protocol.   
 Based on such limitations, there has been great interest in developing alternative 
protein scaffolds that can be engineered for a variety of functions [170].  These alternative 
scaffolds, including affibodies [171,172], Designed Ankyrin Repeats (“DARPins”) 
[173,174], fibronectins (“Adnectin” and “monobody”) [175,176], knottins [151,177], and 
lipocalins (“Anticalins”) [178] incorporate diverse binding paratopes and conserved 
structural framework in generally small, disulfide-free, stable, single domains capable of 
evolution (Table 1.4) [160,170,179].   
 
1.4.2 The fibronectin scaffold for protein engineering 
 Fibronectins are a family of large glycoproteins with important roles in ECM 
formation and regulation of cellular processes, including adhesion, migration, 
differentiation, and proliferation, through interactions with integrins and non-integrin cell 
surface proteins [180].  Fibronectins consists of many repeats of three types of small 
modules, arranged into several functional and protein-binding domains (Figure 1.20) [180]. 
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 The protein scaffold based on the tenth domain of fibronectin type III (10Fn3, Fn3) 
(also known as a monobody or Adnectin) was first described in 1998 [181].  Since then, 
Fn3 has become one of the most widely used non-antibody scaffold for engineering novel 
binding proteins [175,182]. The Fn3 domain is a small (94 amino acids, ~ 10 kDa), 
monomeric protein consisting of two β-sheets of seven β-strands, all connected by three 
solvent-exposed loops: BC, DE, and FG.  While the Fn3 scaffold lacks sequence homology 
with antibodies, its hydrophobic, β-sandwich structure closely resembles that of 
immunoglobulin (Ig) domains, providing a stable framework structure and high 
thermostability (Tm = 88°C) [183], and its solvent-exposed loops are structurally 
analogous to the Ig’s complementarity-determining regions (CDRs) (Figure 1.21) 
[184,185].  The Fn3 scaffold also contains neither disulfide bonds nor post-translational 
modifications, which allow it to preserve its stability under reducing conditions [149].  
Moreover, the Fn3s can be expressed at high levels in E. coli (50 mg/L) [186], facilitating 
inexpensive production. 
 
1.4.3 Fn3 proteins as molecular imaging agents 
 The small size and high stability of fibronectin proteins have translated into optimal 
pharmacokinetic and biodistribution properties for molecular imaging applications, namely 
high tumor uptake and rapid clearance from non-target tissues.  Fn3 proteins can be evolved 
to bind a variety of cancer biomarkers, the absence of native cysteine or disulfide bonds 




 Fn3 proteins engineered to bind several tumor receptors have shown promise as 
diagnostic molecular imaging agents [160,169,179].  An anti-CD20 molecule engineered 
for PET imaging of B-cell lymphomas has been evaluated in human CD20 tumor-bearing 
mice [187].  Within 4 h following injection, the Fn3 molecules demonstrated high and 
specific accumulation in tumors with low uptake in healthy tissue.  More recently, an anti-
PD-L1 Fn3 molecule was developed and evaluated for PET-CT imaging in human patients 
with lung cancer [188].  The tracer was shown to be safe and its biodistribution was well 
correlated with PD-L1 expression.  Engineered Fn3 molecules have also been used to target 
microbubbles and image VEGFR on tumor neovasculature with ultrasound [189] 
 
1.5 Significance and specific aims 
 While the availability of targeted cancer diagnostics and therapeutics has increased 
in recent years, there are patients who do not currently have effective targeted therapeutic 
options.  As novel tumor biomarkers continue to be identified, it is essential to translate 
their discovery into improved clinical outcomes.  MSLN is a cell surface protein that is 
overexpressed in several cancers with limited expression in healthy tissue.  Increased 
MSLN expression promotes tumor progression, motility, invasion and metastasis in these 
cancers.  The collective data emphasize the importance of MSLN in cancer progression 
and the need for MSLN-targeting agents, but no targeted diagnostics or therapeutics are 
currently FDA-approved.  Addressing this unmet need would have a significant impact and 
on the lives of patients with MSLN-expressing tumors. 
 This dissertation describes work to engineer stable MSLN targeting agents using 
the fibronectin non-antibody protein scaffold for use as targeted therapeutics, for targeted 
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drug delivery applications, and as molecular imaging diagnostics. To achieve the overall 
objective proposed, the following four specific aims were pursued: 
 
Specific Aim 1: Engineer mesothelin-binding Fn3 proteins as tumor targeting agents. 
Directed evolution and yeast surface display were used to engineer high affinity (single-
digit nanomolar dissociation constant) MSLN-binding proteins based on the fibronectin 
protein scaffold (Figure 1.22). We established methods to express and purify soluble 
engineered proteins for further characterization and applications.  
 
Specific Aim 2: Evaluate the therapeutic effects of anti-mesothelin Fn3 proteins.  
Downstream signaling attributed to MSLN expression promotes tumor growth, invasion, 
and metastasis.  In vitro cell proliferation, apoptosis, and caspase-activation assays were 
used to assess the potential of our proteins as targeted cancer therapeutics for MSLN-
expressing tumors. Engineered Fn3 proteins were assessed in combination with 
chemotherapeutic mitomycin C (MMC) to evaluate whether the engineered proteins further 
sensitized cancer cells to chemotherapy.   
 
Specific Aim 3: Develop protein-polymer conjugates for targeted drug delivery 
strategies.  Model protein-polymer conjugates were synthesized using a novel protein-
polymer conjugate system, towards enabling cytotoxic drugs incorporated into the polymer 




Specific Aim 4: Assess diagnostic potential of Fn3 proteins as molecular imaging 
agents. Targeted therapies are only as successful as the ability to identify the appropriate 
patient populations to receive such therapies.  Mouse xenograft models were established 
and validated to evaluate the potential of the anti-MSLN proteins as molecular diagnostic 
agents.   
 
This work will further validate the Fn3 scaffold and provide the foundation for 
development of other targeted diagnostic/therapeutic molecules and protein-polymer 
conjugates for targeted drug delivery strategies. 
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Table 1.1 Classifications of proteins and their functions [190]. 
Function Class of protein Examples Examples of use 





Break down proteins 








Neutralize foreign pathogens 
Immune signaling molecules 
“Self” recognition 













Carry O2 and CO2 in blood 





Transport sugar into cells 




Forms hair and nails 



























Table 1.2 Examples of U.S FDA-approved monoclonal antibodies on the market [158]. 
 
mAb Brand Name Target Indication 
Adalimumab Humira TNFa Rheumatoid 
arthritis 
Bevacizumab Avastin VEGF-A Colorectal cancer 
Brentuximab 
vedotin  
Adcentris CD30 Hodgkin lymphoma 
Cetuximab Erbitux EGFR Colorectal cancer 
Denosumab Xgeva, Prolia RANKL Bone loss 
Dupilumab Dupixent IL-4Ra Atopic dermatitis 
Emicizumab Hemlibra Factor IXa, X Hemophilia A 
Erenumab Aimovig CGRPR Migraine 
prevention 
Guselkumab Tremfya IL-23 p19 Plaque psoriasis 
Omalizumab Xolair IgE Asthma 
Pembrolizumab Keytruda PD-1 Melanoma 
Risankizumab Skyrizi IL23 p19 Plaque psoriasis 
Rituximab MabThera, Rituxan CD20 Non-Hodgkin 
lymphoma 
Secukinumab Cosentryx IL-17a Psoriasis 
Trastuzumab Herceptin HER2 Breast cancer 
Trastuzumab 
emtansine  
Kadcyla HER2 Breast cancer 
Ustekinumab Stelara IL-12/23 Psoriasis 























Table 1.3 Mechanisms of action of antitumor mAbs [161]. 
Class Subclass 
Direct induction of cell death: 
Activation of a death program as 
direct consequence of antibody 
binding 
mAbs inducing non-apoptotic cell death: 
Induction of death mediated by lysosome 




Induction of apoptotic cell death with FcgR-
positive immune cells promoting mAb-
mediated clustering of the TRAIL-R to drive 
apoptotic signaling 
Inhibition of tumor-promoting 
growth or survival signals: 
Quiescence, autophagy or indirect 
cell death due to deprivation of 
growth of survival signals 
Neutralization of tumor-promoting ligands: 
Anti-angiogenic growth factors 
 
Binding to cell surface receptors of co-
receptors: 
Example: Lack of activity of anti-EGFR mAbs 
in the presence of activating KRAS mutations  
Recruitment of FcgR-positive 
immune cells: 
Immune cells expressing FcgRs can 
mediate ADCC or phagocytosis 
 
Complement activation: 
Complement activation may have 
negative effects: infusion toxicity, 
inhibition of ADCC, tumor growth-
promoting effects 
 
Promotion of an adaptive anti-
tumor immune response 
Inhibition of immune suppressive pathways:  
Limited number of patients (typically 10-15%) 
respond. Many responders have immune-
related (“autoimmune-like”) adverse effects 
 
Direct promotion of active antitumor 
immunization: 
Induction of active anti-tumor immunity plays a 











Table 1.4 Examples of non-antibody based alternative protein scaffolds [160].  
 
Scaffold Origin Size Topology PDB Structure 






















EETI (squash seeds) 










storage and transport 
of compounds like 
vitamins and steroids 
20 kDa b-barrel 
 
















Figure 1.1 The ten leading cancer types for the estimated new cancer cases and deaths 
by sex in the US in 2020. Cancer is a global health concern and the second leading cause 
of death in the US.  Prostate, lung and colorectal cancers account for 43% of all cases 
diagnosed in men, with prostate cancer representing more than one in five new diagnoses.  
The three most common cancers in women are breast, lung, and colorectal, with breast 
cancer accounting for 30% of female cancers. Estimates are rounded to the nearest 10. 














Figure 1.2 Mechanisms of traditional chemotherapeutics. Chemotherapeutics target 
rapidly dividing cells by disrupting their cell cycle.  Antimetabolites block the formation 
and/or use of nucleic acids needed for DNA replication, while alkylating agents interfere 
with proper DNA base pairing.  Topoisomerase inhibitors prevent DNA uncoiling and 






















Figure 1.3 Traditional chemotherapy is toxic and ineffective. Chemotherapeutic drugs 
act on rapidly dividing cells, which include normal tissues (hair, gastrointestinal 
epithelium, bone marrow) in addition to cancer cells. This leads to many of the side effects 
associated with chemotherapy, such as hair loss, gastrointestinal distress, and bone marrow 
suppression. Development of chemoresistance is also a persistent problem during the 
treatment of local and disseminated disease. Chemotherapy resistance may be a result of 
an acquired mutation due to continuous drug exposure, or it may be an inherent mutation 





























Figure 1.4 The hallmarks of cancer that promote tumorigenesis. Most cancers acquire 
a set of functional capabilities during their development. The manifestations of these 
essential alterations in cell physiology collectively dictate malignant growth.  (1) 
Sustaining proliferative signaling: cancer cells can stimulate their own growth; (2) invasion 
and metastasis: cancer cells can invade local tissue and spread to distant sites; (3) Evading 
growth suppressors: cancer cells can resist inhibitory signals that would otherwise stop 
their growth; (4) evading immune detection; (5) enable replicative immortality: cancer cells 
can divide indefinitely; (6) tumor-promoting inflammation; (7) induce angiogenesis: 
cancer cells stimulate the growth of blood vessels to acquire nutrients; (8) genomic 
instability: cancer cells generate random mutations, and therefore, genetic diversity that 
can expedite acquisition of hallmarks; (9) Resisting apoptosis: cancer cells evade 
programmed cell death; (10) reprogramming energy metabolism: cancer cells can 
reprogram their glucose metabolism, and therefore their energy production, to better fuel 









Figure 1.5 Targeted therapeutics act on molecules or molecular pathways necessary 
for tumor growth and maintenance. (A) Growth factor receptors, including ER and 
HER2 and (B) angiogenic proteins, such as VEGFR, are heavily explored drug targets. 
New targeted therapies include (C) checkpoint inhibitors, including PD-1/PD/L1 and 
epigenetic modulation. ER, estrogen receptor; HER2, human epidermal growth factor 
receptor; VEGFR, vascular endothelial growth factor receptor; PD-1, programmed cell 
























Figure 1.6 Protein-polymer conjugates as targeted drug delivery vehicles. A 
successfully designed drug delivery complex requires a targeting molecule that binds the 
cancer antigen specifically expressed on the surface of cancer cells, a therapeutic entity 
such as loaded drug molecules, and some approach to link the targeting molecule to the 



























Figure 1.7 Companion diagnostics are critical components of developing targeted 
therapies. Patient populations must be stratified to identify those most likely to benefit, 
those who will experience little to no benefit, or those who may experience adverse effects 
from a particular therapy.  Companion diagnostics, which can include sequencing, cell-
based assays, molecular imaging, and immunological assays, can help deliver the right 




























Figure 1.8 18F-fluorodeoxyglucose (18F-FDG) mechanism of localization is by 
metabolic trapping. 18F-FDG, a glucose analog, is taken up by cells with high rates of 
glycolysis, such as cancer cells.  Phosphorylation of FDG by hexokinase prevents its 
entrance into glycolysis and remains trapped inside the cell. The 2-hydoxyl group in normal 
glucose is required for further glycolysis, but is missing in 18F-FDG which cannot be 

































Figure 1.9 PET/CT scans pinpoint the anatomic location of abnormal metabolism. 
Physiological information obtained by PET, which depicts spatial distribution of metabolic 
activity, can be precisely correlated with anatomical information obtained by CT. (Left) 
Coronal CT image demonstrating organs and bones. (Middle) Coronal PET image 
exhibiting metabolic hyperactivity of mediastinal lymph nodes. Normal biodistribution of 
tracer includes brain, heart, and kidneys. (Right) Coronal PET/CT fused image, showing 





























Figure 1.10 Frequency and distribution pattern of mesothelin in solid malignancies. 
MSLN is expressed in many solid tumors. For most cancers, MSLN expression is 
homogeneously distributed on the cell surface. For stomach and lung cancers, MSLN is 




























Figure 1.11 Schematic of mesothelin protein maturation. MSLN precursor protein is 
synthesized as a 71-kDa polypeptide. The precursor protein has four predicted 
glycosylation sites, a glycosylphosphatidylinositol (GPI) anchor, and a furin cleavage site. 
Cleavage at this site produces membrane-bound MSLN (purple) and secretory 































Figure 1.12 Model for cancer cell implantation and metastasis through MSLN-
MUC16 interaction. MSLN, expressed at low levels on mesothelial cells and high levels 
on tumor cells, binds to tumor biomarker MUC16 on tumor cells. MSLN-MUC16 
interaction mediates homotypic and heterotypic cell adhesion to promote tumor 
progression and metastasis. This interaction is prominent in ovarian cancer metastasis in 
which ovarian cancer cells are uniquely shed from the primary tumor and disseminate 




























Figure 1.13 Molecular role of mesothelin in cancer progression. Overexpression of 
MSLN allows for cancer cell proliferation via NF-κB activation, while aiding in cancer 
cell survival by promoting the expression of anti-apoptotic factors and inhibiting the 





















Figure 1.14 MSLN regulates EMT and cancer stem cell characteristics.  MSLN 
depletion upregulates adhesion molecules such as E-cadherin and caveolin, and 
downregulates mesenchymal and cancer stem cell (CSC) genes that aid in self-renewal, 
proliferation, and metastasis. MSLN depletion, therefore, promotes an epithelial-like 
phenotype.  In contrast, MSLN overexpression upregulates mesenchymal and stem cell 




















Figure 1.15 Mesothelin-targeted therapies currently in development. Several strategies 
have been developed for targeting MSLN on tumors: 1) therapeutic cancer vaccine, 2) 
recombinant immunotoxin, 3) monoclonal antibody, 4) antibody-drug conjugate, 5) CAR 
T cell therapy. GM-CSF, granulocyte-macrophage colony-stimulating factor; GVAX, 
irradiated allogenic cell line-secreting GM-CSF; ADCC, antibody-dependent cell 

















Figure 1.16 Directed evolution mimics natural selection to evolve proteins for novel 
applications. A diverse library of genes is translated into a corresponding library of gene 
products. This library is subjected to iterative rounds of high throughput screening and 
selection (isolating variants with improved or desired properties), replication, and 





























Figure 1.17 Schematic of the yeast surface display platform. (A) Open reading frame 
of the YSD genetic construct. Relevant restriction enzymes are indicated in italics. (G4S)3 
= (Gly4Ser)3 linker. (B) The protein to be engineered (Displayed Protein) is a C-terminal 
fusion to the Aga2p protein and flanked by two epitope tags: an N-terminal hemagglutinin 
(HA) and a C-terminal c-myc. The Aga2p protein forms two disulfide bonds with the 
Aga1p protein, which is covalently anchored to the yeast cell wall. Binding to target protein 
can be measured against a fluorescently labeled target antigen. Reproduced with 



















Figure 1.18 FACS separates a population of cells into sub-populations based on 
fluorescent labeling. Cells are labeled with fluorescent antibodies and laser light excites 
the dye which emits a different wavelength of light that is detected by the light detector. 
Information collected from the light (scatter and fluorescence) determines which cells are 
to be separated and collected, and an electrical charge is applied to the cells. The charged 
cell is deflected left or right by oppositely charged electrodes into sample collection tubes 




























Figure 1.19 The structure of a typical antibody molecule. Antibodies are roughly Y-
shaped molecules constructed from paired heavy and light polypeptide chains. The two 
heavy chains are linked to each other by disulfides bonds at the hinge region, and each 
heavy chain is linked to a light chain by a disulfide bond. The antigen-binding sites are 
located at the tips of each arm. The amino acid sequence of the variable region, located at 
the amino termini of the heavy and light chains, determines the antigenic specificity of the 
























Figure 1.20 The modular structure of fibronectin and its binding domains. Fibronectin 
(FN) is a glycoprotein of the extracellular matrix composed of repeating domains of three 
types of protein modules (I, II, III). FN binds membrane-spanning receptor proteins called 
integrins and extracellular components such as heparin, fibrin, syndecan, and collagen. 
Between type I and type III repeats there is another alternately spliced domain termed 
































Figure 1.21 Comparison of the topology and structures of an immunoglobulin (a, c) 
and the fibronectin scaffold (Fn3) (b, d). The natural physiological function of Fn3, 
integrin binding, is mediated by an RGD tripeptide sequence in the FG loop, and loss of 
this sequence by mutagenesis or library diversification permits production an inert, non-























Figure 1.22 Specific aim 1 design. A naïve yeast surface displayed fibronectin library was 
engineered and matured using directed evolution to isolate Fn3 variant that bind tumor 
biomarker MSLN for use as targeted therapeutics, drug delivery vehicles and molecular 
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2.1 Abstract 
 Mesothelin is a cell surface protein that is overexpressed in numerous cancers, 
including breast, ovarian, lung, liver, and pancreatic tumors. Aberrant expression of 
mesothelin has been shown to promote tumor progression and metastasis through 
interaction with established tumor biomarker CA125.  Therefore, molecules that 
specifically bind to mesothelin have potential therapeutic and diagnostic applications.  
However, no mesothelin-targeting molecules are currently approved for routine clinical 
use.  While antibodies that target mesothelin are in development, some clinical applications 
may require a targeting molecule with an alternative protein fold.  For example, non-
antibody proteins are more suitable for molecular imaging and may facilitate diverse 
chemical conjugation strategies to create drug delivery complexes.  In this work, we 
engineered variants of the fibronectin type III domain (Fn3) non-antibody protein scaffold 
to bind to mesothelin with high affinity, using directed evolution and yeast surface display.  
Lead engineered Fn3 variants were solubly produced and purified from bacterial culture at 
high yield.  Upon specific binding to mesothelin on human cancer cell lines, the engineered 
Fn3 proteins internalized and co-localized to early endosomes.  To our knowledge, this is 
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the first report of non-antibody proteins engineered to bind mesothelin.  The results validate 
that non-antibody proteins can be engineered to bind to tumor biomarker mesothelin, and 
encourage the continued development of engineered variants for applications such as 
targeted diagnostics and therapeutics.   
 
2.2 Introduction 
In recent years, the focus in cancer drug development has shifted from relatively 
non-specific cytotoxic agents, to selective, rationally designed, and mechanism-based 
therapies [1].  Targeted cancer compounds, which are designed to inhibit specific 
molecular targets or molecular pathways critical for tumor growth and maintenance, are 
associated with greater efficacy and fewer side effects compared to traditional 
chemotherapies [2].  Currently, over 75 targeted therapies are approved for clinical use as 
essential treatments for a variety of malignancies [3,4].  For many cancers, however, 
targeted therapeutics are not yet available, and it is imperative to develop targeted therapies 
for patients who do not currently have this treatment option.  Furthermore, it has been 
recognized that a targeted therapy is only effective when a patient’s tumor expresses the 
molecular target; therefore, companion diagnostics, including molecular imaging agents, 
are a critical component for developing targeted therapies [5].  
Mesothelin (MSLN) is a cell surface protein shown to be overexpressed in many 
ovarian [6–8], breast [8–10], pancreatic [11–14], liver [15], and lung [16–18] tumors, 
among others [19], with limited expression in healthy tissues [20].  MSLN has been shown 
to bind with established cell surface tumor marker MUC16, also known as CA125, leading 
to increased tumor cell proliferation and metastasis [8,12,21].  Promising results from 
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ongoing efforts in pre-clinical and clinical trials to target MSLN with antibody and 
antibody derivatives for therapy demonstrate the promise of MSLN-targeting methods 
[16,17,22].  However, no MSLN-targeting agents have thus far received approval from the 
US Food and Drug Administration (FDA).  
Directed evolution by yeast surface display (YSD) has been used extensively in 
protein engineering to improve the molecular recognition, biophysical, and catalytic 
properties of target proteins [23–25].  Directed evolution relies on the generation of mutant 
libraries followed by identification of mutants with improvements in a desired phenotype 
by high-throughput screening and selection.  The YSD platform offers unique advantages 
over other directed evolution display formats, including the ability to incorporate post-
translational modifications such as glycosylation and disulfide bonds, eukaryotic protein 
quality control processes, and compatibility with fluorescent-activated cell sorting (FACS) 
for quantitative discrimination between protein variants.  YSD has been used for a wide 
range of protein classes for a variety of applications, including affinity maturation [26,27], 
improving thermal stability [28], selecting against cell-based targets [29–31], and epitope 
mapping [32,33].  
 While antibodies are widely used for a variety of research and clinical indications, 
non-antibody protein scaffolds are being developed for research, biotechnology, and 
medical applications where the inherent properties of antibodies may be limiting.  For 
example, oncological molecular imaging allows clinicians to non-invasively obtain 
information such as a tumor’s molecular behavior and a patient’s response to treatment 
[34].  An optimal molecular imaging agent should efficiently localize to the tumor, while 
rapidly clearing from non-target tissues and organs [35].  Unfortunately, because of their 
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large size and long clearance half-life, antibodies tend to produce undesirable images with 
high background signals and low contrast [36]. The complex structure of antibodies also 
poses many challenges when developing chemical strategies for conjugating polymers or 
drugs for drug delivery applications, such as in the development of antibody-drug 
conjugates [37].   
Efforts to engineer non-antibody, alternative protein scaffolds for molecular 
recognition have led to binding affinities and specificities once thought to be unique to 
antibodies [38–43]. Here, we report the engineering of MSLN-binding proteins based on 
the non-antibody scaffold Fn3, derived from the tenth domain of human fibronectin type 
III. The hydrophobic core of the immunoglobulin-like fold of Fn3 provides a stable 
framework structure and high thermostability (Tm = 88° C), while the solvent exposed 
loops of Fn3 are amenable to high diversification (Figure 2.1A) [44,45].  The Fn3 scaffold 
has shown great versatility for its ability to be engineered to recognize a variety of targets 
including ubiquitin [44], epidermal growth factor receptor (EGFR) [46], carcinoembryonic 
antigen (CEA) [47], human Fc gamma receptors [46], and Abelson kinase Src homology 2 
(Abl SH2) domain [48]. Further, engineered Fn3 variants have recently been used for 
molecular imaging applications, demonstrating the potential of this scaffold as a molecular 
diagnostic [49,50].  An Fn3 protein that is an antagonist of vascular endothelial growth 
factor receptor 2 (VEGFR-2) has advanced to Phase II clinical trials, demonstrating the 
protein scaffold’s promise as a targeted therapeutic [51,52].   
While engineered Fn3 clones have high affinity for their targets, some engineered 
variants have also exhibited oligomeric states or instability [53,54].  Hackel and colleagues 
demonstrated that an Fn3 YSD library engineered using loop length diversity and recursive 
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mutagenesis could yield highly stable variants that recognized a variety of targets with high 
affinity [55].  Woldring et al. developed a second generation YSD Fn3 library by 
incorporating amino acid distributions that recapitulated binding antigens found in nature, 
which they termed the Gradient 2 (Gr2) library [56] (Figure 2.1B).  The Gr2 library also 
incorporated Fn3 framework mutations that increased variant hydrophilicity towards the 
goal of more desirable in vivo biodistribution for molecular imaging applications [57]. 
Therefore, the Gr2 Fn3 library is as large in diversity as its parent library, and is designed 
to be a higher quality protein library.  The sequence space sampled is biased toward 
sequences that are likely to be more successful for identifying high affinity binding variants 
and for applications in molecular imaging.  
Here, we report the engineering of Fn3 variants that bind with high affinity to the 
MSLN tumor cell surface protein, beginning with the naïve fibronectin YSD Gr2 library.  
The binding interaction of MSLN and MUC16 is facilitated by non-covalent interactions 
between the many carbohydrate chains decorating the surface of MUC16 and a minimal 
binding domain of approximately 64 amino acids on MSLN [58].  Therefore, there is no 
known native polypeptide sequence that recognizes MSLN, necessitating the use of a naïve 
protein library as an initial point for our studies.  To our knowledge, this is the first non-
antibody protein engineered to bind MSLN.  The engineered Fn3 variants were expressed 
and purified at high yields (~10 mg/L) using bacterial culture.  Soluble Fn3 variants 
demonstrated high-affinity binding to tumor cells positive for MSLN expression, and were 
internalized into tumor cells upon binding.  The work described here validates the 
engineered binding proteins for further development as targeted therapeutics and 
companion molecular imaging agents (Figure 2.1C).   
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2.3 Materials and Methods 
 
2.3.1 Reagents and cell lines 
PBSA buffer was composed of phosphate buffered saline (PBS) and 0.1% bovine 
serum albumin (BSA).  Escherichia coli (E. coli) XL1-Blue Supercompetent cells and E. 
coli BL21(DE3) cells were purchased from Agilent Technologies and New England 
Biolabs, respectively.  The Gr2 YSD library (generously provided by B. Hackel, University 
of Minnesota) was grown in selective SD-CAA media containing 20 g/L glucose, 6.7 g/L 
yeast nitrogen base without amino acids, 5 g/L casamino acids, 7.4 g/L citric acid 
monohydrate, 10.4 g/L sodium citrate, pH 4.5.  SG-CAA media for yeast induction 
contained 18 g/L galactose, 2 g/L dextrose, 6.7 g/L yeast nitrogen base without amino 
acids, 5 g/L casamino acids, 5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4×H2O, pH 6.0.  A431/H9 
cells (gift of M. Ho, National Cancer Institute, 2016) [59] were cultured in RPMI-1640 
(Gibco) supplemented with 10% FBS, 1% penicillin-streptomycin and 700 µg/mL 
Geneticin selective antibiotic (G418) (Thermo Fisher).  KB-3-1 cells (gift of M. 
Gottesman, National Cancer Institute, 2016) [60], and MCF-7 cells (ATCC #HTB-22, gift 
of S. Peyton, UMass Amherst, 2017) were cultured in DMEM (Gibco) supplemented with 
10% FBS and 1% penicillin-streptomycin.  
 
2.3.2 Maturation and evolution of mesothelin binders 
The naïve Gr2 library (2.8 x 109 diversity), in which EBY100 yeast cells were 
transformed with the pCT surface display vector encoding for Fn3 variants [56], was sorted 
and affinity matured generally as previously described [61].  Briefly, the induced library 
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was sorted twice by magnetic bead selection with depletion of non-specific binders using 
Dynabeads Biotin Binder magnetic beads (Life Technologies).  This step served as a 
negative selection by depleting yeast that displayed Fn3 binders to bare beads or 
streptavidin.  The negative sort was followed by enrichment of specific binding variants by 
magnetic beads functionalized with biotinylated Fc-tagged recombinant human MSLN 
(Acro Biosystems #MSN-H826x).  The magnetic sorts were followed by a fluorescent-
activated cell sorting (FACS) selection for full-length clones using an antibody against the 
C-terminal c-myc epitope tag (clone 9E10, Life Technologies, 1:50) and a goat anti-mouse 
phycoerythrin (PE) conjugate (Sigma #P9670, 1:25).  Full-length clones were induced and 
incubated with a chicken anti-c-myc antibody (Gallus Immunotech #ACMYC, 1:330) and 
the biotinylated Fc-tagged MSLN.  To increase the sorting stringency, concentrations of 
MSLN were decreased over sorting rounds from 300 nM in the first generation sorting to 
10 nM by the fourth sort of the second generation library.  Cells were washed and incubated 
with a goat anti-chicken Alexa Fluor 647 (AF647) conjugate (Thermo Fisher #A-21449, 
1:250) and either Alexa Fluor 488 (AF488)-conjugated streptavidin (Thermo Fisher 
#S11223, 1:700) to detect the biotin molecules of the biotinylated Fc-tagged MSLN, or a 
goat anti-human IgG Fc FITC conjugate (Thermo Fisher #A18830, 1:500) to detect the 
human Fc domain of the biotinylated Fc-tagged MSLN.  Alternating between the two 
sorting detection methods served to minimize the likelihood of engineering Fn3 variants 
that bound streptavidin.  Cells were washed and double-positive yeast cells were collected 
on a BD BioSciences FACSAria II.   Four iterative rounds of enrichment were performed.  
Plasmid DNA from the enriched library was recovered using a Zymoprep Yeast Plasmid 
Miniprep II kit (Zymo Research) following manufacturer’s protocol, transformed into 
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bacteria, and individual clones were sequenced by standard Sanger DNA sequencing 
methods.  Plasmid DNA was subsequently mutated by error-prone PCR of either the entire 
Fn3 gene or the paratope loops using nucleotide analogues, 8-oxo-2’-deoxyguanosine-5’-
triphosphate (8-oxo-dGTP) (TriLink Biotechnologies) and 2’deoxy-p-nucleoside-5’-
triphosphate (dPTP) (TriLink Biotechnologies) [62].  All error prone PCR reactions were 
conducted using primers previously reported [56].  Reaction components and cycling 
conditions were identical to those previously described [61] with the following exceptions: 
Standard Taq (Mg-free) Reaction Buffer (New England Biolabs) was substituted as the 
reaction buffer and MgCl2 (New England Biolabs, 1.5mM) was added to each reaction.  All 
error prone PCR reactions were conducted as both 10 and 20 cycle reactions to vary the 
extent of mutagenesis.  Mutated plasmid DNA was then amplified and reintroduced into 
yeast by electroporation with homologous recombination [61].   
 
2.3.3 Binding affinity measurements of yeast surface displayed variants 
Plasmids for Fn3 variants 1.4.1 and 2.4.1, as well as wild type Fn3 (Fn3 WT), were 
transformed into EBY100 yeast using the Frozen-EZ Yeast Transformation Kit II (Zymo 
Research) following manufacturer’s protocol.  Yeast were grown in SD-CAA media at 
30°C and induced with SG-CAA media at 20°C with aeration.  Aliquots of 106 yeast cells 
were simultaneously labeled with 9E10 mouse anti-c-myc antibody (1:50) and a range of 
concentrations of either biotinylated MSLN-Fc or biotinylated Fc fragment in a total 
volume of 50 µL PBSA and incubated for 45 minutes with gentle rotation at 23°C.  Cells 
were washed with PBSA and then incubated with a goat anti-mouse PE (1:25) and 
streptavidin-Alexa Fluor 488 (1:700) for 20 min with gentle rotation on ice in a total 
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volume of 25 µL PBSA, protected from light.  Cells were washed with PBSA, pelleted, 
and resuspended in PBSA for analysis on an EMD Millipore Guava easyCyte flow 
cytometer.  Mean fluorescence intensity for MSLN binding was determined for yeast cells 
displaying full length protein using InCyte software (EMD Millipore).  Data was plotted 
and fit with a sigmoidal curve using KaleidaGraph software (Synergy).  Dissociation 
constants (KD) were determined as the half-maximal value of the sigmoidal fit for three 
separate experiments for each protein variant, and the mean and standard deviation for the 
KD values are reported.   
 
2.3.4 Engineered Fn3 protein production and purification 
Engineered Fn3 genes 1.4.1 and 2.4.1 were cloned into the NheI and BamHI sites 
of a pET24b(+) expression vector modified to include a C-terminal His6-KGSGK tag [61] 
(provided by B. Hackel, University of Minnesota) and expressed in BL21(DE3) E. coli.  
Cultures were grown in LB media at 37°C to an optical density at 600 nm of 1.0 before 
induction with 0.5 mM Isopropyl-b-D-thiogalactopyranoside (IPTG).  Fn3 proteins were 
induced for 3 h at 30°C.  Cells were harvested by centrifugation for 15 min at 3,200g, and 
resuspended in lysis buffer (35 mM Na2HPO4×dibasic, 15 mM Na2HPO4×monobasic, 500 
mM NaCl, 5 mM CHAPS, 25 mM imidazole, 5% glycerol) supplemented with protease 
inhibitor (cOmplete, Roche).  Cells were incubated on ice for 30 min, lysed by repeated 
freezing and thawing, then centrifuged at 12,000g for 10 min and passed through a 0.45-
micron filter.  Fn3 proteins were purified by nickel affinity chromatography with Ni-NTA 
agarose resin (Thermo Fisher).  Fn3 variant 1.4.1 was further purified by size exclusion 
chromatography (SEC) on a Superdex 75 10/300 column (GE Healthcare Life Sciences).  
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Fractions of interest were pooled and concentrated with a centrifugal filter unit with a 3 
kDa molecular weight cutoff (EMD Millipore).  Due to likely nonspecific adsorption onto 
our SEC column, Fn3 variant 2.4.1 was alternatively further purified by reversed phase 
high-performance liquid chromatography (HPLC) on a Hypersil ODS C18 column 
(Thermo Fisher) using a linear gradient of 90% acetonitrile in water containing 0.1% 
trifluoroacetic acid.  Fn3 variant 2.4.1 fractions were pooled, lyophilized, and resuspended.  
All protein samples were analyzed by SDS-PAGE on a BioRad ChemiDoc MP imaging 
system using Image Lab 6.0 software (BioRad).   
 
2.3.5 Alexa Fluor-488 dye conjugation  
Pure, folded Fn3 proteins (1 mg/mL) were incubated with  AF488 tetrafluorophenyl 
ester (TFP) (Thermo Fisher) in a 0.1 M sodium bicarbonate solution, pH 8.3, at an 8:1 
dye/protein molar ratio for 1 hr at 23°C with rotation and protected from light.  The 
resulting AF488-labeled 1.4.1 protein was purified by extensive buffer exchange with PBS 
using a 3 kDa centrifugal filter unit.  Because of likely adsorption onto the membrane of 
the centrifugal filter unit, AF488-labeled 2.4.1 protein was purified with an alternative 
method, using fluorescent dye removal columns (Thermo Fisher #22858), according to 
manufacturer’s protocol.  Concentrations and degree of labeling (DOL) were determined 
using UV-Vis spectroscopy, measuring dye absorption at 494 nm (e = 71,000 cm-1 M-1).   
 
2.3.6 Binding affinity measurements of Fn3 protein for MSLN-positive tumor cells   
A431/H9 and MCF-7 cells were cultured to 80% confluency, as described above, 
and detached by 0.25% trypsin-EDTA (Gibco).  Aliquots of 105 cells were washed and 
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pelleted at 200g for 5 min at 4°C.  MSLN expression was detected by a mouse anti-MSLN 
antibody (clone K1, Abcam, 1:50) and a goat anti-mouse PE conjugate (1:25).  Cells were 
incubated with a range of concentrations of AF488-labeled 1.4.1 and 2.4.1 in a total volume 
of 25 µL PBSA for 1 h at 23°C with rotation and protected from light.  Cells were washed 
and pelleted as above, resuspended with ice cold PBSA, and fluorescence was analyzed 
using a Guava easyCyte flow cytometer.  Mean fluorescence intensities for Fn3 variant 
binding were determined using InCyte software.  Data was plotted and fit with a sigmoidal 
curve using KaleidaGraph software.  Dissociation constants (KD) were determined as the 
half-maximal value of the sigmoidal fit for three separate experiments, and the mean and 
standard deviation for the KD are reported.     
 
2.3.7 Imaging flow cytometry 
KB-3-1, A431/H9, and MCF-7 cells were cultured and harvested as described 
above.  Aliquots of 2.5 x 106 cells were washed, pelleted, and incubated with AF488-
labeled 1.4.1 or 2.4.1 (1 µM) in a total volume of 25 µL for 1 hr at either 23°C or 37°C 
with rotation and protected from light.  Cells were washed with ice cold PBSA and pelleted 
as above.  Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 15 min at 23°C 
followed by permeabilization with 0.2% Tween 20 in PBS (PBST) for 20 min at 23°C.  
Cells were washed twice and pelleted then incubated with an AF647-conjugated rabbit 
anti-EEA1 antibody (Abcam #196186, 1:50) in a total volume of 50 µL PBST for 30 min 
at 23°C with rotation and protected from light.  EEA1 is an early endosomal marker.  Cells 
were washed, pelleted, and resuspended in 100 µL PBSA.  Images were acquired on an 
Amnis ImageStream X Mark II (EMD Millipore) with a 40X magnification.  Collected 
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data (5000 images) were analyzed with IDEAS 6.2 software (EMD Millipore).  A 
compensation matrix was created using single color controls acquired with the brightfield 
laser turned off.  Cells were gated for focused cells with the Gradient RMS feature and for 
single cells with the area and aspect ratio.  Co-localization quantification was determined 




2.4.1 MSLN-binding Fn3 proteins engineered using yeast surface display and directed 
evolution 
Yeast surface display has been previously shown to be a robust method for 
engineering proteins with improved biophysical, catalytic, and molecular recognition 
properties [23–25,63].  To engineer MSLN-binding proteins, a naïve Gr2 YSD library of 
2.8 x 109 variants was screened.  Fn3 expression levels were monitored using an antibody 
to the terminal c-myc epitope tag.  Following two rounds of MACS and a FACS sort for 
full-length expression to eliminate truncated protein variants, four iterative rounds of dual-
color FACS were performed for binding to MSLN normalized by full length protein 
expression.  An enriched population of variants was isolated that demonstrated selective 
affinity to MSLN, compared to no visible binding in the unsorted naïve library (Figure 
2.2).  This enriched population of Fn3 variants was then subjected to a single round of 
mutagenesis and transformed back into yeast for further enrichment and selection as a 
second generation library.  An enriching population of yeast cells displaying full length 
protein that bound MSLN was observed throughout rounds of sorting (Figure 2.2).   We 
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note that our initial efforts to engineer Fn3 variants to bind to a small, 64-amino acid 
domain of MSLN responsible for binding to MUC16 and using an earlier variation of the 
Fn3 library were unsuccessful, resulting only in variants that bound to the streptavidin 
secondary reagent and no engineered variants that bound to the MSLN minimal binding 
domain. To overcome this challenge, we changed our target reagent from this small domain 
of MSLN to a full-length extracellular domain of MSLN to provide additional surface 
topology that Fn3 variants could interact with, and alternated sorting detection methods to 
only use streptavidin as a reagent in some sort rounds, thereby limiting the likelihood of 
engineering streptavidin binders.   
From E. coli transformed with plasmids obtained from the engineered first and 
second generation libraries of enriched MSLN-binding Fn3 variants, 30 independent 
clones from each generation were randomly chosen and sequenced.  Following four rounds 
of dual-color FACS sorting of the first generation library, there were 10 unique sequences.  
Of those sequences, one unique clone dominated, representing 18 of the 30 clones 
sequenced, which we refer to as clone 1.4.1, denoting the first generation library, with four 
rounds of sorting by FACS, clone number one.  Following four rounds of sorting of the 
second generation library, a second unique clone, variant 2.4.1, emerged.   Fn3 variants 
1.4.1 and 2.4.1 differ only by their FG loop and incorporate a single K63N framework 
mutation compared to the library wildtype framework sequence (Figure 2.3A).  Plasmids 
for all unique clones were transformed back into EBY100 yeast and their specific binding 
to 200 nM MSLN was assessed by flow cytometry.  Clones 1.4.1 and 2.4.1 had 
substantially greater binding to MSLN compared to all other variants, and were 
subsequently selected for further study.  
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To measure the binding affinity of these two clones for soluble MSLN extracellular 
domain, titration binding assays with the Fn3 variants expressed on the surface of yeast 
were performed (Figure 2.3B).  Clone 1.4.1 exhibited a binding affinity of KD= 700 ± 300 
nM, and clone 2.4.1 exhibited a binding affinity of KD = 290 ± 40 nM, while Fn3 WT 
displayed no specific binding to MSLN.  Furthermore, clones 1.4.1 and 2.4.1 exhibited no 
binding to a biotinylated, Fc fragment alone, demonstrating their specific binding 
interaction with MSLN (Figure 2.3C).  While further rounds of directed evolution to obtain 
higher affinity clones will be necessary for eventual clinical translation, we sought to 
characterize these two variants to learn more about their interaction with tumor cells 
expressing MSLN, to inform further engineering of Fn3 clones to recognize MSLN.  
 
2.4.2 Engineered Fn3 proteins were recombinantly produced  
 To further develop and characterize engineered Fn3 proteins for future diagnostic 
and therapeutic applications, lead variants were solubly expressed and purified.  Fn3 
variants 1.4.1 and 2.4.1 were expressed in bacteria with a C-terminal hexahistidine tag and 
purified by nickel affinity chromatography and either SEC or HPLC.  Chromatograms 
indicated protein elution at expected retention times for Fn3 variant 1.4.1 on SEC (Figure 
2.4A) and Fn3 variant 2.4.1 on HPLC (Figure 2.4B).  Analysis by SDS-PAGE confirmed 
high purity > 99% for 1.4.1 and 2.4.1 and (Figure 2.4C), with routine yields of ~ 10 mg/L.  
 
2.4.3 Soluble engineered Fn3 variants bound tumor cells expressing MSLN  
 We established a tumor cell binding assay to measure the binding affinities of 
soluble engineered Fn3 variants for MSLN-expressing cancer cells.  The A431/H9 cell line 
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is an A431 (human epidermoid carcinoma) cell line transfected to stably overexpress 
MSLN on its surface [16].  MCF-7 is a human breast cancer cell line reported not to express 
MSLN on its surface [7].  Using an anti-MSLN antibody (clone K1, Abcam), high 
levels of MSLN were confirmed on the surface of A431/H9 cells compared to the MCF-7 
cell line expected to be negative for human MSLN (Figure 2.5A).    
 Direct equilibrium binding titrations of the engineered 1.4.1 and 2.4.1 Fn3 variants 
on the A431/H9 and MCF-7 carcinoma cells were performed (Figure 2.5B).  The Fn3 
variants were directly conjugated to Alexa Fluor 488 and incubated over a range of 
concentrations with cells for 1 h at 23°C and analyzed by flow cytometry.  Equilibrium 
binding constant (KD) values were obtained by fitting plots of AF488-labeled 1.4.1 and 
AF488-labeled 2.4.1 concentrations versus the mean fluorescence intensity.  Consistent 
with the yeast surface display binding data, Fn3 variant 1.4.1 bound to A431/H9 cells with 
a binding affinity of KD = 510 ± 90 nM, while Fn3 variant 2.4.1 bound to A431/H9 cells 
with a binding affinity of KD = 440 ± 30 nM.  Neither Fn3 variant displayed binding to the 
MSLN-negative MCF-7 cell line, with only expected, non-specific binding observed at the 
highest concentrations analyzed.    
 
2.4.4 Fn3 variants co-localized to early endosomes following binding to MSLN  
Future application of an engineered Fn3 variant for drug delivery to cancer cells 
could benefit from the internalization of the targeting molecule upon target binding to 
effectively deliver a conjugated payload into the cells.  Mesothelin has been previously 
reported to efficiently internalize [64–66].  Using imaging flow cytometry, we sought to 
assess whether engineered Fn3 variants 1.4.1 and 2.4.1 could be internalized into cancer 
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cells following binding to surface MSLN.  The KB-3-1 cell line is a human cervical 
carcinoma cell line reported to express MSLN on its surface [67].  Using an anti-MSLN 
antibody (clone K1) and a PE-conjugated secondary antibody, MSLN was confirmed on 
the surface of KB-3-1 cells while no MSLN expression was detected on the surface of the 
MCF-7 cell line (Figure 2.6A, B).   
KB-3-1 cells and MCF-7 cells were incubated with either AF488-labeled 1.4.1 
(Figure 2.6C) or 2.4.1 (Figure 2.6D) at 37°C and then fixed and permeabilized before 
incubation with an AF647-conjugated antibody against the early endosomal marker, EEA1.  
Co-localization of EEA1 antibody and engineered variants was quantified using the Bright 
Detail Similarity (BDS) metric, which uses a modified Pearson’s correlation coefficient to 
quantify the degree of similarity between the AF488-labeled 1.4.1 or 2.4.1 image and the 
AF647-EEA1 endosomal image.  Cells with increased AF488-labeled 1.4.1 or 2.4.1 
trafficking to early endosomes have higher similarity values as a result of greater co-
localization of the two fluorescent channel signals.  Imaging flow cytometry data 
demonstrated that when KB-3-1 cells were incubated with AF488-labeled 1.4.1 (Figure 
2.6C, top) or 2.4.1 (Figure 2.6D, top), the AF488-labeled 1.4.1 and 2.4.1 was internalized 
and co-localized with early endosomes with a BDS = 1.31 and 0.919, respectively, for 5000 
cells.  Further, efficient binding and subsequent internalization is not observed when 
AF488-labeled 1.4.1 (Figure 2.6C, bottom) or 2.4.1 (Figure 2.6D, bottom) is incubated 
with the MSLN-negative MCF-7 cell line.  BDS values were not determined for the 
negative control cell line as this metric requires a substantial population of double positive 
cells, which was not present for the negative control cell line.  In an additional imaging 
flow cytometry study, MSLN was again confirmed on the surface of KB-3-1 and A431/H9 
 
 89 
cells, and AF488-labeled 1.4.1 internalized and co-localized with early endosomes when 
the experiment was conducted at 23°C (Figure 2.7).  
 
2.5 Discussion 
Mesothelin has broad potential as a novel tumor target for both diagnosis and 
therapy, yet no MSLN-targeting molecules are currently FDA approved.  Thus, there 
remains critical need for MSLN-targeting therapeutics and for molecular diagnostics that 
can identify patients who are most likely to respond to such therapies.  In this work, we 
used directed evolution and a yeast surface display library to engineer Fn3 variants that 
bind specifically to MSLN, for future application in diagnosis and therapy.  Variants 1.4.1 
and 2.4.1 demonstrate specific affinity for the MSLN tumor marker present on the surface 
of tumor cells, and, upon MSLN binding, are internalized and co-localize with early 
endosomes.  Internalization could be valuable for delivery of cytotoxic molecules 
conjugated to engineered Fn3 variants into tumor cells.  The work described here validates 
our approach for engineering MSLN-binding variants, using yeast surface displayed Fn3 
libraries and directed evolution.  The results demonstrating specific binding to, and 
internalization into, a tumor cell line encourage further engineering of higher affinity 
variants towards clinical applications.  To our knowledge, this is the first report of a non-
antibody protein engineered to bind MSLN.     
In an initial protein engineering strategy, we sought to engineer Fn3 variants that 
were selected to bind to a 64-amino acid domain of MSLN previously reported to be the 
minimal domain for binding to MUC16 [58].  It was expected that an Fn3 variant that 
targeted this binding domain would likely block MSLN and MUC16 interactions, 
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enhancing therapeutic activity of such Fn3 variants.  MSLN and MUC16 binding has been 
reported to enhance tumor cell proliferation and metastasis [8,12,21].  This initial protein 
engineering strategy did not successfully yield MSLN binding variants, potentially due to 
insufficient binding topography on the 64-amino acid domain, and, instead, resulted in Fn3 
variants that bound the streptavidin secondary reagent.  While we had attempted to prevent 
selecting streptavidin-binding variants by using negative magnetic sorts, this method is not 
always adequate to influence the selection towards the desired interaction with target 
protein. Because naïve libraries are not based on pre-existing binding interactions, such 
libraries display no initial bias toward a specific target molecule or epitope [68]. We were 
ultimately successful in engineering Fn3 variants that bound to our target protein by using 
the full-length extracellular domain of MSLN and by avoiding the use of streptavidin in 
some FACS rounds.  Determining the epitopes on MSLN that the engineered variants bind 
is of interest to further evaluate therapeutic potential of the Fn3 proteins.  
Diagnostic molecular imaging is one promising application for non-antibody 
proteins engineered to bind MSLN positive tumors.  While antibodies can be engineered 
to bind to a variety of targets with high affinities, their large size and slow clearance from 
circulation can often result in low contrast images [69].  Instead, non-antibody scaffolds 
have been explored and have demonstrated promising results in preclinical and clinical 
evaluations [70].  Recently, Fn3 proteins engineered to bind EGFR and EphA2 have been 
shown to identify tumors expressing their respective molecular target in murine molecular 
imaging models [50,71,72].  The cystine-knot, or knottin, protein scaffold has also been 
engineered for tumor targeting applications and has shown promise for molecular imaging 
in pre-clinical studies targeting tumors and tumor vasculature expressing integrins [73–77].  
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Likewise, affibodies and DARPins engineered to bind human epidermal growth factor 2 
(HER2) or EGFR have been used to image tumor xenografts in mice [78–80].  Recently, a 
novel Gp2 scaffold has been developed for molecular imaging of EGFR [81].  In each of 
these studies, the imaging agents were proteins engineered to have picomolar to single-
digit nanomolar dissociation constants for their targets, and the importance of this high 
affinity for tumor targeting applications is further supported by theoretical modeling [82], 
motivating additional rounds of mutagenesis and directed evolution for our engineered 
proteins targeting the novel tumor target MSLN.   
There is also sustained interest around using engineered proteins as drug delivery 
agents, such as by conjugating cytotoxic molecules or polymeric systems to proteins that 
recognize a tumor biomarker [83,84].  Current drug delivery strategies, such as antibody-
drug conjugates (ADCs), take advantage of the specificity of antibodies to selectively 
deliver cytotoxic drugs to antigen-expressing cancer cells [85].  ADCs, including 
AdcentrisÒ (Seattle Genetics) [86] and KadcylaÒ (Genentech)[87], have received FDA 
approval for targeted treatment of relapsed Hodgkin Lymphoma and Her-2 positive breast 
cancer, respectively.  ADCs are comprised of a targeting antibody, a stable linker with acid 
labile bonds, and the cytotoxic payload [88].  Upon antigen recognition and binding, the 
ADC is internalized via receptor-mediated endocytosis and trafficked through endosomal 
vesicles to the lysosome [89].  The low pH of the lysosome will trigger degradation of the 
antibody and hydrolysis of the linker, thereby releasing the drug to exert its cytotoxic effect 
[85].  Dose-limiting toxicities, however, can limit penetration of ADCs into solid tumors, 
whereas small non-antibody scaffolds may be advantageous by efficiently delivering 
cytotoxic payloads deep within a tumor while maintaining rapid clearance from circulation 
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[90].  The observed internalization of the MSLN-targeting Fn3 variant is intriguing toward 
the goal of delivering a payload across the membrane of MSLN-positive tumor cells.  
Further understanding of the trafficking of engineered proteins that bind MSLN will inform 
development of anti-MSLN therapeutic strategies.   
In summary, we demonstrate that the Fn3 protein scaffold is suitable for 
engineering targeting molecules for the underdeveloped tumor target MSLN.  To our 
knowledge, this is the first report of a non-antibody protein engineered to bind MSLN.  Our 
data demonstrating specific binding of the engineered variants to tumor cells positive for 
MSLN, followed by subsequent internalization of the engineered Fn3 proteins, establishes 
the potential for further development of MSLN-targeting Fn3 proteins for a variety of 
clinically relevant applications in diagnosis and therapy.   
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Figure 2.1 Approach to engineering Fn3 proteins to recognize tumor biomarker 
MSLN for diagnostic and therapeutic applications. (A) The tenth domain of human 
fibronectin type III (Fn3) (PDB 1TTG) is a highly stable protein structure with three loops 
(BC, DE, and FG) broadly tolerant of mutation to confer novel binding properties.  
Structure was rendered in PyMOL.  (B) We employed a previously developed hydrophilic 
Fn3 yeast surface display library [56] that incorporates a range of loop lengths and biased 
amino acid composition to mimic the diversity of naturally occurring antibody 
complementarity-determining regions.  (C) Fn3 proteins that bind cell surface protein 
MSLN have numerous potential clinical applications, such as through diagnostic imaging, 
internalization for drug delivery, and metastatic reduction by blocking MSLN-MUC16 





Figure 2.2 Directed evolution of a naïve yeast surface display library yielded Fn3 
variants that bind soluble MSLN.  We started with a naïve yeast surface display library 
with 2.8 x 109 variants of the Fn3 non-antibody scaffold.  The library was sorted for full-
length protein expression, detected by an antibody to a terminal c-myc epitope tag, and 
binding to MSLN using MACS and FACS.  Red polygon indicates example cell population 
collected for further enrichment and analysis.  Additional diversity was introduced into the 
enriched library through a single round of mutagenic PCR and sorting of this second 
generation library resulted in further enrichment for MSLN binding variants.  A double-




















Figure 2.3 Yeast displayed Fn3 variants 1.4.1 and 2.4.1 bound specifically to tumor 
biomarker MSLN. (A) Two dominant Fn3 variants, 1.4.1 and 2.4.1, were recovered from 
a first generation and second generation Fn3 library, respectively.  (B) Individual clones 
and Fn3 WT were displayed on the surface of yeast and incubated with a range of 
concentrations of soluble MSLN.  Experimental triplicate data were collected, and the 
dissociation constant is reported as the mean and standard deviation of the KD values 
calculated for each replicate.  A representative binding curve is shown for each variant.  
(C)  Individual clones were displayed on the surface of yeast and incubated with a range of 
concentrations of a biotinylated, Fc fragment.  Experimental triplicate data were collected. 






















Figure 2.4 Production and characterization of selected Fn3 variants.  Engineered Fn3 
clones 1.4.1 and 2.4.1 were expressed in bacteria with a C-terminal hexahistidine tag and 
a short peptide tag containing GKSK residues for later bioconjugation chemistry.  (A) Fn3 
protein 1.4.1 was purified by nickel affinity chromatography followed by SEC, 
demonstrating desired product with retention time of ~ 42 min.  (B) Fn3 protein 2.4.1 was 
purified by nickel affinity chromatography followed by HPLC, demonstrating desired 
product with retention time of ~30 min.  (C) Proteins were purified to high purity > 99% 























Figure 2.5 Engineered Fn3 protein variants bound cancer cells expressing MSLN.  
A431/H9 cells, epidermoid carcinoma cells transfected to express high levels of MSLN, 
and MCF-7 cells, breast cancer cells lacking surface MSLN, were used in all binding 
assays.  (A) Analysis by flow cytometry confirms MSLN presence on the surface of 
A431/H9 cells as detected by an anti-MLSN antibody.  The MCF-7 cell line does not 
express MSLN.  (B) Fn3 variants 1.4.1 and 2.4.1 were isolated and binding to MSLN was 
measured using equilibrium binding assays.  A431/H9 and MCF-7 cells were incubated 
with a range of concentrations of soluble fluorescently labeled 1.4.1 or 2.4.1.  The assays 
were performed in experimental triplicate.  Data from each replicate were fit to a sigmoidal 
curve, and a KD value was calculated for each replicate.  The KD is reported as the mean 

























Figure 2.6 Engineered Fn3 protein variants 1.4.1 and 2.4.1 localized to early 
endosomes upon binding MSLN. Analysis by (A) flow cytometry and (B) imaging flow 
cytometry confirms MSLN presence on the surface of KB-3-1 cells compared to the 
MSLN-negative MCF-7 cells, as detected by an anti-MSLN antibody.  (C, D) KB-3-1 cells 
(top) internalize AF488-labeled 1.4.1 (C) and AF488-labeled 2.4.1 (D), while MCF-7 cells 
show no specific binding or internalization (C bottom, D bottom).  Endosomes are detected 
by an AF647-conjuated antibody recognizing the EAA1 early endosomal marker.  Yellow 
in the merged images indicate co-localization between AF488-1.4.1 or AF488-2.4.1 anti-
MSLN engineered proteins (green) and EEA1 (red).  Original magnification 40X.  Co-
localization is quantified by the Bright Detail Similarity (BDS) metric, with values near 1 
indicating co-localization. KB-3-1 BDS = 1.31 and 0.919 for AF488-1.4.1 and AF488-
2.4.1, respectively.  BDS values are not quantifiable for the negative control cell line, due 
to insufficient fraction of negative control cell population staining for binding or 


































Figure 2.7 Engineered Fn3 protein variant 1.4.1 localized to early endosomes in KB-
3-1 and A431/H9 cells upon binding MSLN. (A) Analysis by imaging flow cytometry 
confirms MSLN on the surface of KB-3-1 (top) and A431/H9 (bottom) cells as detected by 
an anti-MSLN antibody. (B) KB-3-1 (top) and A431/H9 (bottom) cells were incubated with 
AF488-1.4.1 at 23°C for 1 hr. Cells were fixed and permeabilized, then incubated with an 
AF647-conjugated antibody directed against the early endosomal marker EEA1. Yellow in 
the merged image indicates co-localization between AF488-1.4.1 anti-MSLN engineered 
protein (green) and EEA1 (red). Original magnification 40X. Quantification of co-
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ENGINEERED FN3 PROTEIN HAS TARGETED THERAPUTIC EFFECT ON 
MESOTHELIN-EXPRESSING CANCER CELLS AND INCREASES TUMOR 
CELL SENSITIVITY TO CHEMOTHERAPY 
 
as written by Sirois, A.R., Deny, D.A., Li, Y., Fall, Y.D., and Moore, S.J. 
Biotechnology and Bioengineering 2019 
 
3.1 Abstract 
 Mesothelin is a protein expressed at high levels on the cell surface in a variety of 
cancers, with limited expression in healthy tissues.  The presence of mesothelin on tumor 
tissue correlates with increased invasion and metastasis, and resistance to traditional 
chemotherapies, through mechanisms that remain poorly understood.  Molecules that 
specifically recognize mesothelin and interrupt its contribution to tumor progression have 
significant potential for targeted therapy and targeted drug delivery applications.  A number 
of mesothelin-targeting therapies are in pre-clinical and clinical development, although 
none are currently approved for routine clinical use.  In this work, we report the 
development of a mesothelin-targeting protein based on the fibronectin type-III non-
antibody protein scaffold, which offers opportunities for applications where antibodies 
have limitations.  We engineered protein variants that bind mesothelin with high affinity 
and selectively initiate apoptosis in tumor cells expressing mesothelin.  Interestingly, 
apoptosis does not occur through a caspase-mediated pathway, and does not require 
downregulation of cell-surface mesothelin, suggesting a currently unknown pathway 
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through which mesothelin contributes to cancer progression.  Importantly, simultaneous 
treatment with mesothelin-binding protein and chemotherapeutic mitomycin C had a 
greater cytotoxic effect on mesothelin-positive cells compared to either molecule alone, 




 Mesothelin (MSLN) is a cell surface protein that is overexpressed in numerous 
cancers, including ovarian [1–3], triple negative and other breast [4–7], lung [8–10], liver 
[11,12], pancreatic [5,13–15], and mesothelioma [16].  The aberrant expression of MSLN 
is known to promote tumor cell survival, progression, and metastasis in vitro and in vivo 
[1,17–19].  MSLN expression is limited in normal tissue, with only low levels expressed 
on the mesothelial cells of the pleura, peritoneum, and pericardium [20].  The role of MSLN 
in normal development is currently still unknown.  Mice with an inactivated MSLN gene 
display no distinct phenotype and are capable of producing healthy offspring, suggesting 
that MSLN is not essential for mammalian development [21]. The differential expression 
in cancer and healthy tissue, and apparent non-essential role for MSLN in normal tissue, 
makes MSLN a promising biomarker for cancer diagnosis and therapeutic targeting.  
Previous studies have proposed a variety of mechanisms by which MSLN promotes 
tumor progression [22].  Growing evidence indicates that MSLN aids in cell motility, 
implantation, and metastasis through its interaction with another tumor surface protein, 
CA125, also known as MUC16 [14,17,18].  The interaction of these two cell surface 
proteins has been observed to facilitate metastasis in ovarian tumors [3,23], and promote 
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cancer cell motility and invasion in pancreatic cancer [14].  The interaction between MSLN 
and CA125 mediates heterotypic cell adhesion, important for tumor cell invasion and 
metastasis [18].  Moreover, blocking the interaction of MSLN and CA125 with anti-MSLN 
antibodies blocks the observed adhesion [18]. Overexpression of CA125 has been shown 
to induce metastasis, but only when mediated by binding to MSLN [24].  MSLN expression 
may also promote cancer cell survival and proliferation through the NF-kB signaling 
pathway. MSLN expression in pancreatic cancer cells was correlated with constitutive 
activation of the transcription factor STAT3, which lead to increased formation of the 
cyclin E/cyclin-dependent kinase 2 complex, as well as increased G1-S transitions [25]. 
Several studies suggest MSLN expression is associated with chemoresistance, and shorter 
progression-free survival and overall survival [26]. MSLN-induced NF-kB pathway 
activation has been shown to mediate resistance to several chemotherapeutics through 
upregulation of anti-apoptotic proteins, including Bcl-2 and Mcl-1 [27,28]. Altering MSLN 
biochemical signaling pathways or interrupting the binding of MSLN and CA125 are 
viable therapeutic strategies to reduce cancer progression and metastasis. 
 Promising results from pre-clinical and clinical trials to target MSLN with 
antibodies, antibody derivatives, immunotoxins, antibody-drug conjugates, and CAR-T 
cells for therapy demonstrate the promise of MSLN-targeting methods [29–35].  However, 
no MSLN-targeting molecules are currently approved for routine clinical use. Targeted 
therapeutics have made significant impacts in cancer treatment, resulting in increased 
efficacy and reduced toxicity compared to traditional chemotherapies. Novel targeted 
therapy approaches for MSLN-positive tumors have potential for substantial impact in the 
clinic for patients who currently do not have a targeted therapy option.  
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 We have recently reported engineering protein variants based on the fibronectin 
type III (Fn3) non-antibody protein scaffold that bind to MSLN with moderate affinities 
(KD = 100’s nM) [36].  Fn3 variants that specifically bound to MSLN on human cancer 
cells were internalized, and co-localized to early endosomes, indicating their promise for 
drug delivery applications.  MSLN has been previously shown to readily internalize bound 
ligands, underscoring the potential of MSLN as a cell-surface target to mediate intracellular 
drug delivery [37]. While antibody-based therapies have found great success for a variety 
of clinical needs, there are some applications where other protein structures may be 
advantageous and complement clinical contributions from antibodies, motivating the 
development of non-antibody protein scaffolds for engineering molecular recognition, 
including the Fn3 scaffold [38–42].  
Here, we describe further evolved Fn3 variants with enhanced binding affinity for 
MSLN. Our data show that treatment of MSLN-positive tumor cells with engineered 
MSLN-binding Fn3 protein has cytotoxic effects on MSLN-expressing cancer cells, 
leading to tumor cell apoptosis. Our results indicate that apoptosis is by a caspase-
independent pathway, and that the cytotoxic effects are not due to downregulation of 
MSLN on the surface of cancer cells, revealing that a novel signaling pathway is potentially 
being targeted by the engineered MSLN-binding protein, with implications for future drug 
development efforts. Importantly, when MSLN-positive cells are simultaneously treated 
with MSLN-binding Fn3 protein and established chemotherapeutic mitomycin C (MMC), 
the tumor cells exhibit enhanced sensitivity to the chemotherapeutic agent with increased 
apoptosis compared to MSLN-positive cells treated with MMC alone.  These results 
highlight the potential of targeting MSLN with biologic therapeutics in combination 
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therapy with traditional chemotherapeutics for selective, synergistic treatment of tumors 
expressing MSLN. 
 
3.3 Materials and Methods 
 
3.3.1 Reagents and cell lines 
 PBSA buffer was composed of phosphate buffered saline (PBS) and 0.1% bovine 
serum albumin (BSA).  A431/H9 cells (gift of M. Ho, National Cancer Institute, 2016) [43] 
were cultured in RPMI-1640 supplemented with 10% FBS, 1% penicillin-streptomycin and 
700 µg/mL Geneticin selective antibiotic (G418) (Thermo Fisher).  KB-3-1 cells (gift of 
M. Gottesman, National Cancer Institute, 2016) [44] were cultured in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin.  T-47D cells (gift of S. 
Smith-Schneider, Pioneer Valley Life Sciences Institute, 2019) [45] were cultured in 
DMEM supplemented with 10% FBS, 0.2 units/mL human insulin (Sigma # I9278-5ML) 
and 1% penicillin-streptomycin. OVCAR-3 cells (ATCC #HTB-161, 2015) were cultured 
in RPMI-1640 supplemented with 20% FBS, 1% penicillin-streptomycin, and 0.01 mg/mL 
human insulin.  All cells were grown at 37°C in a humidified atmosphere containing 5% 
CO2.  
 
3.3.2 Maturation and evolution of Fn3 variant 3.4.4 by yeast surface display 
 A Gr2 library that we had previously evolved for MSLN-binding Fn3 variants was 
further sorted and affinity matured as a third generation library using yeast surface display 
[36,46].  Briefly, following error-prone PCR with nucleotide analogs, the library was sorted 
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twice by magnetic bead selection (MACS) using biotinylated, Fc-tagged recombinant 
human MSLN (Acro Biosystems #MSN-H826x) followed by a fluorescence activated cell 
sorting (FACS) selection for full-length clones using an antibody against the C-terminal c-
myc epitope tag.  Full-length clones were incubated with a chicken anti-c-myc antibody 
and the biotinylated Fc-tagged MSLN.  To increase the sorting stringency, concentrations 
of MSLN were decreased over four iterative rounds of enrichment, from 20 nM in the first 
sort to 5 nM in the fourth sort.  Cells were washed and incubated with a goat anti-chicken 
Alexa Fluor 647 (AF647) conjugate and Alexa Fluor 488 (AF488)-conjugated streptavidin.  
Cells were washed and double-positive yeast cells were collected on a BD BioSciences 
FACSAria II.  Plasmid DNA from the enriched library was recovered using a Zymoprep 
Yeast Plasmid Miniprep II kit (Zymo Research) following manufacturer’s protocol, 
transformed into bacteria, and individual clones were sequenced by standard Sanger DNA 
sequencing methods.  
 
3.3.3 Engineered Fn3 protein production and purification 
 MSLN-binding Fn3 variant 3.4.4 and negative control protein Fn3 RDG, in which 
the RGD integrin-binding motif has been mutated to RDG (plasmid DNA provided by B. 
Hackel, University of Minnesota), were prepared as previously described [36].  Briefly, 
Fn3 genes were cloned into a pET vector with a C-terminal hexahistadine tag (plasmid 
provided by B. Hackel, University of Minnesota) and expressed in BL21(DE3) E. coli.  
Cultures were grown in LB and induced overnight at 20°C with 0.5 mM Isopropyl-b-D-
thiogalactopyranoside (IPTG).  Cells were resuspended in lysis buffer (35 mM 
Na2HPO4×dibasic, 15 mM NaH2PO4×monobasic, 500 mM NaCl, 5 mM CHAPS, 25 mM 
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imidazole, 5% glycerol) supplemented with an EDTA-free protease inhibitor (Pierce), and 
lysed by repeated freezing and thawing.  The soluble fractions were isolated by 
centrifugation.  Fn3 variant 3.4.4 was purified by cobalt affinity chromatography with 
HisPur cobalt resin (Thermo Fisher) while Fn3 RDG was purified by nickel affinity 
chromatography with Ni-NTA agarose resin (Thermo Fisher) followed by size exclusion 
chromatography (SEC) on a Superdex 75 10/300 column (GE Healthcare Life Sciences). 
Protein samples were analyzed for purity by SDS-PAGE on a BioRad ChemiDoc MP 
imaging system.  
  
3.3.4 Binding affinity measurements of soluble Fn3 proteins for MSLN-positive tumor 
cells   
 A431/H9 and MCF-7 cells were cultured to 80% confluency, as described above, 
harvested, washed, and pelleted at 200g for 5 min at 4°C.  MSLN expression was detected 
by a mouse anti-MSLN antibody (clone K1, Abcam, 1:50) and a goat anti-mouse PE 
conjugate (1:25).  Cells were incubated with a range of concentrations of 3.4.4. or Fn3 
RDG in a total volume of 50 µL PBSA for 1 h at 23°C with rotation.  Cells were washed 
with PBSA and incubated with a mouse anti-His6 DyLight-488 antibody (Abcam 
#ab117512, 1:50) for 20 min at 4°C and protected from light.  Fluorescence was analyzed 
using an EMD Millipore Guava easyCyte flow cytometer.  Mean fluorescence intensities 
for Fn3 variant binding were determined using InCyte software (EMD Millipore).  Data 
was plotted and fit to a sigmoidal curve using KaleidaGraph software.  Dissociation 
constants (KD) were determined as the half-maximal value of the sigmoidal fit for three 
separate experiments, and the mean and standard deviation (SD) for the KD are reported.     
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3.3.5 Cell viability measurements 
 Cell viability was determined using a Cell Counting Kit-8 (CCK-8, Dojindo 
Laboratories, Japan), according to the manufacturer’s instructions.  Briefly, cells were 
seeded at 3 x 103 (KB-3-1) or 5 x 103 (T-47D) cells per well in 96-well plates and cultured 
overnight in a final volume of 100 µL of medium.  After overnight culture, the medium 
was exchanged to serum-free medium containing various concentrations of 3.4.4 or Fn3 
RDG (2, 20, or 200 nM).  As a positive control, cells were treated with 10 µM mitomycin 
C (MMC), a known chemotherapeutic agent.  At 48 h post treatments, spent media was 
removed and replaced with 100 µL of fresh media with 10 µL of CCK-8 reagent and the 
cells were incubated at 37°C for an additional 2 h.  The absorbance of each well was 
measured at 450 nm on a Tecan Infinite M100 microplate reader.  All treatments were 
carried out as triplicates in three independent experiments.  Data were analyzed using the 
Magellan 7.0 software (Tecan).  Measured absorbance was normalized with absorbance 
values of the cell culture media that did not contain cells. Untreated cells were regarded as 
control, and cell viability was calculated as the ratio of the absorbance of test and control 
wells.  
 
3.3.6 Apoptosis experiments 
 Apoptosis was determined using a Dead Cell Apoptosis kit with annexin V-AF488 
and propidium iodide (PI) (Molecular Probes), according to the manufacturer’s 
instructions.  Briefly, KB-3-1 cells were seeded at 2.5 x 105 cells in 35 mm plates and 
cultured overnight in a final volume of 3 mL of medium.  After overnight culture, the 
medium was exchanged to serum-free medium containing 200 nM of 3.4.4 or Fn3 RDG. 
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At 48 h post treatment, cells were trypsinized, washed three times with PBS, and 
resuspended in 1X binding buffer to a density of 1x106 cells/mL.  100 µL of this cell 
suspension was incubated with 5 µL of the supplied annexin V-AF488 and 1 µL of PI (100 
µg/mL) for 15 min while protected from light.  The percentages of annexin V-AF488-
positive and PI-positive cells were determined from the fluorescence of 25,000 cells 
measured on an EMD Millipore Guava easyCyte flow cytometer. All treatments were 
carried out as triplicates.  Data were analyzed using InCyte software (EMD Millipore). 
 
3.3.7 Caspase-3/7 activation 
 Caspase induction was assessed using the Caspase-Glo 3/7 assay (Promega), 
according to the manufacturer’s instructions.  Briefly, KB-3-1 cells were seeded at 5 x 103 
cells per well in 96-well plates and cultured overnight in a final volume of 100 µL of 
medium.  After overnight culture, the medium was exchanged to serum-free medium 
containing 200 nM of 3.4.4 or Fn3 RDG.  As a positive control, cells were treated with 10 
µM MMC.  At the specific time point of either 6, 12, 24, 36, or 48 h, 100 µL of Caspase-
3/7 reagent was added to each well, gently mixed at 300 rpm for 30 s, and incubated at 
23°C for an additional 2 h.  Luminescence was measured on a Tecan Infinite M100 
microplate reader.  All treatments were carried out as triplicates in three independent 
experiments, unless otherwise noted. Data were analyzed using the Magellan 7.0 software.  
 
3.3.8 Receptor downregulation 
 KB-3-1 cells were seeded at 3x104 cells per well in 96-well plates, grown overnight, 
and serum starved for 12-16 h.  Cells were treated with 200 nM 3.4.4 or Fn3 RDG for the 
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indicated time between 0 and 48 h.  Medium was removed and cells were washed with 
PBS, detached with 0.05% trypsin-EDTA, and placed on ice for the remainder of the assay.  
Cells were washed with PBSA and incubated with an anti-MSLN antibody raised in mouse 
for 1 h on ice followed by a goat anti-mouse PE conjugate antibody.  Cells were washed 
and analyzed by flow cytometry. All treatments were carried out in triplicates.  Levels of 
cell surface MSLN expression were determined from the fluorescence of 25,000 cells 
measured on a EMD Millipore Guava easyCyte flow cytometer. Data were analyzed using 
InCyte software (EMD Millipore). 
 
3.3.9 Combination therapy with engineered protein variant and MMC 
 The Dead Cell Apoptosis kit with annexin V-AF488 and propidium iodide (PI) 
described above was used to determine whether treatment with Fn3 variant 3.4.4 could 
enhance the susceptibility of MSLN-expressing cells to MMC-induced apoptosis.  Briefly, 
KB-3-1cells or OVCAR-3 cells were seeded at 1 x 105 cells in 12-well plates and cultured 
overnight in a final volume of 1 mL of medium.  After overnight culture, the medium was 
exchanged to serum-free medium containing 200 nM Fn3 variant 3.4.4, 1 µM MMC, or 1 
µM MMC with 200 nM Fn3 variant 3.4.4.  At 48 h post treatment, cells were trypsinized, 
washed three times with PBS, and resuspended in 1X binding buffer to a density of 1x106 
cells/mL.  100 µL of this cell suspension was incubated with 5 µL of the supplied annexin 
V-AF488 and 1 µL of PI (100 µg/mL) for 15 min at 23°C while protected from light.  The 
percentages of annexin V-AF488-positive and PI-positive cells were determined from the 
fluorescence of at least 20,000 cells measured on an EMD Millipore Guava easyCyte flow 
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cytometer. All treatments were carried out as triplicates.  Data were analyzed using InCyte 
software (EMD Millipore). 
 
3.3.10 Statistical analysis 
 Statistical differences between groups were determined using an unpaired Student’s 
two-tailed t-test.  A p value of < 0.05 was considered statistically significant (* p < 0.05, 
** p < 0.01, *** p < 0.001).  All data are presented as mean ± SD. 
 
3.4 Results and Discussion 
 
3.4.1 Fn3 proteins from further evolved library bind MSLN with high affinity   
 Our previously reported MSLN-binding Fn3 proteins were engineered from a naïve 
yeast surface display Fn3 library [36,47] (Figure 3.1A, B) and their moderate affinity for 
cell surface MSLN motivated additional rounds of directed evolution.  Following 
mutagenesis of our second generation library, the third generation library was subjected to 
two rounds of MACS, a FACS sort for full-length expression and four iterative rounds of 
dual-color FACS for binding to MSLN.  The resultant population yielded enrichment of 
evident MSLN-binding clones (Figure 3.1C). Sequence analysis of individual clones 
identified three dominant variants: 3.1.6, 3.4.4 and 3.4.5 (Figure 3.1D).  All three variants 
included a shared single mutation in the BC binding loop compared to previously reported 
Fn3 clones 1.4.1 and 2.4.1 [Sirois et al., “Fn3 Proteins Engineered to Recognize Tumor 
Biomarker Mesothelin Internalize upon Binding.”36].  Single framework mutations N63K 
and D3Y are incorporated into clones 3.1.6 and 3.4.4, respectively.  In addition to the D3Y 
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mutation, variant 3.4.5 incorporates three further framework mutations, including P64S, 
S82Y, and D94N.  These variants were transformed into EBY100 yeast surface display 
strain and their binding to a range of MSLN concentrations was assessed by flow cytometry 
(Figure 3.1E).  Variant 3.4.4 was selected for further binding and therapeutic 
characterization.    
 
3.4.2 Soluble Fn3 protein selectively binds the surface of MSLN-positive cancer cells  
 Fn3 variant 3.4.4 and the non-binding control, Fn3 RDG, both containing a C-
terminal His6 tag, were solubly produced in E. coli and high purity of proteins following 
metal affinity purification was verified by SDS-PAGE analysis (Figure 3.2A).  Equilibrium 
binding titrations of Fn3 variant 3.4.4 and Fn3 RDG on A431/H9 and MCF-7 cell lines 
were performed (Figure 3.2B).  The A431/H9 cell line is an A431 human epidermoid 
carcinoma cell line transfected to stably overexpress MSLN on its surface and MCF-7 is a 
human breast cancer cell line that does not express MSLN on its surface [2,31,36].  
Previously reported Fn3 proteins engineered to bind cell surface MSLN demonstrated 
moderate binding affinities (KD > 400 nM) [36].  The Fn3 variant reported here, 3.4.4, 
binds to MSLN-expressing A431/H9 cells with a binding affinity of KD = 19 ± 1 nM, while 
displaying no binding to the MSLN-negative control cell line, MCF-7.  The nonbinding 
control also showed no detectable binding to the A431/H9 cell line (Figure 3.2B).     
 
3.4.3 Engineered Fn3 protein reduces the viability of MSLN-positive cancer cells  
 The effect of Fn3 variant 3.4.4 on cell viability was studied using the CCK-8 assay 
based on WST-8, a water-soluble tetrazolium salt that is reduced by dehydrogenase to 
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produce a yellow formazan dye.  The amount of formazan dye generated by dehydrogenase 
activity is directly proportional to the number of living cells. 
 The KB-3-1 cell line is a human cervical carcinoma cell line reported to express 
moderate levels of MSLN on its surface [48], while the T-47D cell line is a human breast 
carcinoma cell line that is not known to endogenously express MSLN [49].  While H9 cells 
that were transfected to express high levels of MSLN were ideal for binding assays, we 
chose the endogenously expressing KB-3-1 cells for therapeutic characterization of Fn3 
3.4.4. Using an anti-MSLN antibody, high levels of MSLN were confirmed on the surface 
of KB-3-1 cells, and no MSLN was detected on the surface of T-47D cells (Figure 3.3A).  
We tested the cytotoxic effect of concentrations of 3.4.4 protein based on the measured 
dissociation constant, selecting to test concentrations equivalent to the dissociation 
constant (20 nM) and one order of magnitude above (200 nM) and below (2 nM) the 
dissociation constant. After 48 h of treatment, Fn3 variant 3.4.4 significantly reduced (p < 
0.05) the number of viable cells in the KB-3-1 cell line in a dose-dependent manner (Figure 
3.3B), but did not affect viability of the T-47D cell line (Figure 3.3C). The non-binding 
Fn3 RDG control demonstrated no effect on cell viability for either cell line.  In contrast to 
the MSLN-dependent effect of Fn3 variant 3.4.4, non-targeted chemotherapeutic MMC 
significantly reduced (p < 0.001) the viability of both the MSLN-positive and MSLN-
negative cell lines (Figure 3.3B, C).   
 
3.4.4 Treatment with Fn3 protein induces apoptosis of MSLN-positive cancer cells  
 We evaluated the induction of apoptosis on KB-3-1 cells after 3.4.4 treatment, 
measured by flow cytometry following staining with fluorescently labeled annexin-V and 
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PI (Figure 3.4).  Annexin V in combination with PI can discriminate between viable cells, 
early apoptotic cells, late apoptotic cells, and cells in necrosis [50].  Cells that are viable 
and intact do not stain with either annexin V or PI, cells that are in the early stages of 
apoptosis undergo changes that alter the cell membrane and allow the incorporation of 
annexin V but still exclude PI, and cells that are in the late stages of apoptosis are stained 
with both annexin V and PI once PI can penetrate a degrading membrane and intercalate 
into nucleic acids.  Cells that are necrotic but not from apoptosis have a permeable 
membrane and stain with PI but not with annexin V.  
 After 48 h of treatment, Fn3 variant 3.4.4 significantly increased the number of 
apoptotic cells compared to vehicle-treated cells (Figure 3.4A, B).  The number of early 
and late apoptotic cells increased from the untreated levels when treated with Fn3 3.4.4 (p 
<0.001 for increase in early apoptosis, p < 0.05 for increase in late apoptosis), and the 
number of necrotic cells also increased with treatment (p < 0.001).  Cells treated with the 
non-binding control Fn3 RDG demonstrated no increase in apoptosis or necrosis compared 
to vehicle-treated cells (Figure 3.4C, D). 
 
3.4.5 Fn3 protein induces apoptosis of MSLN-positive cancer cells in a caspase-
independent manner  
 We examined whether the observed apoptosis of MSLN-positive tumor cells from 
variant 3.4.4 treatment was executed via a caspase-mediated pathway.  Caspases typically 
play a key role in apoptosis [51,52], therefore we assessed the activity of the executioner 
caspases, caspases-3 and -7 (Figure 3.5).  KB-3-1 cells were treated with 3.4.4, Fn3 RDG, 
or MMC.  After 48 h of treatment, caspase 3/7 activities were significantly increased in the 
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MMC-treated cells (p < 0.001) compared to vehicle-treated cells, while neither treatment 
with Fn3 3.4.4 nor negative control Fn3 RDG demonstrated increased caspase activity over 
vehicle treatment (Figure 3.5A).  
 The biochemical pathways associated with apoptosis, and the time required to 
detect activation of these different biochemical pathways, are variable and dependent on 
cell line, specific apoptosis inducer, biochemical events assayed, and the time at which 
events are assayed [53].  To confirm 3.4.4 treatment did not induce caspase activation at 
earlier time points, we monitored caspase-3/7 activities over an extended time course.  
Compared with vehicle-treated cells, 3.4.4-treated cells showed no increase in caspase-3/7 
activities when measured at 6, 12, 24, or 36 h (Figure 3.5B).   
 
3.4.6 Decreased cell viability and increased apoptosis is not due to MSLN 
downregulation 
 We investigated whether the observed 3.4.4-induced apoptosis was due to 
downregulation of surface MSLN. Aberrant signaling via overexpressed receptors is 
implicated in many cancers and interruption of this process can cause antitumor effects 
[54].  Signaling abrogation mechanisms include blocking ligand binding, inhibiting 
downstream signaling pathways following receptor binding, and receptor downregulation 
[55,56]. Ligand-induced endocytosis and degradation of receptor is known to be a 
significant process by which growth-promoting signals are interrupted [55,57–63]. There 
is previous evidence that direct reduction of surface levels of MSLN by shRNA or siRNA 
inhibits cell proliferation, migration, and invasion, and sensitizes cancer cells to 
chemotherapeutics and induces apoptosis [19,25,27,28,64].  To examine if MSLN receptor 
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downregulation contributed to the observed decrease in MSLN-positive tumor cell viability 
and increase in apoptosis following 3.4.4 treatment, we measured levels of MSLN on the 
surface of treated tumor cells using an antibody recognizing MSLN and flow cytometry. 
We did not detect any changes in surface levels of MSLN on KB-3-1 tumor cells over a 
time course of 48 h compared to untreated cells, when cells were treated with either variant 
3.4.4 or non-binding negative control Fn3 RDG (Figure 3.6), indicating that apoptosis 
induction was not mediated by receptor downregulation.   
 
3.4.7 Fn3 protein enhances sensitivity of KB-3-1 and OVCAR-3 cells to 
chemotherapeutic mitomycin C  
 We evaluated the combined effect of MSLN-binding Fn3 protein and standard 
chemotherapeutic MMC on MSLN-positive KB-3-1 cells and OVCAR-3 cells. Having 
observed that variant 3.4.4 increased MSLN-positive cell apoptosis, but not through 
caspase activation and not through receptor downregulation, we hypothesized that 3.4.4 
may act most directly on survival pathways of the tumor cells, accelerating the apoptosis 
of cells that were naturally beginning down an apoptosis pathway.  If 3.4.4 had this effect 
of supporting apoptosis, then we hypothesized that treatment of MSLN-positive cells with 
variant 3.4.4 could increase the sensitivity of cells exposed to a chemotherapeutic agent, 
when the treatments were administered in combination.  Combination therapy has become 
standard practice in the clinic for cancer therapy [65].  Targeting multiple, essential tumor 
pathways is often more effective than monotherapies, and can promote robust anti-cancer 
effects while minimizing the likelihood that resistant cancer cells will develop [65,66].  
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 When MSLN-positive KB-3-1 cells were simultaneously treated with MSLN-
binding Fn3 protein 3.4.4 and chemotherapeutic MMC, the cancer cells exhibited enhanced 
sensitivity to MMC compared to KB-3-1 cells treated with either Fn3 3.4.4 or MMC alone 
(Figure 3.7A, B). The percentage of total apoptotic cells increased significantly when 
comparing cells treated with 200 nM Fn3 3.4.4 to cells treated with the combination of 1 
µM of MMC and 200 nM of Fn3 3.4.4 (23 ± 3% and 62 ± 3%, p-value < 0.001) and when 
comparing cells treated with 1 µM of MMC to cells treated with the combination of 1µM 
of MMC and 200 nM of Fn3 3.4.4 (44 ± 5% and 62 ± 3%, p-value < 0.01) (Figure 3.7B).   
 To determine if a similar therapeutic effect would be observed for another MSLN-
positive tumor cell line, we repeated the combination therapy experiment with OVCAR-3 
ovarian carcinoma cells (Figure 3.7C, D), a cell line with a moderate level of MSLN 
expression (Figure 3.8A). OVCAR-3 cells provide an interesting comparison to KB-3-1 
cells because while KB-3-1 cells do not express CA125, which is a native binding partner 
for MSLN, the OVCAR-3 cells do express high levels of CA125 (Figure 3.8B).  The 
percentage of total apoptotic cells increased significantly when comparing cells treated 
with 200 nM Fn3 3.4.4 to cells treated with 1 µM of MMC and 200 nM of Fn3 3.4.4 (35 ± 
1% and 71 ± 7%, p-value < 0.001) and when comparing cells treated with 1 µM of MMC 
to cells treated with 1µM of MMC and 200 nM of Fn3 3.4.4 (42 ± 2% and 71 ± 7%, p-
value < 0.01) (Figure 3.7D).   
These results highlight the potential of targeting MSLN with biologic therapeutics 
in combination therapy with traditional chemotherapeutics for more selective, synergistic 
treatment of tumors expressing MSLN.  Such combination therapy can allow a reduction 
in chemotherapeutic dose, reducing the nonspecific toxic side effects of non-selective 
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cytotoxic agents. Building on the recent successes of antibody-drug conjugates, one 
promising approach is to create a protein-drug conjugate, coupling a chemotherapeutic to 
an engineered Fn3 variant that targets MSLN, merging targeted drug delivery with 
combination therapy and further reducing nonspecific toxicities. We anticipate that the 
highly stable structure of the Fn3 scaffold and the lack of native disulfide bonds will 
facilitate the development of strategies to synthesize Fn3-drug conjugates for targeted 
combination therapy of MSLN-positive tumors. 
 
3.5 Conclusion 
 In summary, we have successfully engineered a non-antibody Fn3 protein that 
binds cancer antigen MSLN with high affinity and specificity, and has a targeted 
therapeutic effect on MSLN-positive tumor cells, reducing cell viability and increasing 
apoptosis. Further, the Fn3 protein engineered to bind MSLN increases the sensitivity of 
tumor cells to a common chemotherapeutic agent when used as a combination therapy.  In 
recently reported work, treatment with anetumab ravtansine, a MSLN-specific antibody-
drug conjugate, not only inhibited tumor growth in ovarian cancer models as a 
monotherapy, but also exhibited an additive effect when used in combination with targeted 
agents and standard chemotherapeutics [32]. Together, this current report and the recent 
results of related research validate that molecules developed to target MSLN are promising 
for both monotherapy and combination therapy for patients who do not currently have any 
targeted treatment options.  
 Interestingly, the apoptosis of KB-3-1 cells induced by the non-antibody Fn3 
variant 3.4.4 does not occur via caspase activation, and we do not observe downregulation 
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of levels of MSLN on the tumor cell surface of KB-3-1 cells following treatment with 
3.4.4.  The absence of these commonly observed pathways for targeted treatment of tumor 
cells suggests that a currently unknown alternate pathway is engaged in the KB-3-1 tumor 
cell response to variant Fn3 3.4.4.  Future research exploring relevant pathways for 3.4.4-
induced tumor cell death, in the tumor cell lines used in this paper and in other cell lines 
expressing MSLN, has the potential to uncover and further elucidate important signaling 
pathways for MSLN-positive tumor cells, informing ongoing efforts to design effective 
targeted treatments for patients with tumors expressing MSLN.  We are also interested in 
working to understand if and how Fn3 3.4.4 may modulate the interaction of MSLN and 
native binding partner CA125, building on our observation that OVCAR-3 cells had 
enhanced response to 3.4.4 treatment alone compared to the 3.4.4 treatment response of 
KB-3-1 cells. This difference in response could be related to potential disruption of MSLN 
and CA125 interactions by 3.4.4, which would only be relevant for the MSLN+/CA125+ 
OVCAR-3 cells. Combination therapy with molecules targeting MSLN and molecules 
targeting CA125 is another approach warranting further study. 
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Figure 3.1 Engineering and characterization of a third generation anti-mesothelin 
Fn3 library. (A) The human fibronectin type III (Fn3) protein scaffold has a highly stable 
structure with loops that are suitable for mutation to engineer novel molecular recognition 
properties (PDB 1TTG). (B) The Fn3 library sequence [47]. (C) Indicated yeast libraries 
displaying Fn3 variants were labeled with an antibody to a terminal c-myc epitope tag and 
25 nM biotinylated, Fc-tagged MSLN.  Unsorted refers to the original naïve library. 
Generation 1 refers to the library following four rounds of FACS.  Generation 2 refers to 
the library following one round of mutagenic PCR and four rounds of FACS.  Generation 
3 refers to the library that has undergone mutagenic PCR twice, with four rounds of FACS.  
(D) Selected clones from a third generation library demonstrate further evolved sequences 
when compared to our previously reported clones.  (E) Individual clones were displayed 
on the surface of yeast and incubated with a range of concentrations of biotinylated, Fc-
tagged MSLN. Experimental triplicate data were collected, and the dissociation constant is 
reported as the mean ± SD of the KD values calculated for each replicate. A representative 












Figure 3.2 Fn3 protein variant 3.4.4 selectively binds tumor cell-surface MSLN with 
high affinity.  (A) Engineered Fn3 clone 3.4.4 and Fn3 RDG were expressed in bacteria 
and purified to high purity (>99%) as analyzed by SDS-PAGE. Fn3 3.4.4 expected 
molecular weight: 13 kDa, Fn3 RDG expected molecular weight: 11 kDa. (B)  Binding of 
3.4.4 and Fn3-RDG to cell surface MSLN were measured using equilibrium binding 
assays. H9 cells express MSLN, MCF-7 cells do not express MSLN.  The assays were 
performed as experimental triplicates.  Data from each replicate were fit to a sigmoidal 
curve, and a KD value was calculated as the concentration yielding the half-maximal value.  























Figure 3.3 Fn3 protein decreases the viability of MSLN-positive cancer cells. (A) 
Analysis by flow cytometry confirms MSLN presence on the surface of KB-3-1 cells 
(white histogram, solid line) as detected by an anti-MSLN antibody. The T-47D cell line 
does not express MSLN (gray histogram, solid line). Dashed line, unstained T-47D cells.  
(B) KB-3-1 and (C) T-47D cells were treated with various concentrations of 3.4.4, Fn3 
RDG, or MMC for 48 h.  Treated cells were subjected to a CCK-8 assay to measure cell 
viability, which was normalized to vehicle-treated cells.  Error bars indicate mean ± SD (n 












Figure 3.4 Fn3 protein induces apoptosis in MSLN-positive cancer cells.  Induction of 
apoptosis of KB-3-1 cells following Fn3 3.4.4 treatment was evaluated by staining with 
annexin-V and PI. (A, C) KB-3-1 cells were treated with 3.4.4 or Fn3 RDG, then stained 
with annexin-V AF488 and PI and analyzed by flow cytometry.  A representative plot of 
each treatment is shown.  Viable cells (annexin-V-/ PI-) are in the lower left quadrant, early 
apoptotic cells (annexin-V+/ PI-) are in the lower right quadrant, late apoptotic cells 
(annexin-V+/ PI+) are in the upper right quadrant, and necrotic cells (annexin-V-/ PI+) are 
in the upper left quadrant.  Vehicle varies slightly between two treatments, and each vehicle 
control is shown separately. (B, D) Quantitative analysis of induction of apoptosis and 
necrosis after treatments. Data are presented as the mean ± SD (n = 3). * p < 0.05, *** p < 



















Figure 3.5 Analysis of caspase 3/7 activation in MSLN-positive cells treated with Fn3 
protein. (A) KB-3-1 cells were treated with 3.4.4, Fn3 RDG, or MMC for 48 h, and caspase 
3/7 activation was analyzed.  Positive control chemotherapeutic MMC induced caspase 
activation, while Fn3 3.4.4 and negative control Fn3 RDG did not activate caspases.  Error 
bars indicate mean ± SD (n = 9). *** p < 0.001 as determined with an unpaired Student’s 
two-tailed t-test.  (B) Treatment of KB-3-1 cells with Fn3 3.4.4 also did not activate caspase 






















Figure 3.6 Surface MSLN expression is not downregulated following treatment with 
Fn3 variant 3.4.4.  KB-3-1 cells that express MSLN were incubated with 3.4.4 (red square) 
or Fn3 RDG (blue circle).  At the specified time points, surface MSLN was quantified via 
flow cytometry with an antibody that binds MSLN.  Surface MSLN levels relative to 
untreated KB-3-1 cells are plotted as a function of time. Error bars indicate mean ± SD (n 
= 3).  No significant downregulation of surface MSLN was observed, as determined with 




























Figure 3.7 Treatment with Fn3 variant 3.4.4 enhances sensitivity of KB-3-1 cells and 
OVCAR-3 cells to chemotherapeutic.  Induction of apoptosis of KB-3-1 cells and 
OVCAR-3 cells following treatment with 3.4.4, MMC, or MMC in combination with Fn3 
3.4.4 was evaluated by staining with annexin-V and PI. (A) KB-3-1 and (C) OVCAR-3 
cells were treated with 200 nM Fn3 3.4.4, 1 µM MMC, or 1 µM MMC and 200 nM Fn3 
3.4.4, then stained with annexin-V AF488 and PI and analyzed by flow cytometry.  A 
representative plot of each treatment is shown.  Viable cells (annexin-V-/ PI-) are in the 
lower left quadrant, early apoptotic cells (annexin-V+/ PI-) are in the lower right quadrant, 
late apoptotic cells (annexin-V+/ PI+) are in the upper right quadrant, and necrotic cells 
(annexin-V-/ PI+) are in the upper left quadrant.  (B, D) Quantitative analysis of induction 
of apoptosis in (B) KB-3-1 cells and (D) OVCAR-3 cells after treatments. Data are 
presented as the mean ± SD (n = 3). ** p < 0.01, *** p < 0.001 as determined with an 






















Figure 3.8 OVCAR-3 cells co-express mesothelin and CA125 on cell surface. (A) 
Analysis by flow cytometry confirms MSLN presence on the surface of OVCAR-3 cells 
(while histogram, solid line), as detected by an anti-MSLN antibody. (B) OVCAR-3 cells 
also express CA125, as detected by an anti-CA125 antibody (while histogram, solid line). 
The KB-3-1 cell line does not express CA125 (gray histogram). Dashed line indicates KB-
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4.1 Abstract 
 Conjugation of proteins to drug-loaded polymeric structures is an attractive strategy 
for facilitating target-specific drug delivery for a variety of clinical needs. Polymers 
currently available for conjugation to proteins generally have limited chemical versatility 
for subsequent drug loading.  Many polymers that do have chemical functionality useful 
for drug loading are often insoluble in water, making it difficult to synthesize functional 
protein-polymer conjugates for targeted drug delivery. In this work, we demonstrate that 
reactive, azlactone-functionalized polymers can be grafted to proteins, conjugated to a 
small molecule fluorophore, and subsequently internalized into cells in a receptor-specific 
manner. Poly(2-vinyl-4,4-dimethylazlactone) (PVDMA) synthesized using reversible 
addition-fragmentation transfer (RAFT) was modified post-polymerization with 
substoichiometric equivalents of triethylene glycol monomethyl ether (mTEG) to yield 
reactive water-soluble, azlactone-functionalized copolymers. These reactive polymers 
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were then conjugated to proteins holo-transferrin and ovotransferrin. Protein gel analysis 
verified successful conjugation of proteins to polymer, and protein-polymer conjugates 
were subsequently purified from unreacted proteins and polymers using size exclusion 
chromatography. Internalization experiments using a breast cancer cell line that 
overexpresses the transferrin receptor on its surface showed that the holo-transferrin-
polymer conjugate was successfully internalized by cells in a mechanism consistent with 
receptor-mediated endocytosis. Our approach to protein-polymer conjugate synthesis 
offers a simple, tailorable strategy for preparing bioconjugates of interest for a broad range 
of biomedical applications. 
 
4.2 Introduction 
 Treatment of numerous diseases could benefit from improved options for targeted 
delivery of drugs to disease-specific locations.  Two important challenges in medicine for 
which targeted delivery could significantly improve patient outcomes are delivery of 
therapeutics to the central nervous system and delivery of chemotherapeutics selectively to 
tumor cells.  The blood-brain barrier (BBB) frequently prevents therapeutics from 
sufficiently accessing brain tissue, creating a major bottleneck for developing treatments 
for diseases like Alzheimer’s disease and brain tumors [1,2].  Often, drug development 
efforts for neurological diseases must focus on small molecule candidates constrained by 
a set of physicochemical properties that can facilitate their passage across the BBB [3].  
Receptor-mediated transcytosis (RMT) is a promising approach being developed to use 
native transport pathways to shuttle larger therapeutic complexes across the BBB [4,5].  
Initial reports of the ongoing clinical trials for the first RMT-based therapeutic to be used 
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in humans have been positive [6], encouraging continued development of therapeutics 
using RMT pathways for drug delivery.  
Specific targeting of chemotherapeutic agents to tumor cells could significantly 
reduce toxic side effects that are currently caused by the systemic distribution of 
administered cytotoxic drugs in the body [7].  In recent years, substantial progress has been 
made toward the general goal of targeted therapy using both passive and active targeting 
approaches [7].  For example, antibody-drug conjugates have been developed that rely on 
the specific targeting of tumor biomarkers using antibodies to deliver a toxic payload to 
tumor cells [8–10].  There are, however, challenges with finding appropriate chemistries 
for conjugating the drug to the antibody, with continued need for improved linkers between 
antibodies and their drug payload that do not inhibit antibody targeting and that can release 
drug when the conjugate has reached the desired location [8].  Inorganic and polymeric 
nanocarriers have also been explored for both passive and active targeting [11,12].  
Although several nanocarriers that passively target tumor cells have been approved for 
clinical use, no actively targeted nanocarriers have advanced past clinical trials to date [12].  
There remains a need for better drug carriers that actively target pathological cells.  
 Active targeting of drug carriers to particular cell types is generally achieved by 
conjugating a drug carrier to a ligand that binds specific cell-surface receptors.  Drug 
carriers include polymers and nanoparticles, and ligands can be proteins, peptides, or 
certain small molecules [7,11,12].  Proteins are particularly useful as targeting ligands 
because they exhibit precise binding interactions with molecular partners.  Protein 
engineering permits the manipulation of these binding interactions such that a given 
targeting protein can be engineered to meet identified design parameters, such as a desired 
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affinity or binding epitope on the receptor [13,14].  Consequently, proteins, including 
antibodies and other protein classes, have found wide success on their own as therapeutics 
for a variety of diseases [15,16].  To be useful as a targeting ligand for drug delivery 
applications, proteins that interact with a chosen disease marker need to be chemically 
coupled to the drug to be delivered. Versatile and straightforward chemistries to conjugate 
drugs to proteins are still needed [8].  Polymers that link targeting proteins to drug 
molecules are a promising avenue for developing a modular strategy for synthesizing 
targeted drug delivery molecules, where any targeting protein of interest could be readily 
coupled to a drug molecule linked by a polymer that couples to protein and to drug.  Here, 
we report the development of protein-polymer conjugates for targeted drug delivery 
applications.  
Protein-polymer conjugates are being used in a variety of applications in medicine 
and industry [17–19].  The first generation of protein-polymer conjugates were comprised 
of polyethylene glycol (PEG) attached to therapeutic proteins to extend the circulation time 
and reduce the immunogenicity of the therapeutics. Over the past several decades, more 
than a dozen PEGylated molecules have been approved for use in humans [20–22].  While 
PEG continues to be the leading polymer for preparing clinically-relevant protein-polymer 
conjugates, PEG does have limitations, such as non-degradability and potential 
immunogenicity [23], that necessitate the development of protein-polymer conjugates with 
an expanded selection of finely tuned functionalities.  
Numerous advances in the development of protein-polymer conjugates with 
expanded chemistries useful for biomedical applications have been reported in recent years 
[17–19,24,25].  Strategies for controlled polymerization [19,24–26] and site-specific 
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conjugation [24,25,27–34] of polymers to proteins have facilitated the synthesis of more 
well-defined protein-polymer conjugates. Site-specificity and control of polymer synthesis 
are jointly achieved with approaches that grow polymers from proteins functionalized with 
an initiator at a unique location in the protein sequence [24,31,33]. While growing 
polymers from appropriately-functionalized proteins, termed ‘grafting-from,’ affords more 
easily purified conjugates [19,25,26], the grafting-from approach does limit to some extent 
the chemistries that can be incorporated into the polymer structure. In addition, grafting-
from requires a new polymer to be synthesized each time the bioconjugate is prepared, 
which may lead to small variations in the polymer structure, even when controlled methods 
are used. In a ‘grafting-to’ approach, preformed polymers bearing end-group or side-chain 
reactive functionality are conjugated to proteins [25,35,36].  A number of different 
chemistries have been used to facilitate grafting of polymers to proteins, including 
polymers bearing amine-reactive functionality such as NHS-esters or anhydrides 
[25,36,37], maleimide or dibromomaleimide functionality for reaction with cysteine 
residues [25,36,38–40], and biorthogonal “click” reactions [25,34,36,41].  Grafting-to 
permits incorporation of both water-soluble and water-insoluble functionalities into the 
polymer structure.  For example, hydrophobic drugs are an important class of water-
insoluble molecules that can be incorporated into polymer structures when using the 
grafting-to approach.  Grafting-to also allows conjugation of a defined polymer structure 
to a variety of different proteins.  
In the work reported here, we explored the use of side-chain reactive polymers for 
the preparation of protein-polymer conjugates via a grafting-to approach.  Side-chain 
reactive polymers and their subsequent post-polymerization modification [42–45] offer 
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opportunities for combinatorial synthesis of a broad range of polymer structures such that 
the influence of polymer structure on bioconjugate properties can be easily explored [46]. 
Furthermore, these reactive groups could be used to tether drug molecules to the scaffold 
before protein conjugation.  In particular, hydrophobic drugs can be more readily coupled 
to a polymer in organic solvent compared to directly coupling a hydrophobic drug to a 
protein in aqueous solution.  From a drug delivery perspective, a polymer with a tunable 
number of sites for drug attachment is desirable because it permits intentional selection of 
the number of drug molecules per protein-polymer conjugate.  Such flexibility in drug 
loading enables targeting an appropriate concentration in the body within a particular 
drug’s therapeutic window. It is then possible to achieve a sufficiently high concentration 
of the drug at the disease site to have a desired therapeutic effect while remaining below 
concentrations in the body that cause unacceptable toxicities.  The ability to conjugate a 
variety of active drug molecules directly to protein residues is more difficult than 
approaches that use a delivery scaffold.   
 We used the reactive polymer poly(2-vinyl-4,4-dimethylazlactone) (PVDMA, 
Figure 4.1) to prepare a series of protein-polymer conjugates.  PVDMA is attractive for the 
preparation of bioconjugates for several reasons.  It can be synthesized from the vinyl 
monomer using a variety of polymerization methods [43,45,47].  In this current work, we 
synthesized PVDMA using reversible addition-fragmentation chain transfer (RAFT) 
polymerization, which has been demonstrated previously to yield well-defined azlactone-
functionalized polymers (Figure 4.1A) [47–50].  Importantly for this work, the five-
membered lactone of PVDMA rapidly undergoes ring-opening reactions with 
nucleophiles, such as amines and alcohols, including those found in native proteins [45,51].  
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Thus, a broad range of polymeric structures and bioconjugates can be readily synthesized 
starting from the same template polymer.  While azlactone-functionalized polymers have 
been used to immobilize proteins on a variety of solid supports or thin films [45,51], only 
a few examples of soluble protein-polymer conjugates have been reported [48,52,53].  For 
example, Fontaine and coworkers demonstrated the feasibility of using the azlactone 
functional group for conjugation of  polymers to lysozyme [48,52] while Weeks et al. 
reported the conjugation of recombinant elastin-like polypeptides to PVDMA [53].  
However, because PVDMA is not inherently water-soluble, these previous reports used 
organic solvents to conjugate the protein to the polymer [48,52,53]. 
In this work, we demonstrate the feasibility of synthesizing water-soluble, 
azlactone-functionalized polymers and conjugating these reactive polymers to disease-
relevant proteins.  Stover and coworkers reported the synthesis of water-soluble azlactone-
functionalized polymers through copolymerization of the azlactone monomer VDMA with 
a series of water-soluble comonomers [54].  Others have demonstrated that PVDMA can 
be rendered water soluble by exhaustive functionalization with appropriate side chain 
functionality [55].  In this report, we functionalized PVDMA with substoichiometric 
amounts of triethylene glycol monomethyl ether (abbreviated mTEG) to prepare reactive, 
water-soluble polymers (PVDMA-mTEG, Figure 4.1A).  This polymer readily conjugates 
to the proteins holo-transferrin (hTF) and ovotransferrin (OTF) in aqueous solution (Figure 
4.1B).  hTF represents a useful model protein for the development of targeted drug delivery 
scaffolds because the protein binds to and is internalized by cell-surface transferrin 
receptors (TFR) present on endothelial cells that comprise the blood brain barrier and 
expressed at high levels on many tumor cells [56].  hTF has also been used recently in the 
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synthesis of protein-polymer conjugates and shown to facilitate receptor-specific targeting 
of conjugates to cells expressing the transferrin receptor [57].  Using confocal microscopy 
assays, we show that hTF-PVDMA-mTEG conjugates are internalized specifically into a 
tumor cell line that expresses TFR.  This work exemplifies a modular approach for 
synthesizing protein-polymer conjugates and offers a new system that can be easily tailored 
for targeted drug delivery to a variety of disease-specific cell types. 
 
4.3 Results and Discussion 
 
4.3.1 Synthesis and characterization of mTEG-functionalized PVDMA 
 PVDMA was synthesized using RAFT polymerization [58] (Figure 4.1A, step 1) 
to yield a well-defined homopolymer with Mn = 13.1 kg/mol (Table 4.1).  Water-soluble 
azlactone-functionalized polymers for protein conjugation were synthesized by treating the 
homopolymer with 0.3 equivalents of mTEG relative to the azlactone repeat unit (Figure 
4.1A, step 2).  DBU was used as a base catalyst and all reactions were stirred at 40 °C 
overnight.  Figure 2A shows FT-IR spectra of PVDMA homopolymer and PVDMA treated 
with mTEG.  The IR spectrum of PVDMA prior to functionalization (Figure 4.2A, black 
dashed curve) reveals peaks characteristic of the carbonyl (1820 cm-1) and imine (1670 cm-
1) bonds of the azlactone ring.  Treatment of PVDMA with 0.3 equivalents of mTEG (red 
curve) leads to a decrease in the carbonyl and imine peaks and the appearance of peaks at 
1735 cm-1 (ester), 1650 cm-1 (amide I), and 1540 cm-1 (amide II) that result from ring-
opening of the lactone with an alcohol nucleophile.  Quantitative analysis of mTEG 
functionalization using NMR spectroscopy revealed that mTEG was incorporated into the 
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polymer in nearly quantitative yield (Table 4.1).  GPC analysis of PVDMA functionalized 
with mTEG revealed an increase in molecular weight consistent with functionalization of 
the polymer (Table 4.1).  GPC analysis also confirmed that no polymer crosslinking 
occurred during treatment with mTEG, based on observing no increase in dispersity 
comparing polymer before and after mTEG functionalization.  The absence of crosslinking 
is expected since mTEG only has one nucleophile that is reactive with the azlactone group. 
Finally, while PVDMA can be functionalized with larger amounts of mTEG, polymers 
modified with 0.3 equivalents proved to be soluble in water. Thus, this polymer, referred 
to hereafter simply as PVDMA-mTEG, was used for all experiments described here to 
provide the greatest number of remaining reactive groups in the polymer for additional 
modifications and protein conjugation.  
One potential challenge associated with using the azlactone moiety for protein 
conjugation in aqueous solution is that these groups are susceptible to hydrolysis.  
However, hydrolysis reactions are typically slower than reactions of azlactones with 
amines.  Furthermore, azlactone groups have been shown to persist for several hours in 
water when copolymerized with certain water soluble monomers [54].  To qualitatively 
characterize the rate of hydrolysis of PVDMA-mTEG, we acquired IR spectra of a polymer 
dissolved in water (Figure 4.2B) over time.  The series of spectra shown in Figure 4.2B 
reveal that the lactone carbonyl peak (1820 cm-1) persists for at least 12 hours.  The polymer 
fully hydrolyzes in 24 hours as evidenced by the complete disappearance of the lactone 
carbonyl peak at 1820 cm-1 (Figure 4.2B).  Based on these data, we hypothesized that, 
following functionalization with mTEG, sufficient azlactones would remain on the 
polymer to permit reaction with amines on a protein (i.e., the N-terminus or lysine 
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residues), but that all residual azlactone groups would fully hydrolyze during or after 
protein conjugation.  This latter hydrolysis reaction is desirable to avoid unwanted 
reactions of the polymer with proteins on cells in cell internalization experiments.  
 
4.3.2 Protein holo-transferrin conjugates to PVDMA-mTEG 
 For our initial experiments, holo-transferrin (hTF) was selected to determine the 
feasibility of conjugating proteins to PVDMA-mTEG.  hTF is an 80 kDa glycoprotein 
containing 58 lysine residues (UniProt P02787) and is the native protein ligand for the 
transferrin receptor (TFR) [56].  Upon binding its receptor, hTF gets internalized into cells 
through receptor-mediated endocytosis.  The hTF-TFR interaction is of interest for a 
variety of clinical applications [56].  For example, receptor-mediated transcytosis 
facilitated by TFR has been studied for drug delivery across the blood-brain barrier to the 
central nervous system [59].  TFR is also overexpressed in many cancers, which makes it 
an interesting receptor system to be used as a model for targeted drug delivery to tumor 
cells [60].  Because PVDMA reacts readily with the primary amines in the N-termini and 
lysine residues in proteins [45,51], hTF provides ample reactive sites for conjugation.  
Conjugates were prepared by incubating PVDMA-mTEG with hTF in phosphate 
buffered saline (PBS) containing 15% v/v DMSO at 4 °C.  Low concentrations of DMSO 
are commonly used to facilitate conjugation of reactive small molecules and polymers to 
proteins [37,61].  We examined a range of molar ratios of polymer:protein for hTF 
conjugation reactions.  Successful conjugation of polymer to protein was assessed using 
SDS-PAGE (Figure 4.3).  Lane 1 contains pure hTF protein with no polymer.  Lane 2 
contains PVDMA-mTEG polymer with no protein, which is not detected by the protein gel 
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stain.  Lanes 3 through 6 include conjugation reactions in which the amount of protein was 
kept constant while the amount of PVDMA-mTEG was increased.  Lane 3 reveals the 
presence of a faint band at higher molecular weight than the hTF protein band.  The 
apparent molecular weight of this band is consistent with the molecular weight of one 
protein and one polymer molecule, suggesting the formation of conjugates at a 1:1 molar 
ratio of protein:polymer.  With higher amounts of polymer in the conjugation reaction 
(Figure 4.3, lane 4-6), we observe a band at a molecular weight consistent with a 
protein:polymer molar ratio of 1:2.  Increasing the molar amount of polymer relative to 
protein resulted in a darkening of this higher molecular weight band.  We do not observe 
any protein bands at a molecular weight that suggests two or more proteins in a conjugate 
molecule with at least one polymer.  While all reactions show residual unreacted protein, 
as demonstrated by the presence of the original protein band in lanes 3-6, the intensities of 
these bands are increasingly reduced compared to the intensity of the protein only sample 
shown in lane 1.  The same amount of total protein was loaded into lanes 1 and 3-6, and, 
therefore, reduction in the original protein band intensity further suggests successful 
protein-polymer conjugation.  Taken together, these data demonstrate that hTF conjugates 
to PVDMA-mTEG through reactive, azlactone functionality in aqueous solution. 
 
4.3.3 Protein-polymer conjugates can be purified by size exclusion chromatography 
 Prior to use in receptor targeting experiments with a human cell line, protein-
polymer conjugates were purified from unreacted protein and unreacted polymer.  Samples 
were first concentrated and purified from low molecular weight species by using a 
centrifugal filtration device with a 10 kDa molecular weight cut-off (MWCO) before being 
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loaded onto a size exclusion chromatography (SEC) column.  Samples were analyzed by 
detecting absorbance at 220 nm.  Pure hTF protein exhibits a single narrow peak on SEC 
(Figure 4.4A, red solid curve).  PVDMA-mTEG exhibits a broad high molecular weight 
peak and a narrow low molecular weight peak (Figure 4.5A).  Unpurified protein-polymer 
conjugates eluted at shorter retention times (i.e., higher molecular weight) relative to hTF 
only and included low molecular weight species similar to polymer only samples (Figure 
4.4A, black dashed curve).  We were able to collect the high molecular weight protein-
polymer conjugate peak, which no longer contained unreacted protein when analyzed by 
SEC (Figure 4.4A, red dashed curve) and SDS-PAGE (Figure 4.4B).  Because the 
molecular weight of the polymer is less than the molecular weight of the protein, we 
anticipate that most or all of the unreacted polymer was removed through SEC purification. 
However, because polymer alone does not stain on the protein gel, it is possible that some 
unreacted polymer remains following SEC purification.  
The purified protein-polymer conjugates contained a mixture of conjugates at 
protein:polymer ratios of 1:1 and 1:2 (Figure 4.4B).  On SEC, we did not observe any 
products of the conjugation reaction that would suggest more than one protein per 
conjugate, based on analysis of retention time of the protein-polymer conjugation reactions.  
However, it is possible that any conjugates with two proteins joined by one or more 
polymers may elute at a longer retention time than would be predicted for a globular protein 
of the same molecular weight, so it remains possible that some protein-polymer conjugates 
containing two proteins exist in our reaction mixture.  The lack of molecules in the 
conjugation reaction mixture eluting at less than 20 min retention time does conclusively 
indicate a lack of higher order aggregates. 
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4.3.4 Fluorescent, hydrophobic small molecule can be coupled to PVDMA-mTEG 
prior to polymer conjugation to protein 
 To permit visualization of protein-polymer conjugates in the presence of cells using 
fluorescence imaging techniques, we fluorescently labeled PVDMA-mTEG with the 
amine-functionalized fluorophore fluorescein cadaverine (FC, labeled polymer denoted as 
PVDMAFC-mTEG).  Coupling a small molecule fluorophore directly to the polymer 
models a way in which drugs could be tethered to the polymer for future drug delivery 
applications.  FC was reacted with PVDMA-mTEG in DMSO in a molar ratio of FC to 
VDMA monomer such that 1-2 molecules of FC were coupled to each polymer chain. 
Many small molecule drugs are hydrophobic, and the ability to couple drugs to polymer in 
organic solvent prior to an aqueous reaction conjugating polymer to protein is an advantage 
of our approach.  We then coupled the fluorescently labeled PVDMAFC-mTEG to hTF and 
to the protein ovotransferrin (OTF).  OTF is the chicken homolog of human transferrin. It 
has the same overall structure and size as human hTF, but is sufficiently distinct in 
sequence that it does not bind to human TFR [62], making OTF conjugates a suitable 
negative control for TFR binding and internalization experiments.  FC labeled protein-
polymer conjugates were purified from unreacted molecules by SEC as described above, 
yielding a single pure peak when analyzed by SEC (Figure 4.6A).  The peak exhibits 
absorbance at 220 nm (Figure 4.6A, top) and at 494 nm (Figure 4.6A, bottom).  Absorbance 
at 494 nm is characteristic of the fluorophore, and is absent in the sample of pure protein, 
indicating successful conjugation of FC to polymer, and subsequent conjugation of 
PVMDAFC-mTEG to protein.  Analysis of the purified FC labeled protein-polymer 
conjugates using UV-visible spectroscopy resulted in absorbance peaks at 280 nm and 494 
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nm (Figure 4.6B).  In pure hTF protein, there is only an absorbance peak at 280 nm.  In 
PVDMA-mTEG without FC conjugation, we see no absorbance peaks in the UV-visible 
range, as expected (Figure 4.5B).  The presence of the 494 nm absorbance peak in the FC-
coupled PVMDA-mTEG and in the purified protein-polymer conjugates confirms that FC 
was successfully conjugated to PVDMA-mTEG and that PVDMAFC-mTEG subsequently 
was able to be conjugated to hTF and OTF.  
 
4.3.5 Internalization of protein-polymer conjugates into cells is receptor-specific 
 We next determined that protein-polymer conjugates are specifically internalized 
through receptor-mediated endocytosis.  MCF-7 breast cancer cells have been shown to 
overexpress the transferrin receptor on their surface and have been previously used to study 
internalization of molecules targeted to TFR [63,64].  Flow cytometry with an antibody 
that recognizes human TFR confirmed high levels of surface TFR expression on the MCF-
7 cell line (Figure 4.7A).  A titration binding assay was performed with fluorescently 
labeled hTF and MCF-7 cells to determine an appropriate concentration of protein or 
protein-polymer conjugate for cell internalization experiments.  We determined a 
dissociation constant (KD) of 10 ± 5 nM (Figure 4.7B), which is consistent with previously 
reported values [56].  A biological interpretation of the KD is that half of the receptors are 
occupied by ligand when the ligand concentration is equal to the KD.  In subsequent 
conjugate internalization experiments, we incubated MCF-7 cells with 10 nM of conjugates 
to provide ample ligand to visualize receptor-specific internalization, without 
overwhelming the receptor internalization machinery.   
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 All internalization experiments were conducted by incubating protein-polymer 
conjugate samples or control samples with MCF-7 cells for 1 h at 37 °C in culture media 
without serum.  These conditions are on the time scale and at the relevant temperature for 
receptor-mediated endocytosis to occur in MCF-7 cells [65].  Prior to imaging, all cells 
were stained with phalloidin (shown by red fluorescence), which binds to actin filaments 
and demarcates cell boundaries, and DAPI (shown by blue fluorescence), which stains cell 
nuclei.  All protein, protein-polymer, and polymer samples were fluorescently labeled with 
either Alexa Fluor 488 (AF488, samples with protein only) or FC (all polymer-containing 
samples) and are shown as green fluorescence.  
Row 1 of Figure 4.8 shows confocal microscopy images for MCF-7 cells stained 
with DAPI and phalloidin to identify nuclei and actin filaments, but with no protein, 
polymer, or conjugates added; these images show the level of background cellular 
autofluorescence in the channel that was used to visualize targeting molecules.  Row 2 of 
Figure 4.8 shows confocal microscopy images for MCF-7 cells incubated with 10 nM hTF-
488.  The green channel and merged images show punctate regions of green fluorescence 
distributed throughout the cell body (cell boundaries shown in red channel), indicating 
internalization of the protein.  The presence of punctate structures is consistent with protein 
localized to endosomes after receptor-mediated endocytosis.  When treated with increasing 
concentrations of hTF-488, MCF-7 cells show increased levels of internalization (Figure 
4.9), also consistent with receptor-mediated endocytosis.  To further demonstrate that 
ligand-receptor interactions are necessary for internalization, we conducted a competition 
experiment in which cells were treated with hTF-488 (10 nM) and a 1000-fold excess of 
unlabeled hTF (10 µM) (Figure 4.8, row 3).  As expected, when labeled protein was in 
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competition with an excess of unlabeled protein, green fluorescence signal within the cell 
body was reduced to the level of background autofluorescence (Figure 4.8, row 3).  The 
results of these control experiments demonstrate that hTF is internalized into our MCF-7 
cells via a mechanism consistent with receptor-mediated endocytosis.  
Confocal microscopy images of MCF-7 cells treated with hTF conjugated to 
PVDMAFC-mTEG (Figure 4.8, row 4) exhibited punctate regions of green fluorescence 
throughout the cell body, similar to results observed with hTF-488.  These results 
demonstrate successful internalization of the conjugates. A competition experiment similar 
to that described above for hTF-488 was performed in which cells were treated with hTF-
PVDMAFC-mTEG conjugate in the presence of 1000-fold excess (10 µM) unlabeled hTF. 
The green channel and merged confocal microscopy images for this experiment (Figure 
4.8, row 5) reveal the reduction of green signal to the level of autofluorescence, indicating 
that the internalization of hTF-targeted protein-polymer conjugates is dependent on 
specific binding of hTF to TFR.  Internalization of hTF-488 and of hTF-PVDMAFC-mTEG 
molecules was further demonstrated by collecting a series of images from neighboring 
confocal planes of clusters of cells, termed z-stacks, confirming that green fluorescence is 
present within cells, rather than on the cell surface (Supporting Video 1 and Video 2).    
We explored whether non-specific polymer interactions substantially contributed 
to the binding and internalization signal we observed for hTF-PVDMAFC-mTEG (Figure 
4.10).  We co-incubated hTF-PVDMAFC-mTEG with an excess of unlabeled PVDMA-
mTEG, and observed no noticeable reduction in signal, suggesting that non-specific 
interactions of the polymer with the cell surface are not necessary for binding and 
internalization (Figure 4.10, row 1).  To further confirm that specific ligand-receptor 
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interactions are required for internalization, we examined potential binding and 
internalization of the negative control protein-polymer conjugate, OTF-PVDMAFC-mTEG, 
which was not expected to bind any MCF-7 cell surface receptors.  OTF is a chicken 
transferrin, and MCF-7 cells express human TFR.  We did not observe any MCF-7 cell 
binding or internalization of OTF protein directly labeled with AF488 (Figure 4.10, row 
2).  Similarly, we also did not observe MCF-7 cell binding or internalization of the non-
targeted OTF-PVDMAFC-mTEG (Figure 4.10, row 3).  Finally, fluorescently labeled 
polymer not conjugated to any protein (PVDMAFC-mTEG) does not adhere to or 
internalize into MCF-7 cells (Figure 4.10, row 4).  These results provide further 
confirmation that hTF-PVDMAFC-mTEG conjugates are internalized via specific 
interactions of the hTF ligand with cell surface receptor TFR, rather than through non-
specific interactions of polymer with the cells. 
When conjugating polymers to proteins, there is the risk that the polymer will 
destabilize the protein structure, or that the polymer will sterically block the interaction of 
a protein ligand with its receptor, rendering the protein-polymer conjugate irrelevant for 
the intended application.  Importantly, the protein-polymer conjugate internalization 
experiments we have conducted demonstrate that hTF protein maintains its ability to bind 
and be internalized by TFR when conjugated to PVDMA-mTEG, suggesting that hTF 
maintains its structure and function when conjugated to PVDMA-mTEG. 
 
4.4 Conclusion 
 We have developed a new, modular strategy for conjugating diverse proteins to 
hydrophilic polymers using the reactive, azlactone-functionalized polymer PVDMA with 
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the goal of developing conjugates for applications in targeted drug delivery.  In our 
approach, we first functionalized PVDMA with mTEG to render the polymer water-
soluble.  We demonstrated the conjugation of this reactive polymer with proteins in 
aqueous solution.  When the targeting protein holo-transferrin was conjugated to a 
fluorescently-labeled analog of PVDMA-mTEG, protein-polymer conjugates were 
internalized into tumor cells expressing the TFR in a receptor-specific manner.  
Internalization of hTF-PVDMA-mTEG conjugates into human cells expressing 
TFR has implications for targeted delivery to the central nervous system and to tumor cells 
with overexpressed receptors [4,56,60,66–68].  Our approach to synthesizing protein-
polymer complexes for drug delivery could be extended to encompass protein ligands that 
bind other receptors relevant for a variety of clinical needs to generate protein-polymer-
drug conjugates for diverse targeted drug delivery applications.  Although in this initial 
report proteins were conjugated to PVDMA through primary amines contained naturally 
in the native protein sequences, both the targeting protein and the polymer could be further 
modified for site-specific conjugation reactions. 
While the experiments described here focused on mTEG-modified PVDMA, this 
post-polymerization modification approach to the synthesis of multifunctional 
bioconjugates permits rapid and straightforward access to a broad range of macromolecular 
structures without requiring the synthesis of new polymers each time a new structure is to 
be investigated.  For example, diverse side chain chemistries and degrees of 
functionalization can readily be explored. In addition, because the polymer modification 
reactions are conducted initially in organic solvents, non-water soluble functionality, such 
as hydrophobic drugs, may be incorporated into the polymer prior to conjugation to the 
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proteins.  The synthetic versatility of PVDMA and ease with which it can be conjugated to 
proteins offers opportunities for preparing a range of bioconjugates tailored to specific 
biomedical applications. 
 
4.5 Experimental Procedures 
 
4.5.1 Materials 
 Triethylene glycol monomethyl ether (mTEG), 1,8-diazabicylo[5.4.0]undec-7-ene 
(DBU), 2,2’-azobis(2-methylpropionitrile) (AIBN), 2-(dodecylthiocarbonothioylthio)-2-
methylpropionic acid, ovotransferrin (OTF), 4-iodoanisole, and anhydrous dioxane were 
purchased from Sigma Aldrich and used without further purification unless otherwise 
noted.  The monomer 2-vinyl-4,4-dimethylazlactone (VDMA) was synthesized as 
previously described [69].  Fluorescein cadaverine (FC) was purchased from Biotium. 
Alexa Fluor 488 tetrafluorophenyl ester, NuPAGE 4-12% Bis-Tris gels, MES buffer, and 
LDS buffer were purchased from ThermoFisher Scientific.  Inhibitor removal resin was 
purchased from Alfa Aesar.  Holo-transferrin (HTf, Cat.: 616397) was purchased from 
CalBiochem.  PBS (10X) were purchased from Fisher Scientific.  THF was purified using 
alumina drying columns.  All other solvents were purchased from Pharmco-AAPER 
(Brookfield, CT). Deuterated DMSO (DMSO-d6) and deuterated chloroform (CDCl3) were 
purchased from Cambridge Isotope Laboratories, Inc.  Dulbecco’s Modified Eagle’s 
Medium (DMEM) was purchased from ATCC, and all other cell culture reagents were 
obtained from Gibco.  Phalloidin conjugated to Alexa Flour 594 was purchased from 
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Thermo Fisher, formaldehyde as a 3.7% solution in PBS was from Fisher Scientific, and 
Vectashield mounting medium with DAPI was from Vector Labs. 
 
4.5.2 General considerations 
 1H-NMR spectra were collected on a Bruker 500 MHz NMR spectrometer. 
Attenuated total reflectance infrared (ATR-IR) spectra were obtained using a Bruker 
ALPHA FTIR spectrometer and analyzed using OPUS software version 7.5.  Gel-
permeation chromatography (GPC) was performed on an Agilent 1260 GPC instrument 
equipped with PLgel Mixed C and Mixed D columns and an RI detector, operating in THF 
at 40 °C with a flow rate of 1 mL/min.  Molecular weights and dispersities were measured 
against polystyrene calibration standards.  SEC was performed using a Superdex 75 10/300 
GL column (GE) and an Agilent 1200 series liquid chromatography system.  Flow 
cytometry was performed on a Guava easyCyte flow cytometer (Millipore-Sigma).  Laser 
scanning confocal microscopy images were acquired on a Leica TCS SP5 laser scanning 
confocal microscope and analyzed using LAS AF software version 2.7.3.9723. 
 
4.5.3 Synthesis of poly(2-vinyl-4,4’-dimethylazlactone) (PVDMA) 
 VDMA was passed through a phenolic inhibitor removal resin followed by passage 
through a short plug of silica gel prior to polymerization.  The initiator 2,2′-
azobisisobutyronitrile (AIBN) was recrystallized twice from methanol prior to use.  AIBN 
(5.9 mg, 0.036 mmol, 0.5 equiv.) and CTA (26 mg, 0.072 mmol, 1 equiv.) was weighed 
into a 25 mL schlenk-flask equipped with a stir bar.  Anhydrous toluene (4.5 mL) was 
added to the flask and the mixture was stirred to dissolve the AIBN.  VDMA (1.5 g, 10.8 
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mmol, 150 equiv.) was added to the flask, the flask was capped with a septum and placed 
in a dry ice and isopropanol bath at ~7 torr.  Atmosphere was purged from the flask using 
three freeze-pump-thaw cycles and filled with nitrogen.  The reaction solution was stirred 
at 70 °C for 12 h (~85% conversion).  The slightly viscous reaction mixture was cooled to 
room temperature and acetone (~3 mL) was added to the flask. The polymer was 
precipitated twice into hexanes to yield a pale yellow solid (1.26 g, 92% yield).  1H-NMR 
(500 MHz, CDCl3): δ = 1.37 (br s, (-CH3)2), 1.62-2.1 (br m, -CH2CH-), 2.69 (br s, -CH2CH 
). FT-IR (ATR, cm-1): 2980-2900 (C-H), 1820 (lactone C=O), 1672 (C=N). GPC: Mn = 
13.1 kg/mol; PDI = 1.35. 
 
4.5.4 Synthesis of PVDMA-mTEG 
 PVDMA (100 mg, 0.72 mmol with respect to the molecular weight of the repeat 
unit VDMA) and mTEG (35 mg, 0.216 mmol, 0.3 equiv.) were combined in a 5 mL round-
bottomed flask and dissolved in anhydrous THF (3 mL).  DBU (16.1 µL, 0.108 mmol, 0.15 
equiv.) was added to catalyze the reaction.  4-Iodoanisole (50.5 mg, 0.216 mmol, 0.3 equiv) 
was added as an internal standard for determining degree of functionalization.  The flask 
was capped with a rubber septum and purged with nitrogen for 15 minutes.  The reaction 
was stirred at 40 °C for 10 h.  Prior to purification, an aliquot (~0.2 mL) of the reaction 
mixture was removed for 1H NMR analysis to determine the degree of mTEG 
functionalization.  The remaining polymer solution was purified by precipitation into 
diethyl ether (100 mL) followed by centrifugation (9,000xg at 4℃, 2 min) to yield a yellow 
product.  1H-NMR (300 MHz, CDCl3): δ = 1.37-1.50 (br m, (-CH3)2), 1.62-2.1 (br m, -
CH2CH-), 2.5 (br s, -CH2CH-), 2.84 (br s, -CH2CH-), 3.38 (br s, CH3-O-), 3.45-3.65 (br m, 
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-CH2-O-), 4.22 (br s, -C(=O)O-CH2). FT-IR (ATR, cm-1): 2880-2900 (C-H), 1820 (lactone 
C=O), 1735 (ester C=O), 1672 (C=N), 1650 (amide C=O), 1540 (amide II CN and NH). 
 
4.5.4.1 PVDMAFC-mTEG 
 PVDMA-mTEG (50 mg, 0.26 mmol relative to the repeat unit) was dissolved in 
anhydrous DMSO (1 mL) in a 1.5 mL microcentrifuge tube.  Fluorescein cadaverine (FC) 
(0.95 mg, 1.3 µmol) was dissolved in anhydrous DMSO (9.5 µL) and added to the polymer 
solution.  The reaction was mixed by gentle rotation for 2 h at room temperature.   
 
4.5.4.2 Hydrolyzed PVDMAFC-mTEG 
 Unreactive, hydrolyzed PVDMAFC-mTEG used for control experiments was 
synthesized by dissolving PVDMAFC-mTEG (100 mg) in DMSO (2 mL) in a 5 mL round 
bottom flask.  Water (95.7 mg, 5.32 mmol, 10 eq relative to the azlactone repeat unit) and 
DBU (202 mg, 1.33 mmol, 2.5 eq relative to the azlactone repeat unit) was added and the 
solution was allowed to react at 40 °C for 3 h.  Complete hydrolysis was confirmed using 
ATR-FTIR spectroscopy.  Samples were then dialyzed against PBS for 24 h (MWCO = 
3.5 kDa) to remove any small molecule impurities, including unreacted fluorophore, prior 
to incubation with cells. FT-IR (ATR, cm-1):  3500-2600 (O-H), 2880-2900 (C-H), 1725 
(carboxylic acid C=O), 1650 (amide C=O), 1540 (amide II CN and NH). 
 
4.5.5 PVDMA-mTEG hydrolysis study 
 PVDMA-mTEG (244 mg, 1.32 mmol relative to the repeat unit) was dissolved in 
anhydrous DMSO (4.9 mL). PBS (11 mL) was added to simulate the concentration of 
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polymer used in a 1:50 molar ratio conjugation of hTF to polymer.  At each time point (0.5, 
1, 3, 5, 9, 12, 24, 36 hours), a 1 mL sample (15.3 mg of polymer) was flash frozen in liquid 
nitrogen and freeze dried.  The samples were dissolved in acetone and cast directly onto 
the ATR crystal for analysis by FT-IR spectroscopy. 
 
4.5.6 Synthesis of protein-polymer conjugates 
 Proteins (i.e., hTF and OTF) were conjugated to polymer using the following 
general procedure.  Protein stock solutions of 1 mg/ml were prepared in PBS with 0.1 M 
sodium bicarbonate (pH = 8.0), to increase the reactivity of the primary amines of the 
protein.  Polymer samples (i.e., PVDMA-mTEG or PVDMAFC-mTEG) (50 mg) were 
dissolved in DMSO (1 mL) in a microcentrifuge tube.  A 1 ml aliquot of the desired protein 
(1 mg) was added to polymer solution to achieve a protein:polymer molar ratio of 1:50, 
where a mole of polymer was calculated using data from GPC analysis.  The molecular 
weight of a monomer of VDMA is 139 g/mol.  Therefore, a molar ratio of 1 mol protein: 
50 mol polymer is equivalent to a molar ratio of 1 mol protein: 241 mol VDMA monomer. 
For studies examining the effect on conjugation of the molar ratio of protein:polymer 
molecules, ratios of 1:5, 1:10, 1:20, and 1:50 were compared.  The samples were reacted 
at 4 oC with gentle rotation overnight.  Samples were then dialyzed against PBS for 24 h 
(MWCO = 3.5 kDa) if the sample was not being purified by SEC.   
 
 4.5.7 Analysis of protein-polymer conjugates by SDS-PAGE 
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to analyze conjugation of protein to polymers.  NuPAGE LDS buffer (4X) was added to 
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each sample to a final concentration of 1X, without reducing agent.  All proteins studied 
contain disulfide bonds, and therefore the absence of reducing agents can shift their 
apparent molecular weight from the predicted molecular weight.  The samples were heated 
in a water bath for 10 min at 70 °C to denature the proteins.  Samples were loaded onto a 
NuPAGE 4-12% Bis-Tris gel. The gel was run in NuPAGE MES running buffer (1X).  
Gels were then stained with Simply Blue Safe Stain. 
 
4.5.8 Protein-polymer conjugate purification 
 Protein-polymer conjugation reactions were first concentrated and purified from 
low molecular weight species using a centrifugal filtration device with a MWCO of 10 kDa 
(EMD Millipore) and extensive washing with PBS.  The protein-polymer conjugation 
reaction was then purified by SEC on a Superdex 75 10/300 column (GE Healthcare Life 
Sciences).  Fractions of interest were pooled and concentrated with a centrifugal filtration 
device with a 10 kDa MWCO.  All samples were analyzed by SDS-PAGE and imaged on 
a BioRad ChemiDoc MP imaging system using Image Lab 6.0 software (BioRad).  
 
4.5.9 Cells, cell culture, and receptor detection 
 The MCF-7 human breast cancer cell line (ATCC #HTB-22, acquired in 2018) was 
used to test internalization of protein-polymer conjugates via receptor-mediated 
endocytosis of TFR.  MCF-7 cells were cultured at 37 °C in a humidified atmosphere with 
5% CO2 in DMEM with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml 
streptomycin.  Cells were subcultured after reaching 80% confluency using 0.25% trypsin-
EDTA.  The presence of human TFR on the surface of MCF-7 cells was confirmed with 
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an anti-human TFR antibody directly labeled with fluorescein isothiocyanate (antibody 
clone CY1G4, from BioLegend, Cat.: 334103).  MCF-7 cells were harvested with 0.05% 
trypsin-EDTA.  1 x 106 cells were incubated with antibody at a 1:20 dilution in PBS with 
0.1% bovine serum albumin (PBSA) for 30 min at room temperature with gentle rotation.  
Cells were washed with PBSA to remove unbound antibody, resuspended in PBSA, and 
analyzed by flow cytometry. 
 
4.5.10 Labeling hTF and OTF with Alexa Fluor-488 
 Holo-transferrin (hTF) or ovotransferrin (OTF) (1-2 mg/mL) were labeled with 
AF488 by primary amine chemistry.  Sodium bicarbonate (1M stock solution) was added 
to the protein to a final concentration of 0.1 M to change the pH of the solution to 8.0.  The 
fluorescent dye AF488 5-tetrafluorophenyl ester was dissolved in anhydrous DMSO to a 
final concentration of 11.3 nM.  Dye was added to protein solution, using an amount of dye 
calculated following manufacturer’s protocol to achieve a desired molar excess of dye.  The 
sample was incubated with gentle rotation at room temperature for 1 h.  Labeled protein 
was purified from free dye and concentrated using an Amicon centrifugal filtration device 
with a molecular weight cutoff of 10 kDa by washing extensively with PBS. 
Concentrations and degree of labeling were determined by UV-Vis spectroscopy, 
measuring dye absorption at 494 nm (e = 71,000 cm-1 M-1).  
 
4.5.11 Titration binding assay of hTF-488 with MCF-7 cells 
 Titration binding assays were performed to experimentally determine the binding 
affinity (dissociation constant, KD) of hTF with MCF-7 cells.  MCF-7 cells were harvested 
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with 0.05% trypsin-EDTA. Aliquots of 1x105 cells were incubated for 1 h at 4°C with a 
range of concentrations of fluorescently labeled hTF (hTF-488, 0.5-500 nM) in PBS with 
0.1% BSA (PBSA) with gentle rotation.  Following incubation to reach equilibrium 
binding, cells were washed in PBSA and resuspended in PBSA for analysis.  Data were 
collected and analyzed using flow cytometry.  Experimental triplicate data were collected 
to determine the binding affinity of hTF to its receptor.  For each replicate, the data were 
fit to a sigmoidal binding curve using Kaleidagraph software (Synergy).  The concentration 
of hTF-488 that resulted in the half-maximal value of each best-fit line was determined as 
the KD. The mean of the three individually fit dissociation constants was determined and 
reported with the standard deviation.  
 
4.5.12 Internalization assays and confocal microscopy 
 MCF-7 cells were seeded in a 4-well Millipore EZ chamber slide using 4x104 
cells/well and allowed to establish adherence and reach 50-80% confluency.  The media 
was then replaced with serum-free DMEM containing the specified conjugate sample in a 
500 µl total volume.  hTF-488, hTF-PVDMAFC-mTEG, OTF-488, or OTF-PVDMAFC-
mTEG were added to the wells to a final concentration equivalent to 10 nM of protein per 
well.  For the internalization sample with hydrolyzed PVDMAFC that was not conjugated 
to protein, an amount of polymer equivalent to the amount of polymer in 10 nM of protein-
polymer conjugate was used, as determined by measurement of samples by UV-vis 
spectroscopy, using absorbance at 494 nm due to the presence of fluorophore.  For 
competition experiments with unlabeled hTF, 10 µM unlabeled hTF was included.   For 
the competition experiment with excess unlabeled polymer, 0.5 mg of hydrolyzed 
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PVDMA-mTEG was included.  Samples were incubated for 1 h at 37°C in a humidified 
environment with 5% CO2.  Media with samples were removed, and cells were washed 
with PBS.  Cells were fixed with 3.7% formaldehyde for 5-10 minutes at room temperature, 
and washed with PBS.  Cells were permeabilized by incubation with 0.1% Triton X-100 in 
PBS at room temperature for 5 min, and washed with PBS.  Actin filaments were stained 
with an Alexa Fluor 594 conjugate of phalloidin to help identify cell boundaries by adding 
250 µl per well of phalloidin in PBS diluted following manufacturer’s protocol, and cells 
were washed with PBS.  Wells were removed from the slide and Vectashield mounting 
media containing DAPI for staining cell nuclei was applied to the fixed samples.  Samples 
were then covered with 1.5 mm glass coverslips and sealed with transparent nail polish. 
Samples were imaged using a 63X oil immersion objective.  Images were collected using 
sequential scanning, and an overlay of the sequential images was used to analyze 
internalization, for single focal plane images and for z-stacks collected as a series of 
neighboring focal planes. 
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Figure 4.1 Synthesis of protein-polymer conjugates via a modular grafting-to 
approach using water-soluble, azlactone-functionalized polymers. (A) PVDMA was 
synthesized by RAFT polymerization and functionalized with a substoichiometric 
equivalent of mTEG (0.3 molar eq. relative to repeat unit) to make the polymer soluble in 
water (PVDMA-mTEG). (B) PVDMA-mTEG can be subsequently grafted to a protein, 
























Figure 4.2 Water-soluble, azlactone-functionalized copolymers can be synthesized by 
post-polymerization modification of PVDMA. (A) FT-IR spectra of PVDMA (black 
dashed curve) and PVDMA modified with 0.3 molar equivalents (Eq.) of mTEG relative 
to the repeat unit (red curve). The peaks at 1820 cm-1 (carbonyl) and 1670 cm-1 (imine) are 
characteristic of the azlactone ring. Ring opening of the lactone with an alcohol nucleophile 
results in the disappearance of the azlactone peaks and the appearance of ester (1720 cm-
1), amide I (1650 cm-1), and amide II (1540 cm-1) peaks. (B) FT-IR spectra as a function of 
time of PVDMA-mTEG incubated in water.  FT-IR spectra revealed the disappearance of 
the azlactone carbonyl (1820 cm-1) peak and an increase in the peaks at 1735 cm-1 
(ester+carboxylic acid carbonyl), 1650 cm-1 (amide I), and 1540 cm-1 (amide II). The strong 
peak at 1710 cm-1 corresponds to acetone, which was used to cast the polymer film on the 












Figure 4.3. Protein hTF conjugates to PVDMA-mTEG.  Holo-transferrin (hTF) 
conjugates to PVDMA-mTEG in aqueous solution. The appearance of higher molecular 
weight bands and decrease in intensity of primary protein band indicate protein conjugation 
to polymer. Protein amounts in each lane were held constant. Lane 1 contains protein only, 
lane 2 contains PVDMA-mTEG only.  Lanes 3-6 contain unpurified protein-polymer 
conjugation reactions at an increasing amount of polymer relative to protein, keeping 
amount of protein constant. Molar ratios of protein to polymer molecules in reactions are: 
lane 3 = 1:5; lane 4 = 1:10; lane 5 = 1:20; lane 6 = 1:50. Samples are not reduced. Apparent 
molecular weights of the two protein-polymer conjugate bands are most consistent with 



















Figure 4.4 Purification of hTF-PVDMA-mTEG conjugates. (A) SEC was used to 
analyze and purify hTF-PVDMA-mTEG conjugates from unreacted hTF and from 
unreacted PVDMA-mTEG. Larger molecules have a shorter retention time.  Pure hTF 
protein (red solid line) exhibits a single narrow peak for absorbance at 220 nm.  The 
protein-polymer conjugation reaction (black dashed line) has overlapping peaks that 
include an unreacted hTF peak and a new larger molecule with shorter retention time 
consistent with protein-polymer conjugates, as well as a low molecular weight peak from 
polymer byproducts.  There are no peaks in the conjugation reaction that elute < 20 min, 
indicating the absence of higher order protein-polymer aggregates.  Following collection 
of the protein-polymer conjugate peak and reinjection onto SEC, a narrow peak is observed 
as purified hTF-PVDMA-mTEG (red dashed line). (B) SDS-PAGE analysis of hTF (lane 
1), protein-polymer conjugation reaction before purification (lane 2), and SEC purified 
hTF-PVDMA-mTEG conjugate (lane 3) demonstrates successful purification of 
conjugates using SEC.  In the purified product (lane 3), unreacted hTF is absent. Polymers 
are at lower molecular weight than hTF and should therefore also be removed by SEC 
purification. Molecular weights of purified conjugates are consistent with protein:polymer 













Figure 4.5 PVDMA-mTEG analysis by size exclusion chromatography and UV-Vis 
spectroscopy. (A) PVDMA functionalized with 0.3 molar equivalents of mTEG was 
analyzed on a Superdex 75 30/100 SEC column run at 0.4 ml/min, and absorbance was 
detected at 220 nm and at 494 nm. For absorbance at 220 nm, the functionalized polymer 
sample contained a broad peak characteristic of polymers with a molecular weight 
distribution eluting between 20 and 30 minutes, and a second peak of low molecular weight 
byproducts eluting around 50 minutes. There was no absorbance at 494 nm. (B) PVDMA-
mTEG analyzed using UV-Vis spectroscopy has no absorbance in the 240-700 nm range, 






Figure 4.6 Fluorescent, hydrophobic small molecule can be coupled to polymer and 
protein-polymer conjugates. Small molecule fluorophore fluoresceine cadaverine (FC) 
was conjugated to PVDMA-mTEG, and the resulting PVDMAFC-mTEG was conjugated 
to hTF or OTF. (A) SEC was used to purify and analyze hTF-PVDMAFC-mTEG and OTF-
PVDMAFC-mTEG conjugates from unreacted component molecules.  A single peak for 
hTF-PVDMAFC and for OTF-PVDMAFC with retention time shorter than for the 
corresponding protein alone, and with absorbance at 220 nm (top) and for 494 nm (bottom), 
demonstrates small molecule fluorophore incorporation into the purified protein-polymer 
conjugates. Protein alone does not absorb at 494 nm.  The FC molecule absorbs at 494 nm. 
(B) UV-Vis absorption spectra for hTF protein, PVDMAFC-mTEG, purified hTF-
PVDMAFC-mTEG, and purified OTF-PVDMAFC-mTEG.  The characteristic absorption 
peaks for protein (*) and FC (**) are indicated at 280 nm and 494 nm, respectively. 




Figure 4.7 MCF-7 cells express TFR and bind hTF. (A) MCF-7 cells, which are a human 
breast cancer cell line, express high levels of transferrin receptor (TFR) on their surface, as 
detected by an anti-human TFR antibody directly conjugated to fluorescein and analyzed 
by flow cytometry. (B) The binding of hTF to TFR was measured as the dissociation 
constant (KD) using an equilibrium binding assay. MCF-7 cells were incubated with a range 
of concentrations of hTF directly labeled with Alexa Fluor 488 (hTF-488). The assay was 
performed in experimental triplicate. Data from each replicate were fit to a sigmoidal curve, 
and the KD value was calculated for each replicate. The KD is reported as the mean +/- 





















Figure 4.8 hTF-PVDMAFC-mTEG targeted protein-polymer conjugates are 
internalized into MCF-7 cells through receptor-specific interactions.  Cells not treated 
with protein or protein-polymer conjugate exhibit a low background level of 
autofluorescence in the green channel (row 1). As a positive control, holo-transferrin 
protein directly labeled with fluorophore (hTF-488) is internalized into MCF-7 cells that 
express transferrin receptor, as seen by green punctate structures throughout the cell body 
(row 2).  hTF-488 internalization can be blocked by competition with an excess of 
unlabeled hTF protein (row 3). Fluorescently labeled polymer conjugated to human holo-
transferrin (hTF-PVDMAFC-mTEG) is similarly internalized into the cell line (row 4). 
Competition between hTF-PVDMAFC-mTEG and excess unlabeled hTF blocks 
internalization and reduces signal to the level of autofluorescence (row 5), indicating that 
binding and internalization of the protein-polymer conjugate is mediated by specific 
interactions between hTF its receptor, TFR.  Cells were incubated with samples for 1 h at 
37 °C to allow receptor-mediated internalization to occur.  Blue indicates DAPI stain for 
cell nuclei; red indicates phalloidin conjugated to Alexa Fluor 594, which stains actin 
filaments and helps to identify cell boundaries; and green indicates the protein or protein-
polymer conjugate, with positive control protein labeled with Alexa Fluor 488 or polymer 





























Figure 4.9 hTF-488 internalization into MCF-7 cells is concentration dependent. 
MCF-7 cells, which are a human breast cancer cell line, express high levels of transferrin 
receptor (TFR) on their surface. Fluorescently labeled holo-transferrin (hTF-488) was 
internalized into the cells after incubation for 1 h at 37 °C. Increasing the concentration of 
hTF-488 from 10 nM to 100 nM to 1000 nM (rows 1, 2, and 3) showed increasing 
internalization, as visualized by increasing green signal within the cell boundaries and at 
the cell surface. Blue indicates DAPI stain for cell nuclei; red indicates phalloidin 
conjugated to Alexa Fluor 594, which stains actin filaments and helped to identify cell 
boundaries; and green indicates the protein fluorophore conjugate labeled with Alexa Fluor 














Figure 4.10 Polymer does not cause non-specific cell staining for protein-polymer 
conjugates.  Including excess unlabeled polymer during the internalization period of hTF-
PVDMAFC-mTEG does not block receptor-specific internalization of hTF-PVDMAFC-
mTEG (row 1).  MCF-7 cells neither bind nor internalize non-targeted chicken 
ovotransferrin protein labeled directly with fluorophore (OTF-488) (row 2) or fluorescently 
labeled OTF-polymer conjugates (OTF-PVDMAFC-mTEG) (row 3).  Fluorescently labeled 
polymer not conjugated to protein (PVDMAFC-mTEG) similarly does not stain cells (row 
4).  Blue indicates DAPI stain for cell nuclei; red indicates phalloidin conjugated to Alexa 
Fluor 594, which stains actin filaments and helps to identify cell boundaries; and green 
indicates the protein or protein-polymer conjugate, with OTF control protein labeled with 
Alexa Fluor 488 and polymer labeled with fluorescein cadaverine.  Scale bar shown applies 
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DEVELOPMENT OF MOLECULES AND ANIMAL MODELS FOR FUTURE 
MOLECULAR IMAGING STUDIES 
 
5.1 Introduction 
 Pancreatic cancer, malignant pleural mesothelioma, and ovarian cancer are all 
characterized by extremely poor prognoses, with 5-year survival rates of only 9%, 10% 
and 48%, respectively [1].  These low survival rates are attributed to non-specific clinical 
symptoms, late detection, and the tendency of these cancers to metastasize early.  The 
majority of these cancer patients are only diagnosed after their cancer has spread distantly 
throughout the body, further limiting treatment options and worsening their prognoses.   
 Early detection of these cancers, when the disease is still confined to the organ of 
origin and more easily treatable, has been shown to drastically reduce overall mortality, 
morbidity and medical costs [2].  For example, since the introduction of the simple Pap 
smear screening test in 1950, there has been a 70% decline in cervical cancer deaths in 
developed countries [3].  For many cancers, however, including the abovementioned 
malignancies, early diagnostics are not currently available due to a lack of reliable and 
sensitive biomarkers.  While measuring the levels of the CA-125 protein in the blood of 
ovarian cancer patients can be used to help evaluate therapeutic response, and its level often 
declines when a treatment is effective, CA-125 is rarely used for screening purposes 
because of its high false positive rates due to the elevated levels of CA-125 that occur for 
common benign conditions such a pelvic inflammatory disease and endometriosis [4].  
Further, not all ovarian cancer patients have high levels of CA-125.  Additionally, the 
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majority of cancer funding continues to be allocated towards late stage disease treatments 
as opposed to prevention and early detection research. In 2018, less than 11% of funding 
was used for prevention and early detection [5].  Molecular imaging is a highly sensitive 
and noninvasive diagnostic that could help address the unmet need of early detection of 
cancer.  As previously discussed, molecular imaging can detect molecular events 
associated with early carcinogenesis, as well as guide appropriate treatments regimens and 
assess patients’ responses to therapy.  Unfortunately, because of the lack of reliable 
biomarkers associated with mesothelioma, pancreatic cancer, and ovarian cancer, very few 
imaging agents have been developed for these cancers.   
 Mesothelin (MSLN) has emerged as an attractive tumor biomarker because of its 
limited normal expression profile, with low expression only on normal mesothelial cells, 
and high expression in a variety of aggressive cancers, including in 80-85% of pancreatic 
cancers, 85-90% of mesotheliomas, and 60-65% of ovarian cancers [6].  Currently, patients 
with MSLN-expressing tumors are identified by a tumor biopsy and/or blood testing.  As 
previously discussed, however, heterogeneous expression of tumor biomarkers, including 
MSLN, within a tumor and between a primary tumor and metastases, which may not be 
accessible for biopsy, is often observed.  Further, serum MSLN levels are not upregulated 
in all cancers, such as pancreatic cancer, despite their significant overexpression of 
membrane-bound MSLN [7].  
 Recently, MSLN-specific imaging agents have been developed and evaluated in 
preclinical trials using a variety of human cancer mouse models [7–13].  Several of these 
imaging probes incorporate radioactively-labeled anti-MSLN antibodies for positron 
emission tomography (PET) imaging [8,11].  As previously discussed, antibody-based 
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imaging agents are often limited in their clinical utility due to their hepatic elimination and 
slow blood clearance.  In one study, optimal imaging occurred day four post injection of 
the imaging agent because that was when there was maximum tumor uptake. However, the 
tumor-to-background ratio was significantly lower at day four because of increasing liver 
uptake [11].  In another strategy, authors conjugated a radioactive anti-MSLN antibody to 
magnetic nanoparticles for dual PET/ magnetic resonance (MR) imaging [9,10].  In 
addition to the delayed imaging protocol required due to poor antibody penetration, there 
was rapid sequestration of the colloidal particles from the blood into the liver and spleen 
by the reticuloendothelial system [14].  The spleen is an especially problematic off-target 
organ because it is composed of lymphatic tissue and is, therefore, highly radiosensitive 
and it can interfere with imaging pancreatic tumors due to the two organs’ close anatomical 
positions [15].  Most recently, anti-MSLN nanobodies, a class of antigen-binding 
fragments derived from naturally occurring antibodies in the serum of camelids, have been 
evaluated for single photon emission computed tomography (SPECT) imaging [7,12,13].  
The smaller size of  the nanobodies, compared with antibodies, provides optimal 
pharmacodynamics and biodistribution properties for same day imaging but SPECT 
imaging lacks the specificity and sensitivity of PET imaging [16–18].   
 In the thesis work reported in this chapter, an Fn3 library engineered for MSLN 
binding, as described in previous chapters, was further evolved to acquire binding affinities 
relevant for molecular imaging applications, as demonstrated in equilibrium binding assays 
with human cancer cell lines.  Several human cancer cell lines that express either moderate 
or high levels of MSLN expression on their surface were successfully used to form tumor 
xenografts when injected into immunocompromised mice.  These tumor xenografts were 
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confirmed to maintain overexpression of MSLN, as determined by immunohistochemistry, 
thereby establishing appropriate in vivo models for molecular imaging studies. 
 
5.2 Materials and Methods 
 
5.2.1 Ethics statement  
 All animal procedures were performed according to approved Institutional Animal 
Care and Use Committee (IACUC) protocols (# 288-15) of Smith College.  All procedures 
were conducted while animals were under general anesthesia and all efforts were made to 
minimize discomfort. 
 
5.2.2 Evolution and maturation of fifth generation Fn3 variants 
 A Gr2 library previously evolved for MSLN-binding Fn3 variants, as reported in 
previous chapters, was further affinity matured as a fifth generation library [21–23].  
Briefly, following error-prone PCR with nucleotide analogs, the library was sorted twice 
by MACS using biotinylated, Fc-tagged recombinant human MSLN (Acro Biosystems 
#MSN-H826x) followed by a FACS selection for full-length clones using an antibody 
against the C-terminal c-myc epitope tag.  Full-length clones were incubated with a chicken 
anti-c-myc antibody and the biotinylated Fc-tagged MSLN.  To increase the sorting 
stringency, concentrations of MSLN were decreased over three iterative rounds of 
enrichment, from 5 nM in the first sort to 1 nM in the third sort.  Cells were washed and 
incubated with a goat anti-chicken Alexa Fluor-647 (AF647) conjugate and AF488-
conjugated streptavidin.  Cells were washed and double-positive yeast cells were collected 
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on a BD BioSciences FACSAria II.  Plasmid DNA from the enriched library was recovered 
using a Zymoprep Yeast Plasmid Miniprep II kit (Zymo Research) following 
manufacturer’s protocol, transformed into bacteria, and individual clones were sequenced 
by standard Sanger DNA sequencing methods.   
 
5.2.3 Production and purification of Fn3 variants 
 MSLN-binding Fn3 variants 5.3.1 and 5.3.2 were prepared as previously described 
[22,23].  Briefly, the Fn3 genes were cloned into a pET vector with a C-terminal 
hexahistadine tag (plasmid provided by B. Hackel, University of Minnesota) and expressed 
in BL21(DE3) E. coli.  Cultures were grown in LB and induced overnight at 20°C with 0.5 
mM Isopropyl-b-D-thiogalactopyranoside (IPTG).  Cells were resuspended in lysis buffer 
(35 mM Na2HPO4×dibasic, 15 mM NaH2PO4×monobasic, 500 mM NaCl, 5 mM CHAPS, 
25 mM imidazole, 5% glycerol) supplemented with an EDTA-free protease inhibitor 
(Pierce), and lysed by repeated freezing and thawing.  Soluble fractions were isolated by 
centrifugation.  Fn3 variants 5.3.1 and 5.3.2 were purified by cobalt affinity 
chromatography with HisPur cobalt resin (Thermo Fisher).  Protein samples were buffered 
exchanged into 1X PBS and analyzed for purity by SDS-PAGE on a BioRad ChemiDoc 
MP imaging system.   
 
5.2.4 Alexa Fluor-488 and -680 dye conjugation  
 Pure Fn3 5.3.2 protein was incubated with either AF488 tetrafluorophenyl (TFP) 
ester or AF680 N-Hydroxysuccinimide (NHS) ester (Thermo Fisher) in a 0.1 M sodium 
bicarbonate solution (pH 8.3) at a 10:1 dye/protein molar ratio for 2 hr at 23°C and 
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overnight at 4°C with gentle mixing. The conjugates were purified by extensive buffer 
exchange with PBS using a 3 kDa centrifugal filter unit. Protein concentrations and DOL 
were determined using UV-Vis spectroscopy, measuring dye absorption at 494 nm (e = 
71,000 cm-1 M-1) or 679 nm (e = 184,000 cm-1 M-1) for AF488 and AF680, respectively. 
 
5.2.5 Reagents and cell lines 
 PBSA buffer was composed of phosphate buffered saline (PBS) and 0.1% bovine 
serum albumin (BSA).  TBSA buffer was composed of tris-buffered saline (TBS) and 1% 
BSA.  A431/H9 cells (gift of M. Ho, National Cancer Institute, 2016) [19] were cultured 
in RPMI-1640 supplemented with 10% FBS, 1% penicillin-streptomycin and 700 µg/mL 
Geneticin selective antibiotic (G418) (Thermo Fisher).  KB-3-1 cells (gift of M. 
Gottesman, National Cancer Institute, 2016) [20] were cultured in DMEM supplemented 
with 10% FBS and 1% penicillin-streptomycin. All cells were grown at 37°C in a 
humidified atmosphere containing 5% CO2. 
 
5.2.6 Binding affinity measurements of soluble 5.3.2 for MSLN-positive tumor cells 
 A431/H9 cells were cultured to 80% confluency, as described above, harvested, 
washed, and pelleted at 200g for 5 min at 4°C.  MSLN expression was detected by a rabbit 
monoclonal anti-MSLN antibody (clone EPR 19025-42, Abcam, 1:50) and a goat anti-
rabbit PE conjugate (Abcam, 1:250).  Cells were incubated with a range of concentrations 
of AF488-labeled 5.3.2 in PBSA for 1 h at 23°C.  Cells were washed and pelleted as above, 
resuspended with ice cold PBSA, and fluorescence was analyzed using a Guava easyCyte 
flow cytometer.  Mean fluorescence intensities for Fn3 variant binding were determined 
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using InCyte software.  Data was plotted and fit with a sigmoidal curve using KaleidaGraph 
software.  Dissociation constants (KD) were determined as the half-maximal value of the 
sigmoidal fit for three separate experiments, and the mean and standard deviation for the 
KD are reported.     
 
5.2.7 Mouse xenograft models and tumor processing 
 Athymic nude mice (Charles River Laboratory) at 20 weeks of age were 
anesthetized with 1-4% isofluorane in oxygen (1 L/min).  H9/A431 or KB-3-1 cells (5x106 
cells) suspended in 50 µL PBS and 50 µL of Matrigel Basement Membrane Matrix (BD 
Biosciences), were injected subcutaneously into the right shoulder of mice to generate 
human tumor xenografts. Tumor formation was monitored daily and tumors were excised 
when they measured greater than 5 mm in at least two dimensions by caliper. Excised 
tumors were fixed in 10% buffered formalin (Fisher Scientific) for 24 h at 4°C. After 
fixation, tumors were washed in PBS and stored in 70% ethanol at 4°C. Fixed tumors were 
processed using a Leica TP1200 automatic tissue processor. Tumors were placed in 
individually labeled cassettes and processed in 70% ethanol for 30 min, 80% ethanol for 
30 min, 95% ethanol for 90 mins, 100% ethanol for 90 min, xylene for 90 mins, and 
paraffin for 2 h. After processing, the cassettes were removed from the tissue processor 
and paraffin-embedded. 
 
5.2.8 Mesothelin immunofluorescence microscopy 
 Sections (5 µm) of formalin-fixed and paraffin-embedded tumor xenografts were 
deparaffinized in xylene and progressively rehydrated from 100% to 50% ethanol and 
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rinsed in water.  All washing steps between incubations were performed in TBS with gentle 
agitation.  Tissue sections were subjected to heat-induced epitope retrieval using Tris-
EDTA (10mM Tris, 1mM EDTA, 0.05% Tween 20, pH 9.0) buffer.  Sections were washed 
and autofluorescence was blocked by incubation in 0.3M glycine buffer for 10 min at 23°C.  
Sections were washed and blocked with 10% normal goat serum (Thermo Fisher) for 1 h 
at 23°C.  Incubation with rabbit anti-MSLN antibody (Abcam, 1:1500) in TBSA was 
performed overnight at 4oC in a humidified chamber.  After washing, tissue sections were 
incubated with an Alexa Fluor 594 (AF594)-conjugated polyclonal goat anti-rabbit 
secondary antibody (Abcam, 1:400) in TBSA for 1 h at 23°C, in a humidified chamber, 
and protected from light.  Sections were washed and mounted with VectaShield Antifade 
Mounting Medium with DAPI (Vector Laboratories).  Stained sections were examined 
with a Zeiss Axio Imager M2 fluorescent microscope.  A negative control omitted the 
primary antibody.  
 
5.3 Results and Discussion 
 
5.3.1 Fifth generation Fn3 variants exhibit single nanomolar affinities for MSLN   
 Our previously reported MSLN-binding Fn3 library [22,23] was further sorted and 
affinity matured as a fifth generation library using yeast surface display. Following 
additional rounds of mutagenesis, the fifth generation library was subjected to two rounds 
of magnetic sorting, a fluorescent-activate cell sort (FACS) for full-length expression and 
three iterative rounds of dual-color FACS for binding to MSLN.  The resultant population 
yielded enrichment of evident MSLN-binding clones and sequence analysis of individual 
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clones identified two dominant variants: 5.3.1 and 5.3.2.  When displayed on the surface 
of yeast, these fifth generation variants demonstrated further enhanced affinity for MSLN 
(Figure 5.1).  Variant 5.3.1 exhibited a binding affinity of KD = 3.2 +/- 0.4 nM and variant 
5.3.2 exhibited a binding affinity of KD = 2.5 +/- 0.4 nM (Figure 5.1).   
 
5.3.2 Fn3 variant 5.3.2 retains high affinity binding to cancer cells expressing MSLN 
 Because of its high recombinant expression and ease of purification by cobalt 
affinity chromatography, Fn3 variant 5.3.2 was further pursued (Figure 5.2A).  Soluble Fn3 
variant 5.3.2 was directly labeled with AF488 (5.3.2-AF488) and evaluated using 
equilibrium binding titrations on A431/H9 cells, a MSLN positive cell line (Figure 5.2B).  
In an initial titration, Fn3 5.3.2-AF488, bound to MSLN-expressing A431/H9 cells with a 
binding affinity of KD = 7.2 nM.  
 
5.3.3 Mesothelin is overexpressed on the surface of tumor xenografts 
 Female nude mice (age 20 weeks) were inoculated into their right shoulders with 
5x106 cells of either the A431/H9 cell or KB-3-1 cell lines.  Mice were monitored daily for 
tumor formation.  Both mice successfully formed tumors within one week (KB-3-1 cells) 
or two weeks (A431/H9 cells) post-inoculation.  It was observed that the KB-3-1 tumor 
appeared irritated, but did not look inflamed or purulent in any way that would suggest it 
had become infected.  Instead, because of the size and more midline position of the tumor, 
it suffered from abrasions as the mouse entered and exited the provided plastic housing.  
On the day of excision, the length (as measured from head to tail), width (as measured from 
belly to midline) and depth (as measured from deepest to most superficial tumor tissue of 
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the KB-3-1 tumor measured 9 mm x 9 mm x 3 mm (Figure 5.3A).  The A431/H9 tumor 
measured 6 mm x 6mm x 3 mm (L x W x D) (Figure 5.3B).  Both tumors were observed 
to have several small blood vessels supplying them.  
 To confirm tumors generated from A431/H9 and KB-3-1 cells express MSLN on 
their surface, excised tumors were evaluated by IHC analysis (Figure 5.4). In agreement 
with our in vitro data (Chapter 2), KB-3-1 tumor xenografts maintained high levels of 
MSLN on their surface (Figure 5.4, Bottom) compared to a no antibody control (Figure 5.4, 
top) and a secondary antibody only control (Figure 5.4, middle).  These results validate our 
established tumor xenografts as appropriate in vivo models for molecular imaging studies. 
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Figure 5.1 Affinity maturation of fifth generation anti-mesothelin Fn3 proteins.  
Dominant proteins recovered from each generation of our affinity matured Fn3 libraries 
were individually displayed on the surface of yeast and incubated with a range of 
concentrations of soluble MSLN.  The assays were performed in experimental triplicate.  
Data from each replicate were fit to a sigmoidal curve and a KD value was calculated for 
each replicate.  The KD is reported as the mean +/- the standard deviation.  A representative 











Figure 5.2 Fn3 variant 5.3.2 selectively binds tumor cell surface mesothelin with high 
affinity. (A) Engineered Fn3 variants 5.3.1 and 5.3.2 were expressed in bacteria with a C-
terminal hexahistidine tag and purified by cobalt affinity chromatography.  Protein samples 
were purified to high purity (> 99%), as analyzed by SDS-PAGE, and buffer exchanged 
into 1X PBS. (B) Binding of 5.3.2 to cell surface MSLN was measured using a single 
equilibrium binding assay. The data were fit to a sigmoidal curve, and a KD value was 




















Figure 5.3 A431/H9 and KB-3-1 cell lines successfully form tumors in athymic nude 
mice. Tumors were measured L x W x D daily and excised when at least two dimensions 
surpassed 5 mm. (A) KB-3-1 cells formed a tumor at one week post inoculation, measuring 
9 mm x 9mm x 2mm. (B) A431/H9 cells formed a tumor measuring 6 mm x 6 mm x 3 mm 













Figure 5.4 Immunofluorescence confirms mesothelin expression in KB-3-1 tumor 
xenografts. Paraffin-embedded tissue sections were stained with a rabbit anti-mesothelin 
primary antibody and an AF594-conjugated goat anti-rabbit antibody (Ab). Secondary 
antibody only was used as a negative control. Representative immunofluorescence 
micrographs of tumor xenograft sections are shown. DAPI (blue), nucleus; AF594 (red), 
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 CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
 Cancer is a global health concern and many patients suffering from a malignant 
disease are in need of more effective and less toxic therapeutic options.  Proteins represent 
diverse and promising biological entities that can be further developed for both research 
and biomedical applications, including targeted cancer diagnostics and therapeutics.   
 Protein engineering investigates and takes advantage of the unique relationship 
between a protein’s structure and function to generate proteins with modified or novel 
activities and/or properties.  Protein engineering provides approaches by which naturally 
existing proteins can be customized, or new proteins can be created, for targeted biomedical 
applications.  While antibodies have provided significant clinical advances, increased 
understanding about the complexities of human diseases, including cancer, demands 
additional, and potentially complementary, molecules that expand the therapeutic 
spectrum.  The work presented in Chapter 2 of this dissertation focused on engineering 
proteins based on the non-antibody fibronectin protein scaffold (Fn3) to target tumor 
biomarker mesothelin toward applications as targeted cancer diagnostics and therapeutics.  
To our knowledge, this was the first report of non-antibody proteins engineered to bind 
mesothelin.  These results validated that the Fn3 non-antibody protein scaffold can be 
engineered to bind to tumor biomarkers, and encourages the continued development of 
engineered variants for applications such as targeted diagnostics and therapeutics.   
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 Targeted drug development has, and will continue to benefit from increased 
knowledge about a particular molecular target and its specific roles in disease 
pathobiology.  Knowing and understanding the beneficial mechanisms of actions to exploit 
and/or the mechanisms of resistance needed to overcome will advance rational and 
effective drug design.  In Chapter 3 of this dissertation, engineered protein variants that 
bind mesothelin with high affinity were shown to selectively initiate apoptosis in tumor 
cells expressing mesothelin.  Interestingly, apoptosis did not occur through a caspase-
mediated pathway, and did not require downregulation of cell-surface mesothelin.  The 
absence of these commonly observed pathways for targeted treatment of tumor cells 
suggests a currently unknown pathway through which mesothelin contributes to cancer 
progression.  Importantly, simultaneous treatment with mesothelin-binding protein and 
chemotherapeutic mitomycin C had a greater cytotoxic effect on mesothelin-positive cells 
compared to either molecule alone, underscoring the potential for combination therapy 
including biologics targeting mesothelin.   
 A primary goal of a targeted therapeutic is to achieve maximum bioavailability, or 
active effect, at the site of disease while limiting the toxicity of that therapeutic.  Protein-
polymer conjugates, in which a therapeutic entity can be conjugated to a polymer and 
specifically delivered to the site of disease by a targeting protein can address limitations 
caused by systemic distribution of drugs in the body.  The work presented in Chapter 4 of 
this dissertation describes a simple, tailorable and modular approach for synthesizing 
protein-polymer conjugates for targeted drug delivery to a variety of disease-specific cell 
types.  Specifically, we demonstrated that a water-soluble, azlactone-functionalized 
polymer can be efficiently labeled with a small molecule fluorophore, modeling how a 
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small molecule drug may be attached, and conjugated to a targeting protein.  Further, this 
conjugation strategy did not interfere with native protein function, and the protein-polymer 
conjugate was shown to internalize into target cells through receptor-mediated endocytosis.  
 Recent successes of targeted therapies have highlighted the importance of matching 
the right patient with the right therapy.  Companion diagnostics, such as molecular 
imaging, allow clinicians to stratify patients and identify those who are more likely to 
respond to a particular therapy.  Additionally, molecular imaging can provide information 
about therapeutic efficacy before traditional end points, such as tumor shrinkage, are 
observed.  In Chapter 5 of this dissertation, further evolved MSLN-binding proteins with 
binding affinities appropriate for molecular imaging applications were identified, and in 
vivo models for molecular imaging studies were developed.  
 
6.2 Future Directions 
 
6.2.1 Chapter 2: Fn3 proteins engineered to recognize tumor biomarker mesothelin 
internalize upon binding  
 Directed evolution has proven to be a powerful technology for engineering proteins 
with improved properties [1], including, as described in this thesis, evolving proteins for 
novel molecular recognition.  The success of directed evolution is reliant on the ability to 
create highly diverse libraries, effective selection strategies, and iteration of these 
processes.  Many technological advances have further improved and streamlined these 
processes and should be considered for future directed evolution projects [2].  For example, 
characterizing the relationship between sequence and function of engineered proteins was 
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traditionally limited by the requirement of Sanger sequencing after each round of selection.  
While this method provides only a limited glimpse into selected variants, high throughput, 
next-generation sequencing (NGS) technologies allow for investigation of selected 
populations at a much broader scale [2–4].  Additional advances include sequence analysis 
software tailored for protein engineering applications.  While the length variability within 
diversified regions (i.e. antibody CDRs or Fn3 loops) often make alignment processes 
difficult, a recently developed program, the ScaffoldSeq [5] algorithm, exploits conserved 
framework sequences to identify and align these diverse regions.  Further, ScaffoldSeq can 
efficiently filter out the unintended biases in sequence frequency often generated 
throughout the directed evolution workflow.  
 
6.2.2 Chapter 3: Engineered Fn3 protein has targeted therapeutic effect on 
mesothelin-expressing cancer cells and increases tumor cell sensitivity to 
chemotherapy 
 
6.2.2.1 Identify the mechanisms of cytotoxicity of engineered MSLN-binding proteins   
 To have a therapeutic effect, molecules that are developed for targeted therapy must 
interact with a specific cancer biomarker and then exert some change on a molecular 
pathway critical for tumor cell survival, maintenance, and/or progression.  MSLN is a 
relatively new biomarker for targeted cancer therapy, and the molecular pathways by which 
MSLN expression promotes cancer progression are not yet completely understood.  
Elucidating the molecular pathways that MSLN engages with will inform efforts for 
developing targeted therapies for MSLN-expressing cancers.  The preliminary data 
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presented in Chapter 3 indicate that our engineered Fn3 proteins are selectively cytotoxic 
to (Figure 3.3) and induce apoptosis (Figure 3.4) of MSLN-positive tumor cells, and do so 
in the absence of caspase activation (Figure 3.5) and in absence of surface MSLN 
downregulation (Figure 3.6).   
 Apoptosis is a highly-organized, multi-step process that can proceed in either a 
caspase-dependent or a caspase-independent manner [6,7].  Apoptosis-inducing factor 
(AIF) [8], which is normally localized within the intermitochondrial space and functions 
as an NAD-dependent oxidoreductase, has been identified as an integral effector of 
caspase-independent apoptosis.  In response to a lethal signal, AIF is released from the 
mitochondrial intermembrane space into the cytoplasm, after which it translocates into the 
nucleus [9–11].  The AIF surface consists of a strong positive electrostatic potential which 
allows it to interact with DNA, inducing chromatin condensation and DNA fragmentation 
[10].  The Bcl-2 gene family consists of both pro-and anti-apoptotic proteins that are 
thought to regulate the release of AIF from the mitochondria and the subsequent caspase-
independent apoptosis [12–14].  The anti-apoptotic proteins, including myeloid cell 
leukemia-1 (Mcl-1), interact via BH3 domains with the pro-apoptotic proteins, BAK and 
BAX.  BAK and BAX are responsible for forming pores within the mitochondrial 
membrane, releasing AIF [15,16].  Increased Mcl-1 expression promotes malignant cell 
survival and resistance to apoptosis by conventional therapy in a variety of cancers 
including leukemia [17], non-small cell lung cancer [18], prostate cancer [16], ovarian 
cancer [19], colon cancer [20] and breast cancer [15].  Studies in which Mcl-1 expression 
was knocked down resulted in increased DNA strand breaks and apoptotic and necrotic 
cell death, due to mitochondrial release and nuclear translocation of AIF [16].  MSLN 
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expression is thought to promote resistance to several chemotherapeutic agents and is 
significantly overexpressed in several characteristically chemoresistant cancers including 
ovarian [21] and pancreatic [22].  Endogenous MSLN expression enhances the expression 
of anti-apoptotic proteins, including Mcl-1 [23].  Studies in which MSLN expression was 
increased, either exogenously or via transfection, demonstrated subsequent increased Mcl-
1 expression [21,24].  One working hypothesis is that treatment of MSLN-positive tumors 
with Fn3 variants that bind and are internalized by MSLN leads to a reduction in Mcl-1, 
and eventually to release of AIF from the mitochondria, which then induces apoptosis 
(Figure 6.1).  Future experiments will measure if engineered Fn3 variants influence the 
level of Mcl-1 and the subcellular location of AIF in treated, MSLN-positive cancer cells.  
 Autophagy is a highly regulated, multistep process in which cellular organelles and 
proteins are degraded to balance sources of energy and maintain DNA stability, 
mitochondrial turnover and tissue homeostasis [25–27].  Autophagy was traditionally 
considered a tumor suppression mechanism due to the reported allelic loss of the essential 
autophagy gene (BECN1) in many human breast, ovarian and prostate cancers [28].  It is 
now known, however, that once a tumor is established, cancer cells can hijack this process 
to avoid apoptosis, which contributes to cancer therapy resistance [26,29–31].  Indeed, 
autophagy inhibition has been shown to sensitize tumor cells to anticancer agents, and is 
currently being evaluated as a therapeutic intervention in many preclinical and clinical 
studies [32].  Recent work has identified that the levels of p53 upregulated modulator or 
apoptosis (PUMA) increase upon autophagy inhibition, and that this increase in PUMA is 
necessary for mediating apoptosis sensitization to anticancer agents [33,34].  Interestingly, 
studies in which MSLN has been depleted from MSLN-overexpressing cancer cells, by 
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either shRNA or siRNA, resulted in an increase in PUMA expression, and a corresponding 
decrease in cancer cell proliferation and invasive capacity [35,36].  Further, MSLN 
depletion combined with cisplatin demonstrated a marked increase in apoptosis compared 
to cells treated with each agent alone [36].  Future experiments will measure if engineered 
Fn3 variants influence the level of PUMA and the sensitivity of MSLN-positive cancer 
cells to common anticancer drugs (Figure 6.2). 
 
6.2.2.2 Measure the impact of Fn3 variants on tumor cell invasion and metastasis 
 Metastasis is driven by increased cell migration and invasion and MSLN expression 
has been shown to positively correlate with metastatic potential [37–43].  This increased 
tumor cell invasion and metastasis is mediated by the MSLN-CA125 binding interface and 
the subsequent homotypic and heterotypic cell adhesions (Figure 1.12). 
 In our initial protein engineering approach, we sought to specifically engineer Fn3 
variants that blocked the MSLN-CA125 interaction, hypothesizing that blocking this 
interaction could enhance the therapeutic efficacy of Fn3 variants and enable a reduction 
in metastasis.  After modifying our protein engineering approach to select for Fn3 variants 
that bound anywhere along the extracellular domain of the MSLN protein, we now need to 
assess whether our selected variants do alter MSLN-CA125 binding.  In future 
experiments, we will determine if our engineered anti-MSLN Fn3 variants reduce binding 
of MSLN to CA125.  Additionally, migration and invasion of MSLN-positive tumors cells 
will be measured after treatment with MSLN-binding Fn3 variants, to determine if Fn3 




6.2.3 Chapter 4: Protein-polymer conjugates synthesized using water-soluble 
azlactone-functionalized polymers enable receptor-specific cellular uptake toward 
targeted drug delivery  
 Preliminary data in Chapter 2 demonstrated that engineered MSLN-targeting 
proteins internalize into early endosomes (Figure 2.6 and Figure 2.7), providing an 
opportunity for intracellular delivery of toxic molecules into MSLN-positive cancer cells.  
The data in Chapter 4 showed that polymer PVDMA-mTEG can be loaded with a small 
molecule cargo, by coupling the polymer to a small molecule fluorophore as a model for 
loading with a small molecule drug (Figure 4.6).  Additionally, polymer PVDMA-mTEG 
was shown to readily conjugate to multiple model proteins in aqueous solution through the 
primary amines of the protein, including to native transferrin receptor ligand hTF (Figure 
4.3).  This non-specific conjugation through primary amine chemistry, however, made 
controlling the stoichiometry of protein:polymer difficult to control, and the location of 
polymer attachment to protein was not define. Continuing with this approach could lead to 
variations in conjugation structure.  
 In future work, our protein-polymer conjugate system will be further developed to 
become a versatile approach for delivering small molecule therapeutics to tumor cells 
mediated by engineered Fn3 proteins that target MSLN.  The Fn3 protein scaffold is ideal 
for this proposed work because it contains no cysteine residues, allowing the introduction 
of a unique cysteine residue for subsequent site-specific conjugation to polymer and drug 
payload.  PVDMA polymer functionalized with maleimides could easily couple to the Fn3 
proteins with a single cysteine residue.  Alternatively, it is possible to mutate all lysine 
residues in the Fn3 scaffold and maintain structure and function [45], leaving only the N-
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terminus as a primary amine, enabling site-specific primary amine conjugation for polymer 
and drug payload.  Coincidentally, I have engineered an Fn3 variant that binds MSLN with 
high affinity and contains no lysine residues.  
 Confocal microscopy will be used to perform cell internalization assays with the 
MSLN-targeting polymer conjugates to assess whether the conjugates can be internalized 
by MSLN.  Preliminary data from Chapter 4 in which the hTF-polymer conjugates are 
selectively internalized into cells that express the transferrin receptor demonstrate that 
protein remains functional following polymer conjugation (Figure 4.8). Targeting 
specificity will be examined with blocking experiments in which unlabeled Fn3 proteins 
are co-incubated with Fn3-polymer conjugates.  We expect cell lines that express MSLN 
to exhibit receptor-specific internalization of the Fn3-polymer conjugates, and we 
anticipate cell lines that do not express MSLN will not bind or internalize the MSLN-
targeting Fn3-polymer conjugates.   
 
6.2.4 Chapter 5: Development of molecular and animal models for future molecular 
imaging studies.  
 In future work, our proteins will be validated for use as in vivo molecular imaging 
diagnostic agents.  The high-affinity candidate proteins identified in Chapter 5 (Figure 5.2) 
will be labeled with a far-red fluorescent dye, whose excitation and emission spectra are 
appropriate for optical imaging.  Preliminary tumor contrast measurements using our 
developed mouse xenograft models and an IVIS SpectrumCT imaging system will be 
performed.  Candidate proteins with the greatest tumor contrast and lowest retention in 





Figure 6.1 Anti-MSLN Fn3 proteins may modulate Mcl-1 levels and induce caspase-
independent apoptosis via AIF. Apoptosis-inducing factor (AIF) is normally localized 
within the mitochondria and has been identified as an integral effector of caspase-
independent apoptosis.  In response to a lethal signal, AIF is released from the 
mitochondria into the cytoplasm and translocates into the nucleus.  AIF interacts with 
DNA, inducing chromatin condensation and DNA fragmentation.  Pro-and anti-apoptotic 
proteins regulate the release of AIF.  Myeloid cell leukemia-1 (Mcl-1), prevents pore 
formation and AIF release from the mitochondria. MSLN expression enhances the 
expression of anti-apoptotic proteins, including Mcl-1. One working hypothesis is that 
treatment of MSLN-positive tumors with Fn3 variants that bind and are internalized by 
MSLN could lead to a reduction in Mcl-1, and eventually to release of AIF from the 








Figure 6.2 Anti-MSLN Fn3 proteins may inhibit cancer cell autophagy to sensitize 
cancer cells to chemotherapy. Levels of p53 upregulated modulator or apoptosis (PUMA) 
increase upon autophagy inhibition, and is required for mediating apoptosis sensitization 
to anticancer agents.  MSLN depletion is known to increase PUMA expression and when 
combined with anticancer drugs, demonstrates a marked increase in apoptosis compared to 
cells treated with each agent alone.  One working hypothesis is that treatment of MSLN-
positive tumors with Fn3 variants inhibits cancer cell autophagy making them more 
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8-oxo-dGTP  8-oxo-2’-deoxyguanosine-5’-triphosphate 
Abl SH2  Abelson kinase Src homology 2  
ADC   antibody-drug conjugate 
AF488   Alexa Fluor 488 fluorescent dye 
AF594   Alexa Fluor 594 fluorescent dye 
AF647   Alexa Fluor 647 fluorescent dye 
AF680   Alexa Fluor 680 fluorescent dye 
Aga1p, Aga2p  yeast agglutinin proteins 
AIBN   2,2’-azobis(2-methylpropionitrile) 
ATR-IR  attenuated total reflectance infrared spectroscopy 
BBB   blood brain barrier 
BDS   bright detail similarity 
BSA   bovine serum albumin 
CA-125  cancer antigen 125 
CAR    chimeric antigen receptor 
CCK-8   cell counting kit-8 
CDCl3   deuterated chloroform 
CDK2   cyclin-dependent kinase 2 
CEA   carcinoembryonic antigen 
CT   computed tomography 
CTA   chain transfer agent 
DARPins  designed ankyrin repeats 
DBU   1,8-diazabicylo[5.4.0]undec-7-ene 
DMSO   dimethylsulfoxide 
DMSO-d6  deuterated DMSO 
DOL   degree of labeling 
dPTP   2’deoxy-p-nucleoside-5’-triphosphate 
ECD   extracellular domain 
ECM   extracellular matrix 
EGFR   epidermal growth factor receptor 
ER   estrogen receptor 
FACS   fluorescence activated cell sorting 
FBS   fetal bovine serum 
Fc   antibody crystalizable fragment 
FC   fluorescein cadaverine 
FDA   Food and Drug Administration 
FDG   fluorodeoxyglucose 
FITC   fluorescein isothiocyanate 
FLAG   epitope tag comprised of the residues DYKDDDDK 
Fn3   fibronectin domain scaffold 
FT-IR   Fourier transform infrared spectroscopy 
Fv   antibody variable domain 
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GM-CSF  granulocyte-macrophage colony-stimulating factor 
GPC   gas permeation chromatography 
GPI   glycosylphosphatidylinositol 
Gr2   Gradient 2 fibronectin library 
HA   hemagglutinin  
HER2   human epidermal growth factor 2 
His6   hexahistadine tag 
HPLC   high pressure liquid chromatography 
hTF   holotransferrin 
IACUC  Institutional Animal Care and Use Committee 
IgG   immunoglobulin G 
IL-6   interleukin-6 
IHC   immunohistochemistry 
KD   equilibrium dissociation constant 
kDa   kilodaltons 
MACS   magnetic activated cell sorting 
MMC   mitomycin C  
MMP-7  matrix metalloproteinase-7 
Mn   number average molecular weight 
MPF   megakaryocyte-potentiating factor 
MRI   magnetic resonance imaging 
MSLN   mesothelin 
mTEG   triethylene glycol monomethyl ether) 
MW   molecular weight 
MWCO  molecular weight cut-off 
NGS   next-generation sequencing 
NHS   N-hydroxysuccinimide 
NMR   nuclear magnetic resonance 
NOPR   National Oncologic PET Registry 
OTF   ovotransferrin 
PBS   phosphate buffered saline 
PBSA   phosphate buffered saline with 0.1% bovine serum albumin 
PBST   phosphate buffered saline with 0.2% Tween 20 detergent 
PCR   polymerase chain reaction 
PE   phycoerythrin 
PEG   polyethylene glycol 
PET   positron emission tomography 
PET/CT  positron emission tomography/ computer tomography dual 
   imaging modality 
PFA   paraformaldehyde 
PI   propidium iodide 
PNGaseF  peptide-N-glycosidase 
PVDMA  poly(2-vinyl-4,4-dimethylazlactone) 
RAFT   reversible addition-fragmentation transfer 
RDG   Fn3 variant in which the RGD integrin-binding motif has been  
   mutated to RDG 
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RES   reticuloendothelial system 
RISC   RNA-induced silencing complex 
RIT   recombinant immunotoxin 
RMT   receptor-mediated transcytosis 
ROI   region of interest 
scFv   single chain variable fragment of antibodies 
SD   standard deviation 
SDS-PAGE  sodium dodecyl sulfate – 3polyacrylamide gel electrophoresis 
SE   standard error 
SEA   sea urchin sperm protein, enterokinase and agrin 
SEC   size exclusion chromatography 
STAT3  signal transducer and activator of transcription 3 
TBST   tris-buffered saline with 0.1% Tween 20 detergent 
TEF-1   transcriptional enhancer factor 1 
TFA   trifluoroacetic acid 
TFP   tetrafluorophenyl 
TFR   transferrin receptor 
TME   tumor microenvironment 
TR   tandem repeat 
VEGF   vascular endothelial growth factor 
VEGFR-2  vascular endothelial growth factor receptor-2 
YAP1   yes-associated protein 1 
YPD   yeast peptone dextrose media for yeast 
YSD   yeast surface display 
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